This World Pancreatic Cancer Day, November 19, we honor everyone affected by this disease and recognize the urgent need to find new treatment options to improve outcomes.
Visit @PanCAN and pancan.org/awareness to learn more this Pancreatic Cancer Awareness Month.
#pancreaticcancerawarenessmonth #pancanawareness #krasg12d #clinicaltrials #verastemonc #pcam #pancchat
Verastem Oncology
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. More on Wikipedia
-
Verastem Oncology
@VerastemOncolog
-
Verastem Oncology
@VerastemOncolog
A late-breaking abstract featuring updated clinical data from the Phase 1/2 TARGET-D-101 study of VS-7375 in previously treated patients with KRAS G12D-mutated metastatic non-small cell lung cancer has been selected for oral presentation at the @IASLC/@ASCO 2026 North America Conference on Lung Cancer, taking place December 4–6, 2026.
Presentation details available here: investor.verastem.com/news-releases/news-release-details/…
#naclc2026 #krasg12d #nsclc $VSTM -
Verastem Oncology
@VerastemOncolog
At Verastem Oncology, our clinical trials are evaluating VS-7375, an investigational KRAS G12D inhibitor, both alone and in combination with other treatments, to better understand its potential in this disease.
This Pancreatic Cancer Awareness Month, we thank the patients, families and clinical teams whose participation makes this research possible.
Learn more about our research: www.verastem.com/our-science/clinical-trials/target-d-201/
#pancreaticcancerawarenessmonth #krasg12d #clinicaltrials $VSTM -
Verastem Oncology
@VerastemOncolog
Today, we announced our third quarter 2026 financial results and shared our latest business updates across the commercial and VS-7375 clinical development program.
Read more: investor.verastem.com/news-releases/news-release-details/…
$VSTM -
Verastem Oncology
@VerastemOncolog
Our management team is looking forward to presenting at the upcoming Guggenheim, Wolfe Research, and Jefferies Healthcare Conferences to discuss progress across Verastem's commercial and VS-7375 clinical development program.
Learn more about the fireside events and webcast details on our Events page:
investor.verastem.com/events
$VSTM -
Verastem Oncology
@VerastemOncolog
We will be holding our Q3 earnings call on Thursday, November 5, 2026, at 4:30pm ET and we plan to share financial results and highlight recent business updates.
Read the details here: investor.verastem.com/news-releases/news-release-details/…
$VSTM -
Verastem Oncology
@VerastemOncolog
In new positive efficacy and updated safety and tolerability data announced today by Verastem, VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor, demonstrated anti-tumor activity across advanced KRAS G12D-mutant cancers, highlighted by 50% confirmed overall response rate in second-line pancreatic ductal adenocarcinoma and two complete responses in second-line plus disease.
Read the full press release here about the data to be presented today in an investor event and web cast at 8:00 am ET.
investor.verastem.com/news-releases/news-release-details/…
#kras #krasg12d #pdac #nsclc #crc $VSTM -
Verastem Oncology
@VerastemOncolog
Today, we announced a planned transition plan with the appointment of Michael P. Bailey to succeed Dan Paterson as President and Chief Executive Officer, effective January 1, 2027.
Read the full press release here: investor.verastem.com/news-releases/news-release-details/…
$VSTM -
Verastem Oncology
@VerastemOncolog
Verastem’s Chief Scientific Officer, Jonathan Pachter, will join distinguished experts in the RAS field at the 6th RAS Initiative Symposium at the Frederick National National Laboratory for Cancer Research October 7-9, 2026, to discuss RAS biology and therapeutics. His presentation is one of only 12 invited short talks selected through blinded review by Members of the RAS Initiative Scientific Leadership Team.
Read about the conference program here: frederick.cancer.gov/events/6th-ras-initiative-symposium
#rasdrugdevelopment #kras #krasg12d #rasintiative #precisiononcology $VSTM -
Verastem Oncology
@VerastemOncolog
New Phase 2 RAMP 201 molecular profiling and external control arm analyses describing outcomes for avutometinib plus defactinib in patients with KRAS-mutated recurrent low-grade serous ovarian cancer will be presented today during rapid oral and poster presentations at the @IGCSociety 2026 Global Annual Meeting.
Additional details are available here: investor.verastem.com/news-releases/news-release-details/…
#igcs2026 #lgsoc #kras $VSTM -
Verastem Oncology
@VerastemOncolog
New in @SscienceMagazine, the paper, “FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer,” provides preclinical evidence that combining the RAF/MEK clamp avutometinib and the FAK inhibitor defactinib with a KRAS G12C inhibitor enhances anti-tumor efficacy by overcoming resistance mechanisms that limit the effectiveness of monotherapy in KRAS G12C-mutated non-small cell lung cancer.
Read the publication: www.science.org/doi/10.1126/scitranslmed.aea4608
#scienceresearch #sciencetranslationalmedicine $VSTM -
Verastem Oncology
@VerastemOncolog
Living with low-grade serous ovarian cancer (LGSOC) can affect many aspects of a person’s life—including fertility, reproductive health, and sexual health. Yet, many patients do not feel prepared for these impacts to their life, and conversations about them can be difficult to navigate or are not addressed early enough in their care journey.
Emily Campbell from @NotTheseOvaries shares why it’s important to have these conversations and consider the full impact of LGSOC on a person’s life, helping ensure patients receive the information and support they need throughout their care.
#ovariancancerawarenessmonth #gynecologiccancerawarenessmonth #gcam #ovariancancer #lgsoc #patientadvocacy #rarecancer #reproductivehealthThis media couldn't be displayed. See it on the original post. -
Verastem Oncology
@VerastemOncolog
We are honored to receive the 2026 Industry Innovation and Rare Impact Award from the @RareDiseases recognizing the first treatment specifically approved by the FDA for people who have KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), a rare ovarian cancer that is typically diagnosed at an advanced stage and recurs in over 80% of women with LGSOC.
Read more here about the award: rarediseases.org/nord-announces-the-2026-rare-impact-awar…
#rareimpactaward #rarediseases #lgsoc #lowgradeserousovariancancer $VSTM
National Organization for Rare Disorders (NORD)
@RareDiseases
For bringing new hope of treatment to adults with KRAS-mutated recurrent low-grade serous ovarian cancer (#lgsoc), a rare and historically overlooked #ovariancancer, NORD is proud to present a 2026 Industry Innovator #rareimpactaward to @VerastemOncolog.
In the lead up to #rarecancerday, more than 100 Verastem employees gathered as NORD CEO Pamela Gavin presented this award to CEO Dan Paterson and CSO Jonathan Pachter this week in celebration of this achievement, which was powered by years of collaboration and insights from patients and caregivers, investigators, clinicians, research teams, and patient advocacy organizations like the STAAR Low-Grade Serous Ovarian Cancer Foundation.
True innovation in #raredisease and rare #cancer takes all of us working together, and that was on display at Verastem. Alone we are rare. Together we are strong. -
Verastem Oncology
@VerastemOncolog
More than two-year median follow-up data from the RAMP 201 study of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (LGSOC) has been published in @gynoncjnls, the official journal of the @SGO_org.
Read the release here: investor.verastem.com/news-releases/news-release-details/…
#lgsoc #lowgradeserousovariancancer #cancerresearch #kras #precisiononcology $VSTM -
Verastem Oncology
@VerastemOncolog
A cancer diagnosis brings an overwhelming amount of information, and for many women living with low-grade serous ovarian cancer (LGSOC), conversations about biomarker testing can be difficult to absorb and process in the moment.
Our LGSOC advocacy partners, including Nicole Andrews, Chair of @STAAROC is dedicated to helping patients better understand topics like KRAS mutational testing and how clear communication can support more informed conversations about treatment options throughout their care journey.
#ovariancancerawarenessmonth #gynecologiccancerawarenessmonth #gcam #ovariancancer #lgsoc #patientadvocacy #rarecancerThis media couldn't be displayed. See it on the original post. -
Verastem Oncology
@VerastemOncolog
Late-breaking and seminal abstracts highlighting the RAMP 201 and RAMP 201J clinical trials, respectively, of avutometinib plus defactinib will be shared during oral presentations at the @IGCSociety2026 Annual Meeting.
Presentation details available here: investor.verastem.com/news-releases/news-release-details/…
#igcs2026 #lgsoc #kras $VSTM -
Verastem Oncology
@VerastemOncolog
Compelling new external control arm analysis of avutometinib plus defactinib versus standard-of-care treatment for low-grade serous ovarian cancer (LGSOC) will be presented during the Poster Rounds with the Professor session at the @IGCSociety 2026 Annual Meeting on Friday, October 2.
Read the abstract here: cslide.ctimeetingtech.com/igcs26/attendee/confcal/session…
#igcs2026 #lgsoc #kras $VSTM -
Verastem Oncology
@VerastemOncolog
Today, on the 3rd annual LGSOC Awareness Day, we're recognizing the power of community in helping people navigate life with low-grade serous ovarian cancer (LGSOC).
The LGSOC Resource Guide was developed to help make trusted information and support easier to find, bringing together resources from advocacy organizations across the ovarian and LGSOC cancer communities to a single destination for patients, care partners, and families.
Download the Guide from the LGSOC Awareness Day website: www.lgsocawarenessday.org/lgsocguide
@staarovarian @NotTheseOvaries Sandy Rollman Ovarian Cancer Foundation @ovarcome @ocrahope @NOCCNational @UniteforHER Sharsheret: The Jewish Breast & Ovarian Cancer Community @SHARECancerSupt @GYNCancer @WOCCnews
#lgsocawarenessday #lgsoc #ovariancancer #rarecancer #patientadvocacy -
Verastem Oncology
@VerastemOncolog
Verastem Oncology will host an investor event on Oct. 14, at 8:00 am ET to unveil new clinical data highlighting the best-in-class potential of VS-7375, an investigational potent and selective oral KRAS G12D (ON/OFF) inhibitor.
Read the full press release here: investor.verastem.com/news-releases/news-release-details/…
#kras #krasg12d $VSTM -
Verastem Oncology
@VerastemOncolog
Verastem’s Jonathan Pachter and Silvia Coma will take part in the @HansonWade @Undruggable RAS-Targeted Drug Development Summit next week in Boston, shaping discussions on novel combination strategies for targeting RAS-driven cancers.
Read the conference program: ras-drugdevelopment.com
#rasdrugdevelopment #krasg12d $VSTM -
Verastem Oncology
@VerastemOncolog
Our management team is looking forward to participating in the upcoming Wells Fargo Healthcare Conference, the Cantor Global Healthcare Conference, and the H.C. Wainwright Annual Global Investment Conference to discuss progress across Verastem's commercial product and pipeline programs.
Learn more about the fireside events and webcast details on our Events page: investor.verastem.com/events
$VSTM -
Verastem Oncology
@VerastemOncolog
September is Ovarian Cancer Awareness Month, a time to spotlight the experiences of those affected by ovarian cancer, including low-grade serous ovarian cancer (LGSOC).
Robin Cohen, Chief Executive Officer at the Sandy Rollman Ovarian Cancer Foundation reflects on the barriers that can impact timely diagnosis and the importance of helping patients feel heard throughout their journey.
#ovariancancerawarenessmonth #gynecologiccancerawarenessmonth #gcam #ovariancancer #lgsoc #patientadvocacy #rarecancerThis media couldn't be displayed. See it on the original post. -
Verastem Oncology
@VerastemOncolog
Today, @GalienFdn named Verastem Oncology and the first and only treatment approved for adults with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) a finalist in the Prix Galien USA 2026 Awards in the Best Product for Rare/Orphan Diseases category.
We share this recognition with the patients, families & investigators who helped make this progress possible.
Read more: www.prnewswire.com/news-releases/the-galien-foundation-an…
#prixgalien #lgsoc #kras #ovariancancer $VSTM -
Verastem Oncology
@VerastemOncolog
Today, we announced our second quarter 2026 financial results and shared our latest business updates. Read our press release to learn more about our commercial progress and updates on our RAS/MAPK pathway driven pipeline programs.
investor.verastem.com/news-releases/news-release-details/…
#verastemonc -
Verastem Oncology
@VerastemOncolog
Today, we announced that the first patient has been dosed in TARGET-D 203, our Phase 2 registration-directed study evaluating VS-7375 for in patients with KRAS G12D-mutated metastatic colorectal cancer.
With this milestone, all three TARGET-D registration-directed Phase 2 clinical trials across pancreatic (TARGET-D 201), and non-small cell lung cancers (TARGET-D 202) are actively enrolling patients.
Read more: investor.verastem.com/news-releases/news-release-details/…
#colorectalcancer #crc #kras #cancerresearch #clinicaltrials #raspathway $VSTM -
Verastem Oncology
@VerastemOncolog
We will be holding our Q2 earnings call on Thursday, August 6, 2026, at 4:30pm ET and we plan to share financial results and highlight recent business updates.
Read the details here: investor.verastem.com/news-releases/news-release-details/… $VSTM -
Verastem Oncology
@VerastemOncolog
Today, we announced that the first patient has been dosed in TARGET-D 202, our Phase 2 registration-directed study evaluating VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor for people with previously treated KRAS G12D-mutated advanced non-small cell lung cancer. Read more: investor.verastem.com/news-releases/news-release-details/… #lungcancer #nsclc #kras #cancerresearch #clinicaltrials #raspathway $VSTM
-
Verastem Oncology
@VerastemOncolog
For years, #kras #g12d was considered one of the most challenging targets in precision oncology. We believe that achieving durable and selective control of KRAS G12D signaling, and ultimately delivering the greatest benefit for patients, requires moving beyond single-state inhibition.
In a sponsored article in STAT, our CSO, Jonathan Pachter, shares the scientific rationale and differentiation behind our approach to VS-7375, our investigational dual ON/OFF KRAS G12D inhibitor.
Read the article: www.statnews.com/sponsor/2026/07/21/redefining-how-kras-g… $VSTM -
Verastem Oncology
@VerastemOncolog
Today, we provided a preliminary update and progress from our ongoing TARGET-D 101 Phase 1/2 trial for VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor, across multiple tumor types, including metastatic pancreatic cancer, metastatic colorectal cancer and advanced non-small cell lung cancer.
This is another step forward to bring VS-7375 to patients with KRAS G12D-mutated cancers.
Read more here: investor.verastem.com/news-releases/news-release-details/…
#krasg12d #clinicaltrials #pancreaticcancer #pdac #nsclc #crc #colorectalcancer #cancerresearch #raspathway #verastemonc $VSTM -
Verastem Oncology
@VerastemOncolog
Pancreatic cancer remains one of the most difficult cancers to treat, with limited therapeutic advances and a five-year survival rate of approximately 3% for metastatic disease. More than 90% of pancreatic tumors harbor KRAS mutations with KRAS-driven signaling and FAK-mediated resistance pathways a central driver of disease progression.
Today, we announced positive updated results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer. These findings provide encouraging evidence that combined RAF/MEK and FAK inhibition alongside standard-of-care chemotherapy may help address key mechanisms of resistance in pancreatic cancer.
We are especially grateful to the patients, families, and investigators who made this research possible, and to the @PanCAN who selected Verastem Oncology in 2022 to receive the inaugural PanCAN Therapeutic Accelerator Award, which helped support the evaluation of this novel treatment approach and fostered important collaboration between Verastem and the pancreatic cancer research community.
Read more here: investor.verastem.com/news-releases/news-release-details/…
#pancreaticcancer #pdac #kras #oncologyresearch #cancerresearch #clinicaltrials #raspathway #pancan $VSTM -
Verastem Oncology
@VerastemOncolog
Today, we announced that the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor, in patients with KRAS G12D-mutated metastatic pancreatic cancer.
TARGET-D 201 is evaluating VS-7375 both as monotherapy and in combination with cetuximab in the second-line setting and an additional cohort evaluating the combination in the frontline setting.
With FDA Fast Track designation previously granted for VS-7375 in KRAS G12D-mutated advanced or metastatic pancreatic cancer, this milestone represents an important step in advancing the development of a potential new treatment option for patients with this disease.
We are grateful to the patients, caregivers, investigators, and study teams participating in the TARGET-D 201 trial.
Read more here: www.businesswire.com/news/home/20260616690184/en/Verastem…
#pancreaticcancer #pdac #krasg12d #oncologyresearch #cancerresearch #clinicaltrials #raspathway $VSTM -
Verastem Oncology
@VerastemOncolog
We are looking forward to hosting an investor conference call and webcast to share progress and updated preliminary data from the Phase 1/2 TARGET-D 101 VS-7375 oral KRAS G12D (ON/OFF) dose escalation and dose expansion trial evaluating VS-7375 alone and in combination in patients with KRAS G12D-mutated advanced solid tumors.
A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, investor.verastem.com/events.
investor.verastem.com/news-releases/news-release-details/…
$VSTM -
Verastem Oncology
@VerastemOncolog
Today, we are pleased to announce that the U.S. FDA has granted Fast Track designation (FTD) for VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor for the treatment of KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
FDA’s FTD program helps to advance the development and review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.
The FDA previously granted FTD to VS-7375 for the treatment of KRAS G12D-mutated locally advanced or metastatic pancreatic cancer, underscoring the urgent need for new treatment options for patients with KRAS G12D-mutated cancers, including NSCLC and pancreatic cancer.
Read the press release: investor.verastem.com/news-releases/news-release-details/…
Learn more about VS-7375 on our web site: www.verastem.com/our-science/kras-g12d-inhibition/
#nsclc #kras #krasg12d $VSTM -
Verastem Oncology
@VerastemOncolog
“A diagnosis of low-grade serous ovarian cancer can feel overwhelming… patients are often asked to make life-altering decisions in just days,” says Emily Campbell, Executive Director and Co-Founder of @NotTheseOvaries
National Cancer Survivors Day and National Cancer Survivors Month is an important reminder that no two survivorship journeys are alike and that access to clear information, support, and community makes a difference at every step, from diagnosis and beyond.
The LGSOC Resource Guide, available at lgsocawarenessday.org, was created to help patients navigate diagnosis, treatment decisions, and survivorship, helping to connect them with resources and community when they need it most.
Read more: investor.verastem.com/news-releases/news-release-details/…
#lgsoc #ovariancancer #patientadvocacy #rarecancer #nationalcancersurvivorsday #ncsd2026 #cancersurvivorsday -
Verastem Oncology
@VerastemOncolog
Our management team is looking forward to participating in the upcoming Jefferies Global Healthcare Conference to discuss our commercial and pipeline programs.
Learn more about fireside event and webcast details on our Events page: investor.verastem.com/events
$VSTM -
Verastem Oncology
@VerastemOncolog
Today, we announced the appointment of Michael P. Bailey to our Board of Directors. Michael is an accomplished biopharmaceutical executive with deep expertise across the full product lifecycle, and we look forward to drawing on his insights as we enter our next phase of growth. $VSTM #boardappointment
Read the press release: investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
Patient stories are a critical part of advancing understanding in ovarian cancer, including low-grade serous ovarian cancer (LGSOC), a rare type of this disease.
In the latest episode of @NOCCNational Teal Talk Podcast, Emily Campbell, executive director and co-founder of @NotTheseOvaries shares her experience navigating a borderline ovarian tumor diagnosis at a young age and the challenges of misdiagnosis, treatment decisions, and uncertainty.
By supporting initiatives like the Teal Talk Podcast, we want to help these conversations continue reaching and informing a broader audience.
Listen to the podcast: ovarian.org/programs-and-resources/nocc-online-education-…
#knowovarian #tealtalkpodcast #lgsoc #patientadvocacy -
Verastem Oncology
@VerastemOncolog
Our management team is looking forward to participating in the upcoming RBC Global Healthcare Conference and HCW 4th Annual BioConnect Investor Conference where we will be updating the investor community about our commercial launch and pipeline programs.
Learn more about fireside event and webcast details on our Events page: investor.verastem.com/events $VSTM -
Verastem Oncology
@VerastemOncolog
“For many people living with LGSOC, finding clear, relevant information can be an ongoing challenge, especially given how different this disease is, including how it responds to treatment….” says Nicole Andrews, chair of @STAAROC.
Because LGSOC behaves differently from other ovarian cancers, patients often struggle to find information that reflects their specific experience. The LGSOC Resource Guide – available at lgsocawarenessday.org - helps address this gap by bringing together trusted, disease-specific resources so patients and families can make more informed decisions about their care.
Read more: investor.verastem.com/news-releases/news-release-details/…
#lgsoc #ovariancancer #patientadvocacy #rarecancer -
Verastem Oncology
@VerastemOncolog
On World Ovarian Cancer Day, we’re reflecting alongside patient advocacy groups including @STAAROC, @NotTheseOvaries, Sandy Rollman Ovarian Cancer Foundation, and @NOCCNational on a milestone that changed the treatment landscape: the first-ever treatment specifically for KRAS-mutated recurrent LGSOC approved by the FDA.
In a rare disease where 80% of patients experience recurrence, progress like this helps redefine what’s possible — while reinforcing the need for continued momentum in research, treatment, and support.
#worldovariancancerday #lgsoc #ovariancancerawareness #rarecancer $VSTMThis media couldn't be displayed. See it on the original post. -
Verastem Oncology
@VerastemOncolog
On World Ovarian Cancer Day, the LGSOC Resource Guide - available at www.lgsocawarenessday.org - launches to support people living with low-grade serous ovarian cancer (LGSOC), along with caregivers and advocates.
LGSOC is rare, often underrecognized, and difficult to navigate—patients face delays in diagnosis and limited access to relevant information. This guide brings together trusted, disease-specific resources in one place.
Read more: investor.verastem.com/news-releases/news-release-details/…
#worldovariancancerday #lgsoc #rarecancer -
Verastem Oncology
@VerastemOncolog
Today, we announced our first quarter 2026 financial results and shared our latest business updates. Read our press release to learn more about our launch progress and updates on our RAS/MAPK pathway driven pipeline programs.
investor.verastem.com/news-releases/news-release-details/…
$VSTM -
Verastem Oncology
@VerastemOncolog
Congratulations to @ovarcome and @Ovations4cure for hosting two incredible events dedicated to awareness and support of the ovarian cancer community. We were grateful to be involved and attend the events.
#patientadvocacy #lgsoc # OvarianCancer $VSTM -
Verastem Oncology
@VerastemOncolog
Today, we launched the Reimagine Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) campaign to raise awareness of the first and only treatment specifically FDA approved for KRAS-mutated recurrent LGSOC and to help HCPs rethink how they support their patients and help patients reimagine what may be possible at and beyond first recurrence.
Read more: investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
Today, we announced that we will hold our first quarter earnings call on Thursday, May 7, 2026, at 4:30pm ET to share financial results and highlight recent business updates. Read more: investor.verastem.com/news-releases/news-release-details/…
$VSTM #verastemonc -
Verastem Oncology
@VerastemOncolog
New two-year median follow-up data to be presented today during the first oral plenary session at the @SGO_org 2026 Annual Meeting on Women’s Cancer.
New follow-up data consistent with the primary analysis from the RAMP 201 clinical trial, which evaluated avutometinib in combination with defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC), will be presented. The RAMP 201 trial results served as the basis for FDA accelerated approval of the combination therapy.
Read more about the study findings in our press release: investor.verastem.com/news-releases/news-release-details/…
$VSTM #verastemonc #sgo2026 #lgsoc #kras -
Verastem Oncology
@VerastemOncolog
We’re headed to San Juan, Puerto Rico for the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.
Stop by our new booth, #608 to learn about our pipeline across women's cancers and other cancers driven by the RAS/MAPK pathway.
While you are there, experience our new commercial campaign focused on reimagining what's possible for patients with recurrent KRAS-mutated LGSOC.
$VSTM #verastemonc #sgo2026 #lgsoc #kras -
Verastem Oncology
@VerastemOncolog
We’re looking forward to attending the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancer in San Juan, Puerto Rico, and connecting with colleagues who share our commitment to advancing care in low-grade serous ovarian cancer, or LGSOC.
Read more about our planned oral and poster presentations: investor.verastem.com/news-releases/news-release-details/…
If you are attending the meeting, let's connect at our booth, #608
$VSTM #verastemonc #sgo2026 #lgsoc #kras -
Verastem Oncology
@VerastemOncolog
At this year's AACR Meeting 2026, we will be sharing preclinical data for our highly differentiated investigational and potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, VS-7375 from other RAS inhibitors.
Read our release for more details: investor.verastem.com/news-releases/news-release-details/…
$VSTM #verastem #aacr26 #kras -
Verastem Oncology
@VerastemOncolog
Our management team is looking forward to participating in the upcoming 2026 Jefferies Biotech on the Beach Summit and Barclays 28thAnnual Global Healthcare Conference where we will be updating the investor community about our commercial launch and pipeline programs.
$VSTM #verastemonc -
Verastem Oncology
@VerastemOncolog
Today, we announced our fourth quarter and year end 2025 financial results and shared our latest business updates. Read our press release to learn more about our launch progress and updates on our RAS/MAPK pathway driven pipeline programs.
investor.verastem.com/news-releases/news-release-details/…
$VSTM #verastemonc -
Verastem Oncology
@VerastemOncolog
Today, on @rarediseaseday we recognize the millions of people worldwide living with rare diseases. Importantly, we also pause to specifically honor the low-grade serous ovarian cancer (LGSOC) community. For women diagnosed with LGSOC, the journey from diagnosis through treatment and recurrence has been marked by limited treatment options, diagnosis delays, and uncertainty.
We are grateful to have worked alongside patients, investigators, and advocates to bring forward the first approved medicine specifically for KRAS-mutated recurrent LGSOC. This progress reflects years of collaboration with those committed to advancing care in this rare disease.
We remain focused on building on this progress and continuing to pursue innovation for women living with recurrent LGSOC.
$VSTM #verastemonc #rarediseaseday #lgsoc #ovariancancer #kras -
Verastem Oncology
@VerastemOncolog
We’re looking forward to attending the @AACR Special Conference in Cancer Research: RAS Oncogenesis and Therapeutics.
On Saturday, March 7, during Plenary Session #5, on RAS Clinical Trials and New Therapies, Chief Scientific Officer, Jonanthan Pachter, Ph.D., will share some recent updates on our investigational VS-7375 candidate, a selective, oral, and potential best-in-class KRAS G12D (ON/OFF) inhibitor targeted to address KRAS G12D-mutated cancers.
#aacr26 #raspathway #kras -
Verastem Oncology
@VerastemOncolog
Today, we announced that we will hold our Fourth Quarter and Full Year 2025 earnings call on Wednesday, March 4, 2026, at 4:30 pm ET.
Read more: investor.verastem.com/news-releases/news-release-details/…
$VSTM #verastemonc -
Verastem Oncology
@VerastemOncolog
Almost a third of all cancers in patients are associated with mutations of the RAS family of genes, which includes KRAS, NRAS, and HRAS. There are other oncogenes, including EGFR and BRAF, that also activate the RAS pathway—meaning an even higher percentage of cancers depend on this pathway for growth and survival.
As we recognize World Cancer Day, we remain committed to advancing research and developing new therapeutic approaches specifically for patients with RAS/MAPK pathway-driven cancers who often face more aggressive disease and poorer outcomes than those without RAS pathway mutations.
Learn more about our clinical trials: www.verastem.com/clinical-trials/
$VSTM #verastemonc #worldcancerday2026 -
Verastem Oncology
@VerastemOncolog
Our management team will participate in the upcoming Guggenheim Emerging Outlook: Biotech Summit in February. Learn more about fireside event and webcast details on our Events page: investor.verastem.com/events
$VSTM #verastemonc -
Verastem Oncology
@VerastemOncolog
Today we shared key updates on our commercial launch and 2026 strategic priorities for our novel portfolio targeting RAS/MAPK pathway-driven cancers.
Read more in our press release: investor.verastem.com/news-releases/news-release-details/…
$VSTM #verastemonc -
Verastem Oncology
@VerastemOncolog
January is National Pancreatic Cancer Clinical Trials Awareness Month. At Verastem, we are pursuing different approaches to target key drivers of the disease, including targeting RAS directly with our investigational VS-7375 candidate, a potential best-in-class KRAS G12D (ON/OFF) inhibitor, which could address ~40% of pancreatic cancers.
🔗 verastem.com/clinical-trials
$VSTM #pancreaticcancer #clinicaltrials #kras #nationalpancreaticcancerclinicaltrialsawarenessmonth -
Verastem Oncology
@VerastemOncolog
This weekend at #jpm, @danwpaterson, President & CEO, will speak at the @LongwoodLeaders #sanfranciscoceo meeting, sharing perspectives on building effective global partnerships. Learn more: www.longwoodhealthcareleaders.com/sfceo
#verastemonc $VSTM -
Verastem Oncology
@VerastemOncolog
Our management team is participating in the 8th Annual Evercore Healthcare Conference in December. Read our press release to learn about the event and webcast details: investor.verastem.com/news-releases/news-release-details/… $VSTM
#verastemonc -
Verastem Oncology
@VerastemOncolog
Our management team will participate in multiple investor conferences in November. Read our press release to learn about the events and webcast details: investor.verastem.com/news-releases/news-release-details/… $VSTM
#verastemonc -
Verastem Oncology
@VerastemOncolog
Today, we announced our third quarter 2025 financial results and shared our latest business updates. Read our press release to learn more about our launch progress and updates on our pipeline programs. investor.verastem.com/news-releases/news-release-details/… $VSTM
-
Verastem Oncology
@VerastemOncolog
Today we announced a preliminary update on our Phase 1/2a clinical trial evaluating VS-7375, a potential best-in-class oral #kras #g12d (ON/OFF) inhibitor in patients with previously treated advanced KRAS G12D mutant solid tumors $VSTM #pancsm investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Today, we announced that we will hold our Q3 earnings call on Tuesday, November 4, 2025, at 8:00 am ET. Read more: investor.verastem.com/news-releases/news-release-details/…
$VSTM #verastemonc -
Verastem Oncology
@VerastemOncolog
Our partner, GenFleet Therapeutics, shared updated clinical data in advanced #pancreaticcancer at #esmo25 today from their ongoing Phase 1/ 2 study of their investigational agent, GFH375, an oral KRAS G12D (ON/OFF) inhibitor. investor.verastem.com/news-releases/news-release-details/…
$VSTM #kras #pancsm #g12d -
Verastem Oncology
@VerastemOncolog
Our management team will be participating in multiple investor conferences in September. Read our press release to learn about the events and webcast details: investor.verastem.com/news-releases/news-release-details/… $VSTM
-
Verastem Oncology
@VerastemOncolog
Today, we announced updated safety and efficacy data from our partner GenFleet Therapeutics’ study in China of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, known as VS-7375 outside of China, in advanced NSCLC patients. $VSTM #lcsm #wclc25 Read more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Today, we announced our second quarter 2025 financial results and shared our latest business updates. Read our press release to learn more about our launch progress and updates on our pipeline programs. investor.verastem.com/news-releases/news-release-details/…
$VSTM -
Verastem Oncology
@VerastemOncolog
Today, we announced that we will be holding our Q2 earnings call on Thursday, August 7, at 4:30 pm ET.
Read more: investor.verastem.com/news-releases/news-release-details/…
$VSTM -
Verastem Oncology
@VerastemOncolog
Today, we announced that we have received Fast Track Designation from the FDA for VS-7375, our investigational KRAS G12D (ON/OFF) inhibitor, for the treatment of 1L & 2L locally advanced or metastatic #pancreaticcancer.
investor.verastem.com/news-releases/news-release-details/…
$VSTM #kras -
Verastem Oncology
@VerastemOncolog
Today, we shared that the primary analysis from the Phase 2 RAMP 201 clinical trial has now been published in the Journal of Clinical Oncology.
Read more about the publication here: investor.verastem.com/news-releases/news-release-details/…
$VSTM #kras #lgosc -
Verastem Oncology
@VerastemOncolog
The FRAME trial, the first-in-human study to evaluate avutometinib in combination with defactinib in patients with LGSOC, was recently published in @NatureMedicine .
Read about the updated results here: link to PR
$VSTM #lgsoc #cancerresearch #kras -
Verastem Oncology
@VerastemOncolog
Today, we announced the dosing of the first patient with VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, in the U.S.
#verastemonc #g12d #kras $VSTM -
Verastem Oncology
@VerastemOncolog
Our management team will be participating in a fireside chat at Jefferies Global Healthcare Conference tomorrow. We will recap our latest data updates from #asco25 and discuss our future clinical development plans. $VSTM
-
Verastem Oncology
@VerastemOncolog
#breakingnews – Our partner GenFleet Therapeutics presented updated data this morning at #asco25 for their study of GFH375 (VSH-7375), an oral #kras #g12d (ON/OFF) inhibitor.
Read more: investor.verastem.com/news-releases/news-release-details/… $VSTM -
Verastem Oncology
@VerastemOncolog
At #asco25, we will be hosting an R&D investor webcast to review RAMP 205 and updated data from the VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, study in China by partner GenFleet Therapeutics.
Read our press release to learn more: investor.verastem.com/news-releases/news-release-details/…
#vstm -
Verastem Oncology
@VerastemOncolog
Today, we announced positive updated results from our RAMP 205 clinical trial in first-line metastatic #pancreaticcancer. Read our release to learn more: investor.verastem.com/news-releases/news-release-details/… $VSTM #asco25
-
Verastem Oncology
@VerastemOncolog
Today, we announced our Q1 2025 financial results and latest business updates. Read our press release to learn more about our recent FDA approval, steps taken to strengthen our balance sheet, and how we have advanced our novel, potential best-in-class G12D clinical program. $VSTM
-
Verastem Oncology
@VerastemOncolog
Our management team will be participating in multiple investor conferences this month. Read our press release to learn about the events and webcast details: investor.verastem.com/news-releases/news-release-details/… $VSTM
-
Verastem Oncology
@VerastemOncolog
At #asco25, we will be sharing updated data from RAMP 205, our first-line metastatic #pancreaticcancer study. The abstract is under embargo until May 22 and we will be reporting additional data at that time. $VSTM
-
Verastem Oncology
@VerastemOncolog
Don’t miss our multiple oral and poster presentations at this year’s @SGO_org Annual Meeting on Women’s Cancer.
See you there!
#multiplyyourimpact #sgo25 $VSTM -
Verastem Oncology
@VerastemOncolog
On February 5th, we’ll be participating in the Guggenheim SMID Cap Biotech Conference. A live webcast of our session will be available on our website. $VSTM
-
Verastem Oncology
@VerastemOncolog
Today, we shared our 2025 outline of strategic priorities and milestones for our novel pipeline, with hopes to advance new medicines for patients with RAS/MAPK pathway-driven cancers. $VSTM
-
Verastem Oncology
@VerastemOncolog
Today, we announced that we have exercised our option early to license VS-7375, a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor currently in Phase 1 development in China by partner GenFleet Therapeutics. $VSTM #g12d #kras
-
Verastem Oncology
@VerastemOncolog
Today, we announced a new credit facility and equity investment with Oberland Capital and a strategic commercialization collaboration with @IQVIA_Global $VSTM #lgsoc
-
Verastem Oncology
@VerastemOncolog
The FDA has accepted and granted Priority Review to our NDA for our investigational combination of avutometinib and defactinib for the treatment of recurrent KRAS mutant Low-Grade Serous Ovarian Cancer. Read more: investor.verastem.com/news-releases/news-release-details/… $VSTM #lgsoc
-
Verastem Oncology
@VerastemOncolog
Update on our RAMP 203 trial with Amgen: We're evaluating investigational combo of avutometinib + sotorasib +/- defactinib in KRAS G12C mutant NSCLC. Preliminary data on the triplet combo looks encouraging. We look forward to sharing more at a medical meeting in 2H 2025. $VSTM
-
Verastem Oncology
@VerastemOncolog
Next week we will be participating in a fireside chat at the 7th Annual @EvercoreISI HealthCONx Conference on Dec. 3rd. A live webcast of our chat will be available on our website. Learn more: investor.verastem.com/news-releases/news-release-details/… $VSTM
-
Verastem Oncology
@VerastemOncolog
With more than 90% of #pancreaticcancers harboring a KRAS mutation, we’re researching innovative ways to target the RAS/MAPK-pathway and other resistance mechanisms to improve outcomes for patients with pancreatic cancer.
#worldpancreaticcancerday #wpcd #wpcd2024 -
Verastem Oncology
@VerastemOncolog
Today, we’re reporting our Q3 financial results and recent business progress, including completing our rolling NDA submission of our investigational combination of avutometinib plus defactinib for patients with recurrent KRAS mutant LGSOC. investor.verastem.com/news-releases/news-release-details/… $VSTM
-
Verastem Oncology
@VerastemOncolog
We have completed our rolling NDA to the U.S. FDA for the investigational and potential first-in-class combination of avutometinib plus defactinib for recurrent KRAS mutant LGSOC. $VSTM #lgsoc
-
Verastem Oncology
@VerastemOncolog
Exciting news today as we shared updated data from our Phase 2 RAMP 201 trial, and we work to complete our rolling NDA submission in recurrent KRAS mutant #lgsoc. $VSTM #igcs2024
-
Verastem Oncology
@VerastemOncolog
The RAMP 201 study in recurrent #lgsoc, is one of the largest studies ever conducted in this rare #ovariancancer. Later today, we will share detailed findings at the @IGCSociety Annual Meeting. #igcs2024
-
Verastem Oncology
@VerastemOncolog
Today, we announced positive updated RAMP 201 data for our investigational combination being evaluated in recurrent #lgsoc. These data are being presented at the @IGCSociety meeting later today. #igcs2024.
$VSTM #ovariancancer -
Verastem Oncology
@VerastemOncolog
Going to @IGCSociety meeting in Dublin? Visit Verastem at Booth #22 to learn more about our clinical research in the RAS/MAPK pathway.
#igsc2024 #kras #gynonc $VSTM -
Verastem Oncology
@VerastemOncolog
Today for World Mental Health Day we’re elevating how a diagnosis of LGSOC, can take a toll on the mental health and quality of life of people diagnosed with this cancer and their families
#worldmentalhealthday #lgsoc #cancermentalhealth -
Verastem Oncology
@VerastemOncolog
Today, we announced the details for the oral presentation of the late-breaking abstract of mature RAMP 201 data at the @IGCSociety 2024 annual meeting.
#igsc2024 #kras #ras #lgsoc -
Verastem Oncology reposted
National Ovarian Cancer Coalition
@NOCCNational
At 38, Rachel P. was diagnosed with Stage 3A low-grade serous ovarian cancer in 2020. Today, she pays it forward by distributing care packages and mentoring newly diagnosed survivors. 💙#qualityoflife #nocam2024 #knowovarian #ovariancancerawareness
-
Verastem Oncology
@VerastemOncolog
Today at the RAS-Targeted Drug Discovery and Development Summit we will share an overview of the #ras targeting space as well as a few of our own approaches in targeting RAS/MAPK pathway driven cancers. #cancerresearch
-
Verastem Oncology
@VerastemOncolog
This weekend we will be lacing up our shoes for the @NOCC_National Together In Teal walk in Boston to end #ovariancancer. It’s not too late to join us! #lgsoc #ovariancancerawarenessmonth #knowovarian
-
Verastem Oncology
@VerastemOncolog
This past weekend, we presented at the @PanCan Scientific Summit in Boston to provide an overview of our ongoing RAMP 205 study in 1L metastatic #pancreaticcancer and progress with the RAF/MEK translational science working group. #pancsm
-
Verastem Oncology
@VerastemOncolog
Throughout #ovariancancerawarenessmonth, we are sharing educational resources, so no one feels lost in the search for knowledge about #lgsoc, a rare ovarian cancer.
-
Verastem Oncology
@VerastemOncolog
We’ll be participating and presenting at the 2024 Cantor Global Healthcare Conference on Wednesday, Sept. 18. A live webcast of our fireside chat will be available on our website. investor.verastem.com/news-releases/news-release-details/… $VSTM
-
Verastem Oncology
@VerastemOncolog
We’re headed to Dublin in October to share the mature data from our Phase 2 RAMP 201 clinical trial at the @IGSCSociety annual meeting.
#igcs2024 $VSTM -
Verastem Oncology
@VerastemOncolog
It’s not too late to participate in #lgsoc Awareness Day! Help raise awareness by sharing a social media post using the hashtag #lgsocawarenessday and invite others to learn more about LGSOC
#ovariancancer #verastemonc #ovariancancerawarenessmonth -
Verastem Oncology
@VerastemOncolog
Thank you @FiercePharma for shining a light on the inaugural Low-Grade Serous Ovarian Cancer Awareness Day (#lgsocawarenessday). Read the full story here: www.fiercepharma.com/marketing/verastem-sets-first-awaren…
-
Verastem Oncology
@VerastemOncolog
For the inaugural #lgsocawarenessday, Amanda is sharing her story of coping with recurrence. 80% of people treated for LGSOC will have their cancer come back.
#lgsoc #verastemonc -
Verastem Oncology reposted
World Ovarian Cancer Coalition
@WOCCnews
🎗️ Today is the first-ever LGSOC Awareness Day! LGSOC (Low-Grade Serous Ovarian Carcinoma) is a rare ovarian cancer, often diagnosed late due to subtle symptoms like bloating and fatigue. Let’s spread the word and raise awareness today! #lgsocawarenessday #lgsoc
-
Verastem Oncology
@VerastemOncolog
Join us today as we observe the inaugural Low-Grade Serous Ovarian Cancer Awareness Day (#lgsocawarenessday).
#lgsoc #ovariancancer #verastemonc #ovariancancerawarenessmonth #lgsocawarenessday -
Verastem Oncology
@VerastemOncolog
Together with @STAAROC we are establishing the inaugural Low-Grade Serous Ovarian Cancer Awareness Day (LGSOC Awareness Day) on September 9. Join us: www.staaroc.org/lgsoc-awareness-day.html #lgsocawarenessday #lgsoc #ovariancancer #ovariancancerawarenessmonth
-
Verastem Oncology
@VerastemOncolog
Today, we announced our Q2 2024 financial results and highlighted recent progress. $VSTM investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
The FDA has granted ODD to our investigational combo of avutometinib, a RAF/MEK clamp, & defactinib, a selective FAK inhibitor, for the treatment of #pancreaticcancer. In June, we shared positive initial interim results from our ongoing RAMP 205 trial in 1L mPDAC. $VSTM #pancsm
-
Verastem Oncology reposted
PanCAN
@PanCAN
We were encouraged to see @VerastemOncolog, recipients of PanCAN’s Therapeutic Accelerator Award, present the initial data for their RAMP 205 study at #asco24. The goal for this award is to create better therapies for #pancreaticcancer and bring them to patients more quickly. We're thrilled to partner with Verastem to advance progress for this disease!
-
Verastem Oncology reposted
BiotechTV
@BiotechTV
ASCO 2024: @VerastemOncolog's CEO comments on a volatile week and #asco24 data in pancreatic cancer. $VSTM
Full video: www.biotechtv.com/post/verastem-oncology-june-1-2024This media couldn't be displayed. See it on the original post. -
Verastem Oncology reposted
Dr. Despina Siolas, MD, PhD
@DrDespina123
Excited about our poster #asco24 looking at #ras #mek clamp #targetedtherapy with chemo for #pancreaticcancer cancer patients @DrMhidalgo @ASCO @VerastemOncolog @WCMGIcancer @WCM_MeyerCancer
-
Verastem Oncology
@VerastemOncolog
Headed to #asco24? Stop by our poster reporting initial interim results from our RAMP 205 study evaluating avutometinib + defactinib + SOC in first-line metastatic #pancreaticcancer. #pancchat
-
Verastem Oncology
@VerastemOncolog
We are initiating our rolling NDA submission in KRAS mutant recurrent low-grade serous ovarian cancer (#lgsoc) for our investigational combination of avutometinib and defactinib. #ovariancancer
-
Verastem Oncology
@VerastemOncolog
We announced the initial interim safety & efficacy results from the ongoing RAMP 205 trial evaluating avutometinib plus defactinib with gemcitabine and Nab-paclitaxel in the 1L in patients with metastatic #pancreaticcancer. #pancchat #asco24
-
Verastem Oncology
@VerastemOncolog
Today, we announced our Q1 2024 financial results and highlighted recent progress. $VSTM
-
Verastem Oncology
@VerastemOncolog
By 2050 incidence of #ovariancancer is set to rise by 55%. In the absence of a screening test, it is important to note the signs and symptoms and to seek help if you have any concerns. #nowomanleftbehind #wocd2024 @OvCancerDay
-
Verastem Oncology
@VerastemOncolog
Today, for World Ovarian Cancer Day, we come together to help raise awareness, support education, and shed a light on rare forms of ovarian cancers, such as low-grade serous ovarian cancer (#lgsoc). @OvCancerDay #nowomanleftbehind #wocd2024
-
Verastem Oncology
@VerastemOncolog
We will be participating in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 14, 2024. The live audio webcast will be available on our website. $VSTM
-
Verastem Oncology
@VerastemOncolog
Thank you to the @NOCC_national for sharing with our employees the incredible work you do every day to support people living with #ovariancancer and their loved ones/caregivers. #knowovarian
-
Verastem Oncology
@VerastemOncolog
We are at the @Oncologynursing's 2024 Annual Congress meeting. Stop by booth #3072 in the Learning Hall to learn more about our clinical trials for low-grade serous ovarian cancer (#lgsoc), pancreatic cancer, and NSCLC. #onscongress
-
Verastem Oncology
@VerastemOncolog
The KRAS G12D mutation is the most prevalent #kras mutation across human cancers w/ no FDA-approved treatments. For the first time with partner GenFleet we will share preclinical data of GFH375/VS-7375, a potent & selective oral KRAS G12D (ON/OFF) inhibitor at #aacr24
-
Verastem Oncology
@VerastemOncolog
Our CEO Dan Paterson recently sat down with
@PharmaVoice and shared how we are focused on bringing new treatments to address the unmet needs in RAS-mediated cancers, such as #lgsoc. www.pharmavoice.com/news/verastem-oncology-ceo-paterson-k… -
Verastem Oncology
@VerastemOncolog
Tomorrow is #nationaldoctorsday, we’re sharing @LUNGevity's #noonemissed HCP site, created to aid doctors in guiding non-small cell #lungcancer patients towards comprehensive #biomarkertesting & finding an optimal treatment plan: no1missed.org/3T8otox. Thank you #doctors! #lcsm
-
Verastem Oncology
@VerastemOncolog
Meet Shanta Peinado, a Medical Science Liaison who spends her time fostering relationships with opinion leaders and aiding our clinical trials through education and outreach. #verastemonc
-
Verastem Oncology
@VerastemOncolog
While the @SGO_Org Annual Meeting may be over, findings presented from our #lgsocpatientimpactsurvey remain timely. Addressing #lgsoc doesn't end with treatment but includes holistic support to ease the burden placed on patients investor.verastem.com/news-releases/news-release-details/… #sgomtg #cancer
-
Verastem Oncology
@VerastemOncolog
Thank you, Nick Paul Taylor @FiercePharma for shedding light on the importance of raising awareness for rare cancers like #lgsoc, as evidenced by recent #lgsocpatientimpactsurvey findings with medical leaders like Dr. Charlotte Sun and Dr. David Gershenson
www.fiercepharma.com/marketing/verastem-fda-filing-immine… -
Verastem Oncology
@VerastemOncolog
87% of surveyed patients w/ #lgsoc fear making long-term plans. Results from #lgsocpatientimpactsurvey at #sgomtg highlight the impact of LGSOC on patients' lives and the need for comprehensive support and treatment.
investor.verastem.com/news-releases/news-release-details/…
#powerofsharedpurpose -
Verastem Oncology
@VerastemOncolog
Attending @SGO_Org's Annual Meeting on Women's Cancer? Stop by our Booth 420 to learn more about our pipeline and advancements in #lowgradeserous #ovariancancer or #lgsoc.
#sgomtg #powerofsharedpurpose -
Verastem Oncology
@VerastemOncolog
Today, we announced our Q4/FY23 financial results and highlighted our progress, including initiating a confirmatory Phase 3 trial evaluating avutometinib and defactinib in low-grade serous ovarian cancer. $VSTM #lgsoc #cancerresearch
Learn more: investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
With multiple oral presentations at this year's @SGO_Org's Annual Meeting on Women's Cancer, we continue to highlight insights into #lgsoc from treatment and patient well-being perspectives.
Learn more: investor.verastem.com/news-releases/news-release-details/…
#sgomtg #powerofsharedpurpose -
Verastem Oncology
@VerastemOncolog
Today on #internationalwomensday and every day, we honor the resilience and strength of women worldwide. We are committed to illuminating pathways of hope and healing, particularly in RAS pathway-driven cancers affecting women, including #lgsoc, gynecological cancers and more.
-
Verastem Oncology
@VerastemOncolog
Today @US_FDA granted Orphan Drug Designation to avutometinib alone or in combination with defactinib for #lowgradeserous #ovariancancer, reinforcing our commitment to deliver new treatment options for the more than 6,000 US women affected by #lgsoc.
investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
This year at #aacr24 we will be sharing 5 preclinical data presentations, including for the first time with our partner GenFleet Therapeutics, anti-tumor efficacy data from GFH374/VS-7375, a KRAS G12D (ON/OFF) inhibitor. #rasmutations
Learn more: investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
2/3 of American women feel they have no control over their ovarian health.
This is shocking – women point to the need for more patient education when it comes to their #lowgradeserous #ovariancancer or #lgsoc.
To learn more visit: www.verastem.com/patients-and-advocacy/ -
Verastem Oncology
@VerastemOncolog
We are committed to supporting research offering breakthrough cancer therapy to patients so that no one, including those with rare diseases like #lowgradeserous #ovariancancer #lgsoc, runs out of treatment options. #diseaseday #rarediseases
-
Verastem Oncology
@VerastemOncolog
The #lgsocpatientimpactsurvey w/ @HarrisPoll reveals U.S. women aren’t prioritizing their ovarian health & awareness about ovarian cancer, including rare form #lgsoc. Find survey results & info on treating & managing this disease www.verastem.com/patients-and-advocacy/
-
Verastem Oncology
@VerastemOncolog
Our groundbreaking survey of patients with #lgsoc reveals that <1 in 5 U.S. women feel knowledgeable about ovarian cancer. Let’s Talk About LGSOC offers a place for patients, like Ellie, and caregivers to learn more about this rare cancer.
Learn more:
www.verastem.com/patients-and-advocacy/ -
Verastem Oncology
@VerastemOncolog
Verastem Oncology will be attending the @IASLC 2024 Targeted Therapies of Lung Cancer Meeting #ttlc24. We are looking forward to connecting with fellow researchers, sharing knowledge, and contributing to the progress in lung cancer, including #nsclc.
iaslc.eventsair.com/ttlc24/ -
Verastem Oncology
@VerastemOncolog
Meet Tom Macdonald, part of the Finance Team at Verastem since 2019. When asked to describe Verastem in 3 words, Tom chose “innovative, collaborative, and resilient.”
Tom’s journey at Verastem reflects a commitment to growth, leadership, and dedication to financial excellence. -
Verastem Oncology
@VerastemOncolog
On #nationalcaregiversday, we honor those caring for a loved one with #lungcancer. Explore @LUNGevity’s #caregiver guide for resources to support your wellbeing and advocacy tips for you and your loved one: no1missed.org/47VWJYJ #lcsm #noonemissed
-
Verastem Oncology
@VerastemOncolog
We are looking forward to attending the @NRGonc Winter 2024 Meeting where experts in rare #ovariancancer such as #lgsoc can share their experiences to better serve patients. Visit www.nrgoncology.org/Winter-Meeting-2024 to find out more.
-
Verastem Oncology
@VerastemOncolog
The #lgsocpatientimpactsurvey w/ @HarrisPoll reveals that while many U.S. women are knowledgeable about common health conditions, few are knowledgeable about ovarian cancer, including #lowgradeserous #ovariancancer. Learn more about this rare form: www.verastem.com/patients-and-advocacy/
-
Verastem Oncology
@VerastemOncolog
$VSTM is pleased to outline key 2024 strategic priorities and milestones supporting our pipeline of novel drugs that inhibit critical signaling pathways in cancer, including RAF/MEK inhibition, focal adhesion kinase inhibition and KRAS G12D inhibition.
investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
We’re attending the @SGO_org Winter 2024 Meeting. To advance research for those living with ovarian cancer, especially rare forms like LGSOC. It's crucial to bring together subject matter experts. Visit www.sgo.org/events/winter-meeting/ to find out more.
-
Verastem Oncology
@VerastemOncolog
We are pleased to announce that @US_FDA has granted Fast Track Designation for our investigational avutometinib combo w/ @Amgen’s sotorasib as potential second-line treatment for #kras G12C-mutant #nsclc, helping address a significant unmet need: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
We are looking forward to attending @ASCO #gi24 and connecting on progress in #pdac as we continue to enroll for our RAMP 205 clinical trial with avutometinib + defactinib in combination with standard therapy in patients with previously untreated metastatic PDAC.
-
Verastem Oncology
@VerastemOncolog
Meet Lan-Chi Nguyen, Senior Director of Regulatory Affairs, Chemistry, Manufacturing, and Controls. At Verastem, she facilitates health authority submissions & leverages her passion and expertise to support efforts to bring forward new treatments to target unmet medical needs.
-
Verastem Oncology
@VerastemOncolog
We’re joining @BRileyFinancial in a fireside chat at their 4th Annual Oncology Conference to discuss advancements in new medicines for patients with cancer. Learn more: investor.verastem.com/news-releases/news-release-details/…
B. Riley Financial
@BRileyFinancial
B. Riley Securities is pleased to announce our 4th Annual Oncology Conference taking place on January 18, 2024. For more information or to contact your B. Riley representative, please email events@brileyfin.com.
-
Verastem Oncology
@VerastemOncolog
#healthcareproviders: #biomarker testing may point to a tailored treatment plan for #lungcancer and we support @LUNGevity in the push to make it the standard of care. See resources to discuss this crucial step with your #nsclc patients: no1missed.org/47xc1Do #noonemissed #lcsm
-
Verastem Oncology
@VerastemOncolog
Thank you @LongwoodLeaders for an insightful panel on the deal making landscape of the pharma and biotech industry, including our CEO Dan Paterson. #longwoodhealthcareleaders #jpm2024
Longwood Healthcare Leaders
@LongwoodLeaders
A special thank you to the amazing participants for phenomenal discussions and interactions at this year’s #longwoodhealthcareleaders San Francisco CEO. Enjoy the rest of #jpmweek and join us next year: www.longwoodhealthcareleaders.com/events
-
Verastem Oncology
@VerastemOncolog
As 2024 begins, we're celebrating the incredible progress made last year for the #lowgradeserous #ovariancancer #lgsoc community. We look forward to supporting this community through the continued progress to come throughout this year. Learn more: letstalkaboutlgsoc.com/resources
-
Verastem Oncology
@VerastemOncolog
Through collaboration and partnerships, Verastem is developing novel approaches for RAS pathway-driven cancers, providing hope and expanded treatment options. Learn more about how combinations of avutometinib and defactinib can enhance treatment efficacy: www.verastem.com
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology announces selection of oral KRAS G12D inhibitor GFH375/VS-7375 as lead program in discovery and development collaboration with GenFleet Therapeutics. Learn more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
The path to diagnosis is not an easy one if you have #lowgradeserous #ovariancancer. Learn more about the experiences people living with #lgsoc shared in the #lgsocpatientimpactsurvey: letstalkaboutlgsoc.com/resources/patient-impact-survey
-
Verastem Oncology
@VerastemOncolog
In a step toward moving a new therapy forward for patients w/ #lowgradeserous #ovariancancer the #ramp301 Phase 3 confirmatory trial designed to further assess the effectiveness & safety of avutometinib & defactinib for recurrent #lgsoc is open & enrolling investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Verastem is dedicated to illuminating pathways of hope and healing across RAS pathway-driven cancers. As we reflect on the past year, we continue to be guided by the pursuit of turning potential into possible for those living with cancer.
-
Verastem Oncology
@VerastemOncolog
Congratulations to STAAR Ovarian Cancer Foundation for being recognized by World Ovarian Cancer Coalition with the Inspirational Collaboration Award. Your impactful work and leadership have brought meaningful gains to the LGSOC community. Learn more: www.staaroc.org/research--news/staar-honored-for-inspirat…
-
Verastem Oncology
@VerastemOncolog
From symptom onset, the average time to diagnosis #lowgradeserous #ovariancancer is 3 years the #lgsocpatientimpactsurvey revealed. This delayed diagnosis directly impacts treatment outcomes. Learn more about the #lgsoc diagnosis journey: letstalkaboutlgsoc.com/resources/patient-impact-survey
-
Verastem Oncology
@VerastemOncolog
November is Lung Cancer Awareness Month. Alongside @lungevity, we are committed to supporting patients with lung cancer and their loved ones. Join us as we take action and spread awareness this November. lungevity.org/LCAM
-
Verastem Oncology
@VerastemOncolog
The #lgsocpatientimpactsurvey found that few women know the warning signs or about low-grade serous ovarian cancer itself. Read more from @TODAYshow to learn about one woman’s experience with #lowgradeserous #ovariancancer on.today.com/49SbzBz
-
Verastem Oncology
@VerastemOncolog
$VSTM CMO Louis Denis shares power of findings from the #lgsocpatientimpactsurvey to shape the treatment journey of patients with #lowgradeserous #ovariancancer #gyncsm. Learn more: letstalkaboutlgsoc.com/resources/patient-impact-survey
-
Verastem Oncology
@VerastemOncolog
#healthcareproviders: Introducing Let’s Talk About LGSOC for HCPs, a new resource to support doctors treating patients with a rare form of #ovariancancer, #lowgradeserous #lgsoc. Visit the website to learn more: www.avmapkifakzynjaco-pack-hcp.com
This media couldn't be displayed. See it on the original post. -
Verastem Oncology
@VerastemOncolog
“I firmly believe that by bridging innovative research with robust community engagement, we create an empowering environment where those impacted by #lowgradeserous #ovariancancer feel heard, understood & supported.” Hear more from $VSTM CEO Dan Paterson www.verastem.com/our-stories/unpacking-the-complexities-o…
-
Verastem Oncology
@VerastemOncolog
$VSTM announces Q3 2023 financial results and highlights recent company milestones. Read more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
We are pleased to present results from the first-ever, multi-national #lgsocpatientimpactsurvey, revealing the unique challenges experienced by people living with #lowgradeserous #ovariancancer #gyncsm. Learn more: letstalkaboutlgsoc.com/resources/patient-impact-survey
-
Verastem Oncology
@VerastemOncolog
Dr. Grisham presented results of planned subgroup analysis of RAMP 201 trial, showing efficacy & safety of avutometinib & defactinib in recurrent #lowgradeserous #ovariancancer following prior systemic therapy at Annual Global Meeting of @IGCSociety. investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Dr. David Gershenson's been at the forefront of ovarian cancer research for 46 years. He believes the #lgsocpatientimpactsurvey will educate doctors treating patients with low-grade serous ovarian cancer #lgsoc on their unique needs & concerns.
Learn more: letstalkaboutlgsoc.com -
Verastem Oncology
@VerastemOncolog
This #lungcancerawarenessmonth we're committed to supporting those living with lung cancer by researching new treatment options such as avutometinib and defactinib in #kras mt non-small cell lung cancer #nsclc. Learn more about our lung cancer pipeline: www.verastem.com/our-science/pipeline/
-
Verastem Oncology
@VerastemOncolog
Verastem strengthens leadership team with appointments of Mike Crowther as Chief Commercial & Business Strategy Officer, David Mitchell as SVP Head of Regulatory Affairs & Dan Calkins’ promotion to CFO from VP Finance. Learn more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Dr. Rachel Grisham of @MSKCancerCenter hopes the #lgsocpatientimpactsurvey will provide insights to individualize care for patients with low-grade serous ovarian cancer #lgsoc. Learn more: letstalkaboutlgsoc.com
-
Verastem Oncology
@VerastemOncolog
#study: @MSKCancerCenter @TeamOvary_MSK is currently enrolling for the IST #clinicaltrial conducted by Dr. Rachel Grisham to evaluate avutometinib + defactinib in patients with #mesonephric #gynecologiccancer. Supported by Verastem. Learn more: clinicaltrials.gov/study/NCT05787561
-
Verastem Oncology
@VerastemOncolog
No patient with cancer should run out of options. From our lead program in #lowgradeserous #ovariancancer to KRAS mt non-small cell lung cancer & other RAS-Pathway driven cancers, our goal is to find solutions to cancers with high unmet need. Learn more: www.verastem.com/patients-and-advocacy/
-
Verastem Oncology
@VerastemOncolog
Verastem is proud to be a sponsor of @ocrahope's Ovarian Cancer National Conference. Don’t miss this opportunity to get vital updates about treatment & research at the largest conference for the #ovarian & #gynecologiccancer community. Register at ocrahope.org/OvarianConf
-
Verastem Oncology
@VerastemOncolog
As partners of @LUNGevity’s #noonemissed campaign, we’re dedicated to supporting non-small cell #lungcancer patients. Don’t overlook vital #biomarker testing in your #nsclc journey. Learn about this crucial step today: no1missed.org/48nqnaK
-
Verastem Oncology
@VerastemOncolog
Low-grade serous ovarian cancer #lgsoc is drastically different from the high-grade form, #hgsoc. Through the #lgsocpatientimpactsurvey, Dr. Sun wants to bring awareness around the seriousness of this disease and the effect it has on patients. Learn more: letstalkaboutlgsoc.com
-
Verastem Oncology
@VerastemOncolog
Thank you to @NOCC_National for their tremendous work to raise awareness & resources for #ovariancancer at the #togetherinteal walk. We are proud to support the work of the community during #ocam in September & all year long. Learn more: vimeo.com/869871270 #lowgradeserous
-
Verastem Oncology
@VerastemOncolog
$VSTM announces initial #ramp203 results of avutometinib + sotorasib in patients with KRAS G12C-mutant #nsclc to be presented @AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Learn more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
We’re proud to support @AACR’s Special Conference in Cancer Research: Ovarian Cancer. Bringing together experts in the field is vital to furthering research for patients with #ovariancancer, including rare tumors like #lgsoc. Visit www.aacr.org/meeting/aacr-special-conference-ovarian-cancer/ to learn more
#aacrovc23 -
Verastem Oncology
@VerastemOncolog
Dr. @BanerjeeSusana of @royalmarsdenNHS expects the #lgsocpatientimpactsurvey to show the differences in treatments and the impact on women with low-grade serous ovarian cancer #lgsoc. Learn more: letstalkaboutlgsoc.com
-
Verastem Oncology
@VerastemOncolog
Verastem is pleased to share an oral RAMP 201 encore this week at the @ESGO_society European Gynaecological Oncology Congress. Learn more: congress.esgo.org/media/2023/09/ESGO2023-List-of-accepted…
-
Verastem Oncology
@VerastemOncolog
Presentations by Verastem today @HansonWade RAS-Targeted Drug Development Summit to include update on avutometinib and defactinib preclinical and clinical development program. Learn more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
.@AACR Special Conference in Cancer Research: Pancreatic Cancer, we are presenting research on preclinical pancreatic combinations and a RAMP 205 TIP. We look forward to discussing cutting-edge therapeutic strategies with other experts. Learn more: www.aacr.org/meeting/advancing-precision-medicine-2020/pr…
-
Verastem Oncology
@VerastemOncolog
We look forward to sharing presentations on combinations with avutometinib & defactinib and discussing innovative treatment options @HansonWade RAS-Targeted Drug Development Summit with other researchers at the forefront of drug development. Learn more: ras-drugdevelopment.com
-
Verastem Oncology
@VerastemOncolog
.@DrMarkAwad to present initial safety & recommended Phase 2 dose from RAMP 203, a Phase 1/2 study of avutometinib + sotorasib in KRAS G12C mutant #nsclc @AACR NCI-EORTC Int’l Conference on Molecular Targets & Cancer Therapeutics #targets23 www.aacr.org/meeting/abstracts/
-
Verastem Oncology
@VerastemOncolog
Professor @annapoids of @WestmeadInst wants the #lgsocpatientimpactsurvey to uncover key misconceptions around low-grade serous ovarian cancer #lgsoc, like how serious it is. Learn more: letstalkaboutlgsoc.com
-
Verastem Oncology
@VerastemOncolog
#healthcareproviders: Our partner @LUNGevity has a webpage tailored to help you navigate #biomarker testing in non-small cell #lungcancer. Visit #noonemissed to find insightful resources to help you guide your #nsclc patients to an optimal care plan: no1missed.org/44fHyYc
-
Verastem Oncology
@VerastemOncolog
Inherited genetic mutations cause a staggering increase in ovarian cancer risk — and they can be passed down from both mothers and fathers. Visit ocrahope.org/risktoolkit to find out how to assess your risk and what critical actions you can take to reduce it. @ocrahope
-
Verastem Oncology
@VerastemOncolog
Proud to support @ovarcome’s Annual Conference with @RunsiAyona & @sharronmelton01 and Ovarcomers around the world. And inspired by all the insightful discussions that are continuing to advance this vital education and support for people living with #ovariancancer #ovarcon23
-
Verastem Oncology
@VerastemOncolog
As part of Let’s Talk About LGSOC, we aim to support patients as they navigate the disease. Amanda Sobhani, a licensed Nutritionist living with #lgsoc, shares how nutrition choices may impact overall health. Read more here: letstalkaboutlgsoc.com/taking-care-of-yourself/nutrition/…
-
Verastem Oncology
@VerastemOncolog
At the annual Targeting RAS Symposium, we look forward to hearing from Drs. @udai_banerji & Monica Musteanu on targeting RAS signaling with RAF/MEK combinations & $VSTM CSO Jon Pachter's poster on avutometinib and defactinib. Learn more: targetingras.com/symposium-information/
-
Verastem Oncology
@VerastemOncolog
We’re proud to sponsor @ovarcome's Annual Conference. This online & in-person event offers those impacted by #ovariancancer the chance to hear from leading experts & connect with the community. Visit ovarcome.org to learn more & register.
#ovarcome #lowgradeserous -
Verastem Oncology
@VerastemOncolog
We are happy to have hosted the t-shirt pick-up this week and are looking forward to joining our friends @NOCC_National and the New England community at the #togetherinteal walk on Sunday (9/10)!
-
Verastem Oncology
@VerastemOncolog
Nicole Andrews, Board of Directors Chair at @STAAROC, shares why the #lgsocpatientimpactsurvey examining the thoughts, behaviors and perceptions of people living with low-grade serous ovarian cancer #lgsoc is so important. Learn more: letstalkaboutlgsoc.com
-
Verastem Oncology
@VerastemOncolog
$VSTM announces participation in @HCWCO Annual Global Investment Conference on 9/12 at 2 p.m. ET & @cantorfitzgerld 2023 Global Healthcare Conference on 9/26 at 9:55 a.m. ET. Live webcasts & replays of the presentation & fireside chat available at verastem.com/investors
-
Verastem Oncology
@VerastemOncolog
This #ovariancancerawarenessmonth and every month, we work to turn potential into possible for women living with #lowgradeserous #ovariancancer. Learn more about #lgsoc at letstalkaboutlgsoc.com.
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology enters into a discovery and development collaboration with GenFleet Therapeutics with option to advance up to 3 programs in RAS pathway cancers.
Learn more: investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
Dr. Charlie Gourley of Nicola Murray Centre for Ovarian Cancer Research @EdinCRC hopes that the #lgsocpatientimpactsurvey uncovers key low-grade serous ovarian cancer #lgsoc patient knowledge gaps to better serve the healthcare community. Learn more: letstalkaboutlgsoc.com
-
Verastem Oncology
@VerastemOncolog
We support our partner @LUNGevity in working towards removing barriers to ensure every #nsclc patient has equal access to #biomarkertesting and proper care. For more information on this step, visit: no1missed.org/3pBkHs5 #noonemissed #lcsm
-
Verastem Oncology
@VerastemOncolog
Jane Ludemann, founder of @Cure_Ovarian_Ca, shares why the #lgsocpatientimpactsurvey is so important to her: “My hope is that the survey will help clinicians treat the whole person, not just the cancer.”
Learn more: letstalkaboutlgsoc.com #lgsoc -
Verastem Oncology
@VerastemOncolog
$VSTM announces Q2 2023 financial results and highlights recent company milestones. Read more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
The combination of avutometinib + sotorasib
has the potential benefit of a more complete vertical blockade of the RAS pathway in KRAS G12C-mutant #nsclc. Learn more about our RAMP 203 trial with @Amgen. www.verastem.com/wp-content/uploads/2023/04/v3_RAMP-203-o… -
Verastem Oncology
@VerastemOncolog
We partnered with leaders in the community to develop the first multi-national survey for people diagnosed with #lowgradeserous #ovariancancer to understand and support the needs of those impacted. See if you qualify for the #lgsocpatientimpactsurvey here: surveys.harrisinsights.com/survey/selfserve/53b/230684?li…
-
Verastem Oncology
@VerastemOncolog
#lungcancer is different for everyone, but #biomarker testing may point you to a treatment plan that is the best fit for your type of #nsclc. Check out our partner @LUNGevity’s #noonemissed site to learn about this crucial step: no1missed.org/42XyvdV
-
Verastem Oncology
@VerastemOncolog
When Tiffany was diagnosed with #lgsoc in her 30s, there was little information about this rare and distinct form of cancer. At Verastem, we are committed to ensuring patients have the resources and information they need. Learn more: letstalkaboutlgsoc.com
-
Verastem Oncology
@VerastemOncolog
Announcing our new CEO, @DanWPaterson. As our previous President & COO, Dan brings 30+ years of experience in leading healthcare and biotech companies. Current CEO, Brian Stuglik, to retire and remain a member of our Board. Read more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
.@HealthProRadio interviews Dr.
@BanerjeeSusana of @royalmarsdenNHS on #ramp201 data supporting of avutometinib + defactinib in recurrent #lgsoc, presented at #asco23.
Listen here:
Health Radio Online
@HealthProRadio
New Data at the American Society of Clinical Oncology (ASCO) Addressing Rare Form of Ovarian Cancer
Read more: healthprofessionalradio.com.au/new-data-at-the-american-s…
#ramp201 #lgsoc #asco23 -
Verastem Oncology
@VerastemOncolog
#meettheverastemteam: Mark Gonsalves is our Senior Manager for Payroll and Equity Administration. Thank you Mark for helping make an impact on patients!
-
Verastem Oncology
@VerastemOncolog
Announcing #ramp301 Phase 3 trial design to evaluate the efficacy and safety of avutometinib & defactinib for recurrent #lowgradeserous #ovariancancer, another important milestone in bringing us closer to addressing the unmet needs of patients. Learn more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
.@ClearityFnd shares
#ramp201 data supporting avutometinib + defactinib as an active go-forward regimen in recurrent #lgsoc, regardless of #kras status, presented at #asco23 by Dr. @BanerjeeSusana & @royalmarsdenNHS
Read more here: ocrahope.org/clearity-has-joined-ocra/ -
Verastem Oncology
@VerastemOncolog
Watch Lavern McDonald, ambassador for our partner @LUNGevity, share her #lungcancer diagnosis story with @blackdoctor_org. Lavern found an optimal care plan through #biomarker testing. Learn about this crucial step: no1missed.org/3OxV7hA #lcsm #noonemissed
-
Verastem Oncology
@VerastemOncolog
Hear from Dr. @BanerjeeSusana @royalmarsdenNHS, discussing results from the #ramp201 trial presented at #asco23 and their importance in advancing the care of patients with #lowgradeserous #ovariancancer #lgsoc.
This media couldn't be displayed. See it on the original post. -
Verastem Oncology
@VerastemOncolog
Thank you to Dr. @BanerjeeSusana @royalmarsdenNHS for sharing #ramp201 data supporting avutometinib + defactinib as an active go-forward regimen in heavily pretreated recurrent #lgsoc. Learn more: www.royalmarsden.nhs.uk/news-and-events/news/new-drug-com… #asco23
-
Verastem Oncology
@VerastemOncolog
We look forward to attending #asco23 in Chicago and contributing to the scientific discussion in RAS pathway-driven cancers to help improve outcomes for patients.
-
Verastem Oncology
@VerastemOncolog
Updated data from Part A of our RAMP 201 Trial at #asco23 show significant benefit of avutometinib and defactinib combination in women with recurrent low-grade serous ovarian cancer #lgsoc regardless of KRAS status. Learn more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Join us this #lungcancerhopemonth as we highlight our partnership with @LUNGevity on the #noonemissed campaign, which works to ensure all patients with #nsclc receive #biomarker testing & optimal care. Learn about the role of #biomarkertesting today: no1missed.org/3A5QJOw #lcsm
-
Verastem Oncology
@VerastemOncolog
#announcement: We're proud to announce the appointment of Karin Tollefson, SVP & Head of Global Medical Affairs @SeagenGlobal, to our Board of Directors. Learn more here: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
$VSTM announces Q1 2023 financial results & highlights company progress, including updated #ramp201 trial interim data for RAF/MEK clamp avutometinib +/- defactinib in #lgsoc at #asco23 & progress on additional combination studies. investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
We are honored to support the #wocd2023 campaign from @Cure_Ovarian_Ca and STAAR Ovarian Cancer Foundation, encouraging awareness of symptoms and earlier diagnosis of women with ovarian cancer. We're inspired by the important work of these patient advocates today and every day.
LGSOC Initiative
@LGSOCInitiative
May 8 is World Ovarian Cancer Day.
Every year over 300,000 woman get the devastating news that they have ovarian cancer.
Check out our five quick facts about ovarian cancer and help us spread awareness of this devastating disease. -
Verastem Oncology
@VerastemOncolog
When diagnosed with #lgsoc, Jane saw a lack of resources and support for the rare #ovariancancer, so she founded @Cure_Ovarian_Ca. This #worldovariancancerday, we stand with patient advocates who are making a difference in #oncology. Learn more: letstalkaboutlgsoc.com #wocd
-
Verastem Oncology
@VerastemOncolog
This #womenshealthmonth, follow our journey to support patients, advocacy organizations, and researchers working to raise awareness and educate others about #lgsoc, a rare and often misunderstood form of ovarian cancer. Visit letstalkaboutlgsoc.com to learn more.
-
Verastem Oncology
@VerastemOncolog
$VSTM announces participation in @JMPSecurities Life Sciences Conference on 5/16 at 1 p.m. ET & @rbccm Global Healthcare Conference on 5/17 at 2:05 p.m. ET. Live webcasts of the presentations will be available on the investors section of our website, verastem.com/investors
-
Verastem Oncology
@VerastemOncolog
Meredith was diagnosed with stage 3C #lowgradeserous #ovariancancer at 33 and is passionate about raising awareness of the symptoms.
-
Verastem Oncology
@VerastemOncolog
$VSTM announces updated #ramp201 interim results of avutometinib & defactinib in patients with #lowgradeserous #ovariancancer will be presented in a poster discussion session at the @ASCOAnnual Meeting #lgsoc #asco23 investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
We support our partner @LUNGevity as they work to ensure there is #noonemissed in the #nsclc community. This #nationalminorityhealthmonth, we encourage you & your loved ones to learn about #biomarker testing in #nsclc and access resources: no1missed.org/3YNQ51O
#lcsm -
Verastem Oncology
@VerastemOncolog
Thank you Dr Banerji for the important work that led to this excellent presentation on an update on preclinical and clinical activity of the avutometinib + everolimus combination in #kras-mutant #nsclc at #aacr2023.
udaibanerji
@udai_banerji
Intermittent dosing and smart combinations. Love it when a plan comes together abstract 3461 #aacr23 avutometinib+everolimus for the treatment of non-G12C KRAS mutated NSCLC @ICR_DDU_IIT @ICR_London @royalmarsdenNHS @ECMC_UK @cancerBRC
-
Verastem Oncology
@VerastemOncolog
We are pleased to announce that we will be presenting at the @Stifel 2023 Virtual Targeted Oncology Days event on April 25 at 2:30 p.m. ET. A live webcast of the presentation will be available on the investors section of our website, verastem.com/investors
-
Verastem Oncology
@VerastemOncolog
We are pleased to share updates at #aacr2023 across our RAF/MEK clamp avutometinib clinical trial program, including data from combination studies with anti-EGFR and anti-PD1 inhibitors targeting difficult-to-treat RAS pathway-driven cancers.
-
Verastem Oncology
@VerastemOncolog
#meettheverastemteam: Kate Adams is a Sr. Clinical Trial Manager of the RAMP 201 study in #lowgradeserous #ovariancancer. When Kate is not at work you can find her chasing her toddler, skiing, swimming, or at her workbench working on home improvement projects.
-
Verastem Oncology
@VerastemOncolog
Thank you @endpts for highlighting #lgsoc and Let’s Talk About LGSOC, which recognizes LGSOC as a distinct disease and provides resources for patients, caregivers and HCPs. Read more here: endpoints.news/verastems-new-campaign-aims-to-make-distin…
-
Verastem Oncology
@VerastemOncolog
Listen to thoracic oncologist @ROsarogiagbon explain the vital role #biomarkertesting can play in informing treatment options for #nsclc. To learn more about #biomarker testing, visit the #noonemissed page from our partner @LUNGevity: no1missed.org/3KiLIZh #lcsm
-
Verastem Oncology
@VerastemOncolog
Introducing Let’s Talk About LGSOC, a new initiative to support broader awareness, education, and support for patients living with #lgsoc, a rare and often misunderstood form of ovarian cancer. Visit this website to learn more: letstalkaboutlgsoc.com
-
Verastem Oncology
@VerastemOncolog
$VSTM announces Q4/FY 2022 financial results and highlights company progress, including positive RAMP201 trial interim data for RAF/MEK clamp avutometinib +/- defactinib in #lgsoc and additional combination studies for RAS-pathway driven cancers. investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Important information by @NOCC_National about #lowgradeserous #ovariancancer as a distinct, rare form of ovarian cancer. #lgsoc
National Ovarian Cancer Coalition
@NOCCNational
Did you know that there are several types of #ovariancancer? Check out these two types and more by visiting our website: ovarian.org/about-ovarian-cancer/types-and-stages/?hss_ch… #knowovarian
-
Verastem Oncology
@VerastemOncolog
We are pleased to see this comprehensive article by Drs. Cobb @LaurenPCobb & Gershenson @RareOvarCancers of @MDAndersonNews recognizing #lgsoc as a distinct disease and sharing progress in treatment. Read more here: international-journal-of-gynecological-cancer.com
-
Verastem Oncology
@VerastemOncolog
Ellie, 29, spoke with @goodrx about her #lowgradeserous #ovarian cancer diagnosis, sharing the importance of continuing to move forward with life. Read more here: www.goodrx.com/conditions/ovarian-cancer/what-does-ovaria…
-
Verastem Oncology
@VerastemOncolog
Our CSO Jon Pachter looks forward to presenting on how the RAF/MEK clamp avutometinib enhances antitumor efficacy of KRAS G12C and G12D inhibitors at the upcoming @AACR Special Conference on Targeting RAS.
-
Verastem Oncology
@VerastemOncolog
To ensure that no patient runs out of treatment options, including those dealing with rare diseases like #lowgradeserous #ovariancancer, we're advancing research to bring novel cancer treatments to patients. #rarediseases #rarediseaseday
-
Verastem Oncology
@VerastemOncolog
We’re proud to support @LUNGevity Foundation’s ambassadors as they share stories of how comprehensive #biomarkertesting led them to the most appropriate treatment plan for their non-small cell lung cancer. Learn more at no1missed.org/3G7CZ9v
#noonemissed #lcsm -
Verastem Oncology
@VerastemOncolog
We're honored to be part of OCRA's Ovarian Cancer Industry Council to collaborate on awareness and support for #lowgradeserous #ovariancancer
Ovarian Cancer Research Alliance
@ocrahope
OCRA is pleased to welcome @verastemoncolog as the newest member of our Ovarian Cancer Industry Council. We look forward to our continued collaboration! Learn more about OCRA’s Ovarian Cancer Industry Council at ocrahope.org/about/ovarian-cancer-industry-council/. #ovariancancer
-
Verastem Oncology
@VerastemOncolog
#study: Verastem is currently enrolling for the RAMP 205 #clinicaltrial evaluating avutometinib + defactinib in combination with standard of care chemotherapy in patients with previously untreated metastatic #pancreaticcancer #pdac. Learn more: clinicaltrials.gov/study/NCT05669482
-
Verastem Oncology
@VerastemOncolog
In honor of #worldcancerday, we want to express gratitude to all researchers, medical experts & advocates working to advance #cancertreatment, who share our commitment to bringing new solutions to patients with RAS pathway-driven cancers.
-
Verastem Oncology
@VerastemOncolog
$VSTM is pleased to outline key 2023 strategic priorities and upcoming catalysts to support #avutometinib, a RAF/MEK clamp currently in late-stage development for #ras pathway-driven cancers. investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Thank you to @TargetedOnc for covering the interim analysis from Part A of our #ramp201 trial in #lowgradeserous #ovarian cancer. Read more here: www.targetedonc.com/view/avutometinib-plus-defactinib-gen…
-
Verastem Oncology reposted
Precision Oncology News
@PrecOncNews
Verastem Oncology Plans for FDA Submission of Avutometinib-Defactinib Combo in Ovarian Cancer. Verastem reported positive interim data from a trial of the combination, demonstrating therapeutic activity in KRAS-mutant and KRAS-wild type recurrent... www.genomeweb.com/cancer/verastem-oncology-plans-fda-subm…
-
Verastem Oncology reposted
OncLive.com
@OncLive
Avutometinib Plus Defactinib Generates Responses in Recurrent Low-Grade Serous Ovarian Cancer #ovca #gyncsm @BanerjeeSusana @royalmarsdenNHS www.onclive.com/view/avutometinib-plus-defactinib-generat…
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Announcing interim data from the #ramp201 trial evaluating avutometinib +/- defactinib for #lowgradeserous #ovariancancer, which has no approved therapies. Hear more from global study lead investigator Dr. Banerjee, @royalmarsdenNHS & @ICR_London: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Did you know that #kras G12C mutations account for 44% of KRAS mutations? Verastem and @Mirati are enrolling the RAMP 204 #clinicaltrial evaluating RAF/MEK clamp VS-6766 with adagrasib for KRAS G12C-mutant #nsclc Learn more: clinicaltrials.gov/study/NCT05375994
-
Verastem Oncology
@VerastemOncolog
Diagnosed at 30 with #lowgradeserous #ovariancancer, Brittany considers herself a medical unicorn. “I saw doctor after doctor. I always felt like they didn't believe me, that I was making it up. No one would ever take me seriously.” Check symptoms: www.staaroc.org/symptoms.html
-
Verastem Oncology
@VerastemOncolog
Are you familiar with the risk factors of ovarian cancer and #lowgrade #serousovariancancer? Factors include genetics, low-functioning immune system and environmental factors such as #pcos. Learn more here: www.verastem.com/our-science/clinical-trials/
-
Verastem Oncology
@VerastemOncolog
We’re so grateful for our #verastem team and community of partners working together to advance #cancerresearch. Wishing everyone a happy holiday season, and all the best for 2023!
-
Verastem Oncology
@VerastemOncolog
#announcement: We're proud to announce the appointment of Rob Gagnon, CFO and Operating Partner at Gurnet Point Capital, to our Board of Directors. Learn more here: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Verastem, in partnership with @Amgen, is currently enrolling for #ramp 203, evaluating VS-6766 and sotorasib in KRAS G12C-mutant #nsclc. Learn more here: clinicaltrials.gov/study/NCT05074810
-
Verastem Oncology
@VerastemOncolog
Verastem continues to enroll its #ramp 201 trial, evaluating VS-6766 and defactinib in recurrent #lowgrade #serousovariancancer. Learn more here: clinicaltrials.gov/study/NCT04625270
-
Verastem Oncology
@VerastemOncolog
We’re honored to be featured as one of the @BostonGlobe's 2022 #topplacestowork. Our team has a shared purpose of no cancer patient running out of options. Thank you to our employees & partners, who work to make our mission possible every day! www.bostonglobe.com/2022/11/30/magazine/top-25-small-empl…
-
Verastem Oncology
@VerastemOncolog
#lungcancer contributes to approximately 25% of cancer deaths, & #nsclc is the most common form, accounting for 84% of lung cancers. Learn more about the importance of earlier lung cancer screening & diagnosis from organizations like @LUNGevity. #lcam #nsclc
-
Verastem Oncology
@VerastemOncolog
#meettheverastemteam, the Employee Spotlight Program where we share the amazing people who make our mission possible! Cherrees Jones is the Associate Director, Financial Planning & Analysis, who believes everyone at Verastem has a shared purpose.
-
Verastem Oncology
@VerastemOncolog
Do you know the risk factors associated with #lungcancer? Factors include smoking, family history & air pollution. This #lungcancerawarenessmonth, we’re focused on driving awareness of this condition & its risk factors. Learn more from organizations like @LUNGevity. #nsclc #lcam
-
Verastem Oncology
@VerastemOncolog
#meettheverastemteam Introducing the Employee Spotlight Program, where we'll be sharing the amazing people who make our mission possible! Cathy Carew is the Chief Organizational Effectiveness Officer at Verastem.
-
Verastem Oncology
@VerastemOncolog
$VSTM announces Q3 financial results and highlights recent company progress, including ongoing combination trials with investigational RAF/MEK clamp avutometinib (VS-6766) to maximize treatment potential for #ras pathway-driven tumors.
Learn more: investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
VS-6766 is a molecule with a unique mechanism of action, designed to “clamp” two key nodes of the vertical RAS pathway (#raf & #mek), potentially overcoming resistance and creating a more complete and durable anti-tumor response through maximal RAS pathway inhibition.
-
Verastem Oncology
@VerastemOncolog
#announcement: $VSTM is proud to announce the appointment of Anil Kapur, EVP of Corporate Strategy and CCO at Geron Corporation, to our Board of Directors. Learn more here: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
$VSTM CSO Jon Pachter presented at the Fourth RAS Initiative Symposium to discuss the company’s overall approach to addressing #ras pathway driven tumors through combinations with our investigational RAF/MEK clamp. Learn more here: www.verastem.com/our-science/resources/
-
Verastem Oncology
@VerastemOncolog
85% of #lowgradeserous #ovariancancer patients who achieve full remission following first-line therapy will develop recurrent disease #knowovarian
Learn more: www.verastem.com/our-science/clinical-trials/ -
Verastem Oncology
@VerastemOncolog
Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates. Read full press release here investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
A teacher for deaf students, Ellie admits “When I was little, I didn't dream of being bald from chemotherapy at my wedding.”
#lowgradeserous #ovariancancer is underdiagnosed and associated with a lower age at diagnosis. Check symptoms: www.staaroc.org/symptoms.html -
Verastem Oncology
@VerastemOncolog
Searching for answers on biomarker testing in non-small cell lung cancer? Browse through these frequently asked questions, and visit no1missed.org/3ORLerF for more resources from our partner @LUNGevity #noonemissed #nsclc #lcsm
-
Verastem Oncology
@VerastemOncolog
Do you know enough about ovarian cancer? Learn more from @ocrahope to potentially save a life — yours or someone else’s: ocra318304.typeform.com/to/EJsiOiVB #ocrahope
#lowgrade #serousovariancancer -
Verastem Oncology
@VerastemOncolog
We’re honored to partner with @NOCC_National to get involved and spread awareness during #ovariancancerawareness Month. #togetherinteal #knowovarian #lowgrade #serousovariancancer
This media couldn't be displayed. See it on the original post. -
Verastem Oncology
@VerastemOncolog
Heartburn? Indigestion? It could be ovarian cancer. Check your symptoms: www.staaroc.org/symptoms.html
-
Verastem Oncology
@VerastemOncolog
$VSTM CSO Jon Pachter and CMO Louis Denis have the honor of presenting at the annual RAS-Targeted Drug Development Summit. We are excited for the opportunity to share with and learn from fellow researchers who continue to pioneer new #ras-targeted therapeutic approaches.
-
Verastem Oncology
@VerastemOncolog
We’re proud to be working with @PanCAN to help advance research in #pancreaticcancer. Join an upcoming webinar on 9/29 to hear about the latest developments from a panel of experts, including our own #cso Jon Pachter.
PanCAN
@PanCAN
Join us for our upcoming webinar on September 29 at 11 a.m. PT/ 2 p.m. ET where we'll talk with panel of pancreatic cancer research and treatment experts about the newest developments in the field and how your gifts have made it all possible. 🔬💜 pancan.org/researchprogress
-
Verastem Oncology
@VerastemOncolog
#letstalk Do you know your risk for #ovariancancer? Get informed via @ocrahope: ocra318304.typeform.com/to/EJsiOiVB
Share this with 5 friends to help save lives. #lowgrade #serousovariancancer #ocrahope -
Verastem Oncology
@VerastemOncolog
$VSTM #cso Jon Pachter is pleased to be presenting this week at the #nsclc Drug Development Summit.
We look forward to discussing cutting-edge treatment strategies with other academics at the forefront of this field. -
Verastem Oncology
@VerastemOncolog
We’re proud to sponsor @ocrahope's National Conference. This #virtualevent will unite those touched by the disease with those working to #findacure. Visit ocrahope.org/events/conference/ to learn more and register.
#ocrahope #lowgrade #serousovariancancer -
Verastem Oncology reposted
National Ovarian Cancer Coalition
@NOCCNational
Are you looking to learn more about #ovariancancer during #nocam? Check out module one of our You and Ovarian Cancer Animated Patients Guide, "Understanding Ovarian Cancer." #knowovarian www.youandovariancancer.com/en-ovc/view/m101-a101-underst…
-
Verastem Oncology
@VerastemOncolog
Karen was diagnosed with #lowgradeserous #ovariancancer 8 days after her daughter’s birth. But “Most women with my cancer aren’t this lucky.”
This type of cancer is underdiagnosed and associated with a lower age at diagnosis. Check symptoms: www.staaroc.org/symptoms.html -
Verastem Oncology reposted
National Ovarian Cancer Coalition
@NOCCNational
Did you know that anyone born with ovaries is at risk for #ovariancancer? Find more information about risk factors at ovarian.org/ovarian-cancer-young-people/?hss_channel=tw-4… #knowovarian
-
Verastem Oncology
@VerastemOncolog
#lowgradeserous #ovariancancer is characterized by a young age at diagnosis compared to other forms of ovarian cancer and resistance to chemotherapy. Learn more here: www.staaroc.org/symptoms.html
-
Verastem Oncology
@VerastemOncolog
Talking about #ovariancancer this September could save a life – your sister, friend, cousin or Insta-bestie. Help us spread the word and #coloritteal
-
Verastem Oncology
@VerastemOncolog
We’re honored to be supporting STAAR OC Foundation’s Step Up America for Ovarian Cancer to help bring awareness to #lowgradeserous #ovariancancer. #coloritteal
-
Verastem Oncology
@VerastemOncolog
#lowgradeserous #ovariancancer is a difficult to treat disease and current treatments are associated with low response rates and high toxicity, making it difficult for patients to stay on therapy
Learn more: www.verastem.com/our-science/clinical-trials/ -
Verastem Oncology
@VerastemOncolog
The Phase 1/2 clinical trial evaluating the combination of our RAF/MEK clamp with @Mirati’s G12C inhibitor in #kras #g12c-mutant #nsclc is open and enrolling participants #ramp204 #cancerresearch
-
Verastem Oncology
@VerastemOncolog
Ashley is a young mother celebrating her 10-year anniversary with her husband Matt this year. She is also living with #lowgradeserous #ovariancancer
This cancer is underdiagnosed & associated with a lower age at diagnosis. Check symptoms: www.staaroc.org/symptoms.html -
Verastem Oncology
@VerastemOncolog
$VSTM reports Q2 financial results and recent company updates. Learn more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
We are honored to receive @PanCAN’s inaugural Therapeutic Accelerator Award & look forward to working with TAA Collaborative members to evaluate the combination of our investigational candidates, VS-6766 & defactinib in #pancreaticcancer. pancan.org/press-releases/pancreatic-cancer-action-networ…
-
Verastem Oncology
@VerastemOncolog
Approximately 4% of people with #nsclc have a #braf mutation. 1/2
Verastem Oncology
@VerastemOncolog
The #ramp202 trial has been expanded to enroll eligible patients with BRAF-mutant #nsclc to evaluate investigational RAF-MEK clamp VS-6766 & defactinib.
Learn more: www.clinicaltrials.gov/study/NCT04620330
2/2 -
Verastem Oncology
@VerastemOncolog
Discussing novel treatments for #nsclc, @clinadvances latest volume highlights $VSTM investigational dual RAF/MEK clamp VS-6766 for use in KRAS mt G12V NSCLC in the #ramp202 trial ± defactinib, our investigational #fak inhibitor.
Learn more: www.hematologyandoncology.net/archives/july-2022/novel-ta… -
Verastem Oncology
@VerastemOncolog
Our #ceo Brian Stuglik and #cso Jon Pachter talked to @alisonkanski @PrecOncNews abt $VSTM unique approach to developing therapies for RAS-pathway driven cancers. “With VS-6766 we're blocking both RAF and MEK which leads to a more complete blockade within the signaling pathway.”
Precision Oncology News
@PrecOncNews
Drugmakers Going After RAS, MAPK Pathway to Tackle Cancers With Variety of KRAS Mutations. Bolstered by the success of KRAS G12C inhibitors in lung cancer, smaller firms are developing drugs for a range of other KRAS-mutated cancers and trying to... www.genomeweb.com/cancer/drugmakers-going-after-ras-mapk-…
-
Verastem Oncology
@VerastemOncolog
Don't miss this interview with Nicole Andrews of STAAR Research Foundation sharing how #lowgradeserous #ovariancancer is difficult to diagnose and treat, and what advocates are working on to raise awareness and resources.
Health Radio Online
@HealthProRadio
Rare Ovarian Cancer Awareness Campaign 2022
Read more: healthprofessionalradio.com.au/rare-ovarian-cancer-awaren…
#ovariancancer -
Verastem Oncology
@VerastemOncolog
Great to hear expert @RareOvarCancers discussing #lowgradeserous #ovariancancer with @HealthProRadio and raising awareness of this difficult disease
Health Radio Online
@HealthProRadio
Rare Ovarian Cancer Awareness
Read more: healthprofessionalradio.com.au/rare-ovarian-cancer-awaren…
#ovariancancer -
Verastem Oncology reposted
The ICR
@ICR_London
Rather than drugging #kras itself, the new dual #combinationtherapy renders KRAS less effective by simultaneously blocking the two pathways that KRAS relies upon to drive #cancer growth 👇
www.icr.ac.uk/news-archive/asco-2022-drug-combination-sho…
#unlocktreatments #asco22 -
Verastem Oncology
@VerastemOncolog
$VSTM provides update on #ramp201 study evaluating VS-6766 ± defactinib in #lowgradeserous #ovariancancer; interim analysis findings incl encouraging efficacy results, no new safety signals & continued evaluation of both monotherapy and combination therapy
investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
Today kicks off #asco22 in Chicago. We’re looking forward to presentations highlighting continued advances in RAS-driven tumors, including our own research and investigator-sponsored studies of our VS-6766 RAF/MEK clamp and defactinib #cancerresearch
-
Verastem Oncology
@VerastemOncolog
Have you had biomarker testing for #lungcancer? We’re spreading the word with @LUNGevity on how biomarker testing can help inform treatment options. #knowyourbiomarker. #noonemissed
-
Verastem Oncology
@VerastemOncolog
We look forward to @anna_minchom’s (@ICR_London) presentation at #asco22 of a Phase 1 study evaluating our RAF/MEK clamp VS-6766 in combination with everolimus for patients w/ RAS-driven cancers, incl an expansion cohort in #kras mutant #nsclc
Learn more: meetings.asco.org/abstracts-presentations/209970 -
Verastem Oncology
@VerastemOncolog
$VSTM is honored to receive @PanCAN’s inaugural Therapeutic Accelerator Award to evaluate the combination of its lead investigational candidates, RAF/MEK Clamp VS-6766 and defactinib, in front-line metastatic #pancreaticcancer
Learn more: investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
$VSTM announces Q1 financial results and highlights recent company progress #earnings
Learn more: investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
#icymi @Cure_Ovarian_Ca and STAAR Ovarian Cancer Foundation brought their #wocd2022 campaign educating on symptoms of #ovariancancer to Times Square in NYC yesterday, in addition to billboards in London, Canada and New Zealand.
-
Verastem Oncology
@VerastemOncolog
$VSTM is honored to support the #wocd2022 campaign from @Cure_Ovarian_Ca and STAAR Ovarian Cancer Foundation, encouraging earlier diagnosis in younger women. We're inspired by the important work of these patient advocates today and every day.
Learn more: www.multivu.com/players/English/9045451-cure-our-ovarian-… -
Verastem Oncology
@VerastemOncolog
Did you know? Mutations in the #kras gene (KRAS+) are present in 35-57% of #lowgradeserous #ovariancancer cases #dyk #wocd2022
Learn more: www.verastem.com/our-science/clinical-trials/ -
Verastem Oncology
@VerastemOncolog
#lowgradeserous #ovariancancer symptoms may include abdominal bloating, pelvic or abdominal pain, unintended weight loss, feeling full quickly, constipation & other changes in bowel habits #dyk #wocd2022
Learn more: www.verastem.com/our-science/clinical-trials/ -
Verastem Oncology
@VerastemOncolog
Our CMO Louis Denis discusses Verastem's commitment to supporting women with #lowgradeserous #ovariancancer this World Ovarian Cancer Day #wocd2022
Read more: www.linkedin.com/pulse/world-ovarian-cancer-day-louis-denis
Pictured: Nicole Andrews of STAAR Ovarian Cancer Fdn and Jane Ludemann of @Cure_Ovarian_Ca -
Verastem Oncology
@VerastemOncolog
Ovarian cancer is usually asymptomatic, meaning no symptoms in early stages, which may be why most women aren’t diagnosed until their cancer has progressed #dyk #lowgradeserous #ovariancancer #wocd2022
Learn more: www.verastem.com/our-science/clinical-trials/ -
Verastem Oncology
@VerastemOncolog
Low-grade serous ovarian cancer represents 6-8% of all ovarian cancers and has a high mortality rate #dyk #lowgradeserous #ovariancancer #wocd2022
Learn more: www.verastem.com/our-science/clinical-trials/ -
Verastem Oncology
@VerastemOncolog
Low-grade serous ovarian cancer is a type of #ovariancancer characterized by younger age at diagnosis and resistance to #chemotherapy #wocd2022
Learn more: www.verastem.com/our-science/clinical-trials/ -
Verastem Oncology
@VerastemOncolog
It's almost #wocd2022. Did you know these 5 key facts about #ovariancancer?
-
Verastem Oncology
@VerastemOncolog
In honor of this year’s #wocd2022 theme #nowomanleftbehind we’re raising awareness of #lowgradeserous #ovariancancer which affects 80K women worldwide. We are committed to this community and are working urgently to deliver better solutions.
Learn more: www.verastem.com/our-science/clinical-trials/ -
Verastem Oncology reposted
National Ovarian Cancer Coalition
@NOCCNational
#worldovariancancerday is almost here! Join us on #instagram Live Sunday, May 8th at 1 pm to discuss with survivors and caregivers the impact that #ovariancancer has had on their lives and their efforts to raise awareness on this day of action. #knowovarian #nowomanleftbehind
-
Verastem Oncology
@VerastemOncolog
Our CSO Jon Pachter and @Joshua_Reuss, thoracic medical oncologist @lombardicancer, discuss the rationale for adding a #braf cohort to the #ramp202 study investigating VS-6766 alone and with defactinib in non-small cell #lungcancer
Watch here: www.verastem.com/wp-content/uploads/2022/04/Verastem_Pach… -
Verastem Oncology
@VerastemOncolog
New preclinical research published in @PNASNews from @UCSDHealth highlights the importance of FAK inhibition in #ovariancancer
Learn more: www.pnas.org/doi/full/10.1073/pnas.2117065119 -
Verastem Oncology
@VerastemOncolog
This year marks the 40th anniversary of the discovery of #ras genes in human cancer, enabling research into #kras, a mutation found in approximately 25% of #cancers #aacr22
vimeo.com/587430580 -
Verastem Oncology
@VerastemOncolog
We look forward to @Mirati’s presentation at #aacr22 of positive preclinical data evaluating Verastem’s RAF/MEK clamp with Mirati’s SOS1 inhibitor & KRASG12C inhibitor in #kras mutant cancers
-
Verastem Oncology
@VerastemOncolog
Today kicks off the @AACR Annual Conference where $VSTM will present preclinical data that continue to support the versatility of VS-6766 in #ras driven tumors, including #kras #g12c #nsclc #lgsoc and #cutaneousmelanoma #aacr22
-
Verastem Oncology
@VerastemOncolog
$VSTM announces Q4 and full year 2021 financial results and highlights recent company progress, including Part A enrollment completion for the #ramp201 #lgsoc and #ramp202 #kras G12V-mutant #nsclc trials #earnings
Learn more: investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
$VSTM secures up to $150 Million in non-dilutive funding from Oxford Finance LLC, providing additional financial flexibility to support ongoing development, commercial preparation and potential launches for VS-6766 and defactinib
Learn more: investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
$VSTM is proud to announce the appointment of leading oncology researcher, @Cjder23, PhD, Sarah Graham Kenan Distinguished Professor at the University of North Carolina at Chapel Hill, to its Scientific Advisory Board. #oncoalert
Read more: investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
The ongoing #ramp203 Phase 1/2 clinical trial in collaboration with @AmgenOncology is evaluating the potential complete vertical blockade of the RAS pathway in #kras G12C -mutant #nsclc with VS-6766 & #amgen’s KRAS G12C inhibitor #cancerresearch #oncoalert
-
Verastem Oncology
@VerastemOncolog
Our CSO Jon Pachter explains the unique RAF/MEK clamp mechanism of VS-6766 to potentially create a more durable anti-tumor response by maximizing RAS pathway inhibition #oncology #cancerresearch
Full video: www.verastem.com/wp-content/uploads/1647/21/JonPacher_sho… -
Verastem Oncology
@VerastemOncolog
We look forward to presenting new preclinical data for our investigational RAF/MEK clamp VS-6766 at the @AACR Annual Meeting #aacr22 #oncology #cancerresearch
-
Verastem Oncology
@VerastemOncolog
On @womensday and every day, we’re celebrating the women in our lives and honoring their achievements that #breakthebias. We are especially proud to support women through our cancer research that has the potential to positively impact the lives of women worldwide. #iwd2022
-
Verastem Oncology
@VerastemOncolog
We're committed to developing novel #cancer therapies to ensure no patient runs out of treatment options, including those living with rare cancers like low-grade serous ovarian cancer. #rarediseaseday #lgsoc #rarediseases
-
Verastem Oncology
@VerastemOncolog
Ross Camidge, MD of @CUCancerCenter, discusses what piqued his interest to investigate VS-6766 alone and with defactinib in non-small cell #lungcancer patients. #nsclc #ramp202 #lcsm #cancerresearch
-
Verastem Oncology
@VerastemOncolog
What is low-grade serous #ovariancancer? Robert L. Coleman, MD of @TexasOncology, discusses the unique aspects of #lgsoc and targeting the RAS/RAF/MEK pathways in the #ramp201 study to help overcome challenges in treatment for patients.
-
Verastem Oncology
@VerastemOncolog
We’re proud to collaborate with @GOG and @ENGOT on our #ramp201 clinical trial in recurrent low-grade serous ovarian cancer. Thank you Dr. @BanerjeeSusana and Dr. Moore for sharing your insights.
youtu.be/sVi9-wWlkKQ
The GOG Foundation Inc.
@GOG
Click link in bio or go to ht tps://youtu.be/sVi9-wWlkKQ to view this video and learn more about this clinical trial in recurrent low-grade serous ovarian cancer. #clinicaltrials #gynecologiconcology #ovariancancer@VerastemOncolog @BanerjeeSusana
-
Verastem Oncology
@VerastemOncolog
KRAS #g12v, the second most common mutation in non-small cell #lungcancer, currently has no approved targeted therapy. Hear from Ross Camidge, MD of @CUCancerCenter, on the potential of the #ramp202 study for patients with this mutation. #nsclc #lcsm
-
Verastem Oncology
@VerastemOncolog
In honor of @WorldCancerDay, we share our utmost appreciation for researchers, healthcare professionals and advocates working to improve cancer care. And we join together with the community in our collective commitment to ensure patients never run out of options. #worldcancerday
-
Verastem Oncology
@VerastemOncolog
Kathleen Moore, MD of @StephensonCC, shares her insights on the potential benefits of dual RAF/MEK inhibition with VS-6766 in the #ramp201 study. #lgsoc #clinicaltrial
-
Verastem Oncology
@VerastemOncolog
As many as 30% of #nsclc patients have a #kras mutation, which makes treatment more difficult. Melissa Johnson, MD of @SarahCannonDocs, speaks to the #ramp202 study, now enrolling patients with #kras mutant #nsclc, to study a treatment regimen for these patients. #lcsm
-
Verastem Oncology
@VerastemOncolog
An investigator-sponsored trial, led by @ArdamanShergil1 of @UChicagoMed, evaluating our investigational RAF/MEK clamp, VS-6766, and cetuximab in patients with advanced #colorectalcancer is now enrolling and available on clinicaltrials.gov. #oncology #cancerresearch
-
Verastem Oncology
@VerastemOncolog
Robert Holloway, MD of @AdventHealth, explains the unique challenges of treating low-grade serous #ovariancancer, including the lack of effective and tolerable treatment options, and the potential to change that with the #ramp201 study. #lgsoc #clinicaltrial
-
Verastem Oncology
@VerastemOncolog
New article published in @LungCaJournal discusses our investigational dual RAF/MEK clamp, VS-6766, among targeted treatments being studied to treat #kras G12C-mutant #nsclc. #cancerresearch #lcsm
-
Verastem Oncology
@VerastemOncolog
A food effect study of our investigational dual RAF/MEK clamp, VS-6766, is now enrolling and is available on clinicaltrials.gov. #clinicaltrials #oncology #oncoalert #cancerresearch
-
Verastem Oncology
@VerastemOncolog
$VSTM today outlined key 2022 strategic priorities and upcoming catalysts to support its lead compound, VS-6766, a RAF/MEK clamp currently in late-stage development for RAS pathway-driven cancers. #investornews #oncalert
Post not available here, view on X
Verastem Oncology
@VerastemOncolog
$VSTM 2022 Priorities (2): Report preliminary data from Phase 1/2 trial evaluating LUMAKRAS™ (sotorasib) and VS-6766 in 2H 2022 & initiate Phase 1/2 trial evaluating VS-6766 and adagrasib in Q2 2022; both in #kras G12C-mutant non-small cell lung cancer. #nsclc #ramp203 #ramp204
Verastem Oncology
@VerastemOncolog
$VSTM 2022 Priorities (3): Expand ongoing investigator-initiated trial program to explore combination potential with VS-6766 in additional areas of high unmet need; data read-outs expected throughout 2022. #cancerresearch
-
Verastem Oncology
@VerastemOncolog
Many #nsclc patients with a #kras mutation are still in need of targeted treatments. @AlexSpiraMDPhD of @VCSpecialists, talks the #ramp202 study investigating VS-6766 alone and with defactinib, now enrolling #nsclc patients with a #kras mutation with a focus on #g12v. #lcsm
-
Verastem Oncology
@VerastemOncolog
Read more from @OncLive about our clinical collaboration with @Mirati to evaluate the combination of VS-6766 and adagrasib in a Phase 1/2 trial for patients with #krsas G12C-mutant #nsclc. #oncology #cancerresearch #clinicaltrials #lcsm
OncLive.com
@OncLive
Mirati and Verastem Combine to Address Unmet Need in KRAS G12C–Mutant NSCLC #lcsm #oncology www.onclive.com/view/mirati-and-verastem-combine-to-addre…
-
Verastem Oncology
@VerastemOncolog
Robert L. Coleman, MD of @TexasOncology, is passionate about finding targeted treatment options for women with recurrent #lgsoc. Hear his thoughts on the potential of investigational VS-6766 in the #ramp201 study to benefit patients through dual RAF/MEK inhibition. #ovariancancer
-
Verastem Oncology
@VerastemOncolog
$VSTM will participate in the upcoming @HCWCO BIOCONNECT Virtual Conference and the @BRileyFinancial Oncology Conference. A webcast of the fireside chats will be available on verastem.com on January 10 and January 28, respectively. #oncoalert #investornews
-
Verastem Oncology
@VerastemOncolog
We are grateful for the collective commitment of our colleagues, healthcare partners and patients working to realize the potential of #cancerresearch to deliver new treatments that can change lives. Wishing everyone a happy holiday season and all the best for 2022! #patientsfirst
-
Verastem Oncology
@VerastemOncolog
Hear from Melissa Johnson, MD of @SarahCannonDocs, on why she chose medical oncology, and how #biomarkertesting has impacted how she approaches treating patients with #lungcancer, including those with specific mutations such as #kras #g12v. #nsclc #lcsm
-
Verastem Oncology
@VerastemOncolog
Robert Holloway, MD of @AdventHealth, discusses what he finds meaningful and promising about the #ramp201 study for recurrent, low-grade serous #ovariancancer, now enrolling women with #lgsoc who have experienced recurrence of their disease. #cancerresearch
-
Verastem Oncology
@VerastemOncolog
What does it mean to have #kras mutant #lungcancer? Hear from Ross Camidge, MD of @CUCancerCenter, on the #ramp202 study investigating VS-6766 alone and with defactinib for #kras mutant non-small cell #lungcancer. #nsclc #lcsm #cancerresearch
-
Verastem Oncology
@VerastemOncolog
Women with recurrent, low-grade serous #ovariancancer may be eligible for the #ramp201 study. Kathleen Moore, MD of @StephensonCC, discusses the potential of this trial to help address low response rates and tolerability issues associated with current therapies. #lgsoc
-
Verastem Oncology
@VerastemOncolog
#nsclc patients face undeniable burdens. @AlexSpiraMDPhD of @VCSpecialists, talks about the need to find better and more targeted treatments and using comprehensive #biomarkertesting to improve patient outcomes. #lungcancerawarenessmonth #lcam #lcsm
-
Verastem Oncology
@VerastemOncolog
If you have non-small cell #lungcancer, it's important to #knowyourbiomarker. We're partnering with @LUNGevity this KNOWvember to spread awareness about biomarker testing. Learn how to start the conversation with your doctor #noonemissed #lcam #lcsm
-
Verastem Oncology
@VerastemOncolog
Women with low-grade serous #ovariancancer are in need of effective targeted therapies. Hear from Robert Holloway, MD of @AdventHealth, on the potential of the #ramp201 study to provide a better treatment option for #lgsoc patients. #cancerresearch
-
Verastem Oncology
@VerastemOncolog
$VSTM and @Mirati today announced a clinical collaboration to evaluate the combination of VS-6766 and adagrasib in a Phase 1/2 trial to establish triple blockade of the RAS signaling pathway in #kras G12C-mutant #nsclc. #oncology #cancerresearch #clinicaltrials #lcsm
-
Verastem Oncology
@VerastemOncolog
Get to know $VSTM, by hearing from our team member, Faye Seyedi, Head of Chemistry, Manufacturing and Controls. Faye is a co-leader of our Women’s Leadership Forum and is passionate about helping cancer patients get the treatment options they need. #oncology
-
Verastem Oncology
@VerastemOncolog
Thank you @NOCC_National and @NOCC_MA for your tremendous efforts on behalf of patients and their families, we are honored to work with you. #ovariancancer #togetherinteal
National Ovarian Cancer Coalition
@NOCCNational
@verastemoncolog has been partnering with NOCC's New England region for the past two years, creating a Together in Teal team that walks for our cause and as our generous Teal Presenting Partners. Thank you, Verastem, for making our support programs possible! #30yearsofteal
-
Verastem Oncology reposted
GO2 for Lung Cancer
@GO2forLungCancr
Why are younger Americans getting lung cancer? That’s the question researchers are asking—and they need your help. If you were diagnosed with lung cancer before age 40, participating and telling your story can help make a difference. >> alcmi.org/clinical-trials/current-studies/eoylc-study.html
-
Verastem Oncology
@VerastemOncolog
Melissa Johnson, MD of @SarahCannonDocs, shares what you should know if you or a loved one is diagnosed with non-small cell #lungcancer and #clinicaltrials like the #ramp202 study. #lungcancerawarenessmonth #lcam #lcsm #nsclc
-
Verastem Oncology
@VerastemOncolog
Research published in @nature by @sloan_kettering demonstrates the rationale for why combination treatments are needed to address resistance to #kras G12C inhibitors. #cancerresearch go.nature.com/3x2tKlb
-
Verastem Oncology reposted
LUNGevity Foundation
@LUNGevity
November is #nationalcaregivermonth, a time to recognize family caregivers everywhere and raise awareness around issues that affect them. If you know a caregiver or have one in your life, LUNGevity has resources and support to share with them at lungevity.org/caregivers #lcam
-
Verastem Oncology
@VerastemOncolog
Along with @LUNGevity, we’re recognizing KNOWvember as part of #lungcancerawarenessmonth. Know your biomarkers, know your treatment options. Have you had biomarker testing for non-small cell #lungcancer? Share your story and tag #knowyourbiomarker. #noonemissed #lcam #lcsm #nsclc
-
Verastem Oncology
@VerastemOncolog
New preclinical data from @sloan_kettering presented at the @sitcancer Annual Meeting and published in @jitcancer, shows intermittent dosing of RAF/MEK inhibitor VS-6766 (formerly CH5126766/CKI27) augments anti-tumor efficacy of immunotherapy to treat RAS mutant cancers. #sitc21
-
Verastem Oncology
@VerastemOncolog
$VSTM will present at the 2021 @Jefferies London Healthcare Conference. A live webcast of the presentation will be available on verastem.com on Thursday, November 18, 2021, at 8:00 a.m. GMT/ 3:00 a.m. ET and archived for 30 days following. #oncoalert #cancerresearch
-
Verastem Oncology
@VerastemOncolog
Robert L. Coleman, MD of @TexasOncology, discusses the potential of the #ramp201 study to provide better treatment responses for women with recurrent #lgsoc who are in need of alternate treatment options. #ovariancancer #cancerresearch
-
Verastem Oncology
@VerastemOncolog
.@BanerjeeSusana spoke with @DailyMailUK on the ongoing FRAME clinical trial studying RAF/MEK inhibitor, VS-6766 with FAK inhibitor, defactinib to treat advanced low-grade serous #ovariancancer. Read more about why new options are critical for patients. #cancerresearch #lgsoc
-
Verastem Oncology
@VerastemOncolog
$VSTM announces third quarter 2021 financial results and highlights recent company progress including a clinical collaboration with @AmgenOncology in #kras G12C-mutant #nsclc and @myESMO data showing 23-month PFS for VS-6766 with defactinib in patients with #lgsoc #earnings
-
Verastem Oncology
@VerastemOncolog
This #lungcancerawarenessmonth, Ross Camidge, MD of @CUCancerCenter, discusses the importance of comprehensive #biomarkertesting in #nsclc to understand what is driving tumor growth. Learn more about the #ramp202 study targeting tumor mutations in #nsclc including #kras #g12v.
-
Verastem Oncology reposted
OncLive.com
@OncLive
In this episode of #oncliveonair, @MLJohnsonMD2, of @SarahCannonDocs, discusses VS-6766 alone and in combination with defactinib, and expectations for the ongoing phase 2 RAMP 202 trial in KRAS-mutant NSCLC #lcsm #oncology www.onclive.com/view/johnson-previews-the-potential-utili…
-
Verastem Oncology
@VerastemOncolog
This #lunghealthday, hear from Melissa Johnson, MD of @SarahCannonDocs, on the importance of #biomarkertesting in #nsclc to identify existing and emerging targeted therapies, including investigational VS-6766 for #kras mutant #nsclc in the enrolling #ramp202 study. #lcsm
-
Verastem Oncology reposted
OncLive.com
@OncLive
LISTEN: In a previous episode of #oncliveonair, Dr. Moore, of @StephensonCC, discusses studying VS-6766 & defactinib in recurrent low-grade serous ovarian cancer, the phase 1/2 FRAME trial, & the role for the combination in clinical practice. #ovca www.onclive.com/view/moore-voices-excitement-with-vs-6766…
-
Verastem Oncology
@VerastemOncolog
$VSTM is proud to announce the appointment of Michelle Robertson, accomplished financial and commercial operations executive, to its Board of Directors. #oncoalert
-
Verastem Oncology
@VerastemOncolog
Robert Holloway, MD of @AdventHealth, discusses the #ramp201 study investigating VS-6766 alone and with defactinib for low-grade serous #ovariancancer and the hope for better treatment options for women who have not responded to standard therapies. #lgsoc #cancerresearch
-
Verastem Oncology
@VerastemOncolog
For those recently diagnosed with #nsclc, @AlexSpiraMDPhD of @VCSpecialists, shares ways to work with your healthcare team to get the best care including #biomakertesting and exploring emerging #targetedtherapies to determine the best treatment plan for you. #healthylungmonth
-
Verastem Oncology
@VerastemOncolog
A trial in progress assessing $VSTM’s RAF/MEK inhibitor VS-6766 + everolimus was presented at the 2021 AACR-NCI-EORTC conference by @udai_banerji; a recommended Phase 2 dose was defined with an ongoing expansion cohort in #kras mutant #nsclc. #targets21
-
Verastem Oncology
@VerastemOncolog
$VSTM will present preclinical data at the 2021 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics on dual RAF/MEK inhibitor VS-6766 and the potential in MAPK pathway mutations and tumor types beyond #kras mutations, #lgsoc and KRAS G12V #nsclc. #targets21
-
Verastem Oncology
@VerastemOncolog
By better controlling the RAS signaling network, customized RAS-targeted treatment combinations with investigational VS-6766 have the potential to improve outcomes for cancer patients with limited options. Watch the MOA video, linked below.
-
Verastem Oncology
@VerastemOncolog
Hear from Kathleen Moore, MD of @StephensonCC, on the recent @US_FDA #breakthroughtherapy designation of investigational VS-6766 and the potential of the #ramp201 study to bring forward a new treatment option for women with low-grade serous #ovariancancer. #lgsoc
-
Verastem Oncology
@VerastemOncolog
$VSTM is honored to be the presenting regional sponsor for #togetherinteal with @NOCC_National as we break the silence on #ovariancancer at this year’s Everywhere as ONE celebration being broadcast nationally this Sat. at 7pm EDT. #knowovarian #noccea1 give.ovarian.org/index.cfm?fuseaction=cms.home
This media couldn't be displayed. See it on the original post. -
Verastem Oncology
@VerastemOncolog
Today we unveiled Verastem Oncology's new brand that reflects the purpose and the urgency behind ensuring no cancer patient ever runs out of options. Check out our website to learn more. #cancerresearch #oncology
-
Verastem Oncology
@VerastemOncolog
$VSTM proudly welcomes Louis J. Denis, M.D., as Chief Medical Officer, bringing more than 25 years of clinical development and oncology expertise to Verastem. #investornews
-
Verastem Oncology
@VerastemOncolog
.@BanerjeeSusana spoke with @myESMO on the updated Phase 1/2 FRAME data presented at #esmo21 on VS-6766 + defactinib in low-grade serous ovarian cancer. Watch the interview below. #lgsoc www.youtube.com/watch?v=l2I0kIcTaxE
-
Verastem Oncology reposted
Ovacome - the ovarian cancer support charity
@Ovacome
It's encouraging to see promising results from the Phase 1/2 FRAME study into the use of a RAF/MEK inhibitor (VS 6766) in combination with the FAK inhibitor (defactinib) to treat low grade serous ovarian cancer.
#ovariancancer #treatment
Guardian news
@guardiannews
‘Highly effective’ ovarian cancer treatment could help thousands of women www.theguardian.com/society/2021/sep/19/highly-effective-…
-
Verastem Oncology
@VerastemOncolog
$VSTM Chief Scientific Officer, Jonathan Pachter & Global Program Leader, Andrew Koustenis, will present two sessions on dual RAF/MEK inhibitor VS-6766 as a backbone of therapy for RAS pathway-driven cancers at this year’s @Undruggable RAS-Targeted Drug Development digital event.
-
Verastem Oncology
@VerastemOncolog
$VSTM announced a clinical collaboration with @AmgenOncology to evaluate VS-6766 + LUMAKRAS (sotorasib) in a Phase 1/2 trial for a more complete vertical blockade of the RAS pathway in KRAS G12C-mutant #nsclc. #oncology #cancernews #clinicaltrials #kras #lcsm
-
Verastem Oncology
@VerastemOncolog
$VSTM today announced updated data from the investigator-sponsored FRAME study evaluating VS-6766 + defactinib in #lgsoc showing encouraging response rates, progression-free survival and a favorable safety profile, presented at the virtual @myESMO Congress.@BanerjeeSusana #esmo21
-
Verastem Oncology
@VerastemOncolog
Comprehensive #biomarker testing for people living with #nsclc can provide important treatment option guidance. Watch highlights from a recent @LUNGevity panel discussion on the topic and learn more. #noonemissed #lcsm
-
Verastem Oncology
@VerastemOncolog
$VSTM is proud to support the fifth @AACR Virtual Special Conference on Ovarian Cancer this week to better understand needs in #ovariancancer and enhance research and treatments. #aacrovca21 #cancerresearch #ovariancancerawarenessmonth #ocam
-
Verastem Oncology
@VerastemOncolog
$VSTM today presented preclinical data on antitumor effects of investigational dual RAF/MEK inhibitor VS-6766 with G12C or FAK inhibitors in non-small cell #lungcancer with a #kras G12C or G12V mutation during the @IASLC 2021 World Conference on Lung Cancer. #wclc21 #nsclc #lcsm
-
Verastem Oncology
@VerastemOncolog
$VSTM will present virtually at the upcoming @HCWCO Annual Global Investment Conference on Monday, September 13 at 7:00 am ET, and at the Cantor Virtual Global Healthcare Conference on Monday, September 27 at 4:00 pm ET. Presentations will be available on our website. #oncoalert
-
Verastem Oncology
@VerastemOncolog
.@LUNGevity hosted a Facebook Live event on how #biomarker testing can help your doctor create a unique #nsclc treatment plan. Watch clips and learn more about comprehensive biomarker testing. #lcsm #lungcancer #noonemissed
-
Verastem Oncology
@VerastemOncolog
We’re proud to support @LUNGevity and their work to make sure that there's #noonemissed when it comes to comprehensive #biomarker testing in #nsclc. Watch this video to learn about biomarker testing and how to start the conversation with your doctor. www.youtube.com/watch?v=FFUJAKaM8AI #lcsm
-
Verastem Oncology reposted
National Ovarian Cancer Coalition
@NOCCNational
Unite with our teal tribe from coast to coast. JOIN US and REGISTER today to help end ovarian cancer. We are Together in TEAL- Everywhere as ONE. #noccea1 #togetherinteal #knowovarian give.ovarian.org/index.cfm?fuseaction=cms.home?referrer=SM
This media couldn't be displayed. See it on the original post. -
Verastem Oncology
@VerastemOncolog
Proud of our very own Senior Scientific Director, Michael Layon, who completed the @PanMass challenge over the weekend, raising money for @DanaFarber and showing his and $VSTM’s commitment to advancing #cancerresearch for patients. #pmc2021
-
Verastem Oncology
@VerastemOncolog
$VSTM announces second quarter 2021 financial results and highlights recent company progress. #earnings #oncology #investornews
-
Verastem Oncology
@VerastemOncolog
We’re proud to join @LUNGevity in increasing awareness for comprehensive #biomarker testing in #lungcancer and treatment options through the #noonemissed campaign. #lcsm #nsclc
-
Verastem Oncology
@VerastemOncolog
$VSTM announces that updated results from the ongoing FRAME study evaluating investigational VS-6766 with defactinib in low-grade serous ovarian cancer, will be presented in a mini oral session at the upcoming virtual @myESMO Congress. #esmo21 #lgsoc #oncoalert
-
Verastem Oncology
@VerastemOncolog
We’re pleased to be supporting @LUNGevity and their work to ensure there’s #noonemissed when it comes to #biomarker testing for people living with #lungcancer. Learn more and join the cause at the link below. #lcsm #nsclc
-
Verastem Oncology
@VerastemOncolog
.@RachelgrishamMD from @TeamOvary_MSK spoke with @OncLearnNetwork about the potential of VS-6766 plus defactinib in low-grade serous #ovariancancer #lgsoc, and the recent @US_FDA Breakthrough Therapy designation granted to the combination. www.hmpgloballearningnetwork.com/site/onc/interviews/fda-…
-
Verastem Oncology
@VerastemOncolog
$VSTM announces the conversion of remaining 2020 Senior Notes, eliminating substantially all of the Company’s outstanding debt with a cash runway until at least 2024 to deliver on current programs. #investornews
-
Verastem Oncology
@VerastemOncolog
$VSTM Chief Scientific Officer Jonathan Pachter’s presentation at this year’s NSCLC Drug Development Summit, on dual RAF/MEK inhibitor VS-6766 in combination with other agents for #kras G12V and KRAS G12C mutant #nsclc, is now available on the Company’s website. #investornews
-
Verastem Oncology
@VerastemOncolog
$VSTM Chief Scientific Officer Jonathan Pachter will discuss combination of dual RAF/MEK inhibitor VS-6766 with a FAK inhibitor for #kras G12V mutant #nsclc and with a G12C inhibitor for KRAS G12C mutant NSCLC at this year’s NSCLC Drug Development Summit. #cancerresearch #lcsm
-
Verastem Oncology
@VerastemOncolog
$VSTM proudly announces the appointment of world-renowned #oncologist, Dr. Paul Bunn to its Board of Directors, adding additional expertise in academic research, novel diagnostics and treatment strategies to the Board. @CUCancerCenter #oncoalert
-
Verastem Oncology
@VerastemOncolog
$VSTM is proud to welcome Lesley Solomon, accomplished business development executive and #healthcare industry veteran, to its Board of Directors, bringing more than 25 years of experience in business innovation, development and strategy to the Board. #oncoalert
-
Verastem Oncology reposted
CU Anschutz Cancer Center
@CUCancerCenter
#nationalcancersurvivorday is on June 6! This is a day to recognize cancer survivors, bring attention to the ongoing challenges cancer survivors face, and celebrate life. Check out our top survivor stories from the past year! #cancersurvivormonth
news.cuanschutz.edu/cancer-center/cancer-survivors-day-2021 -
Verastem Oncology
@VerastemOncolog
Looking forward to attending the 2021 @ASCO Annual Meeting #asco21 as we move forward our research in low-grade serous ovarian cancer, KRAS mutant NSCLC & metastatic uveal #melanoma. #lgsoc #melsm #oncoalert #cancerresearch
-
Verastem Oncology reposted
HemOnc Today
@HemOncToday
FDA grants breakthrough therapy designation to combination for recurrent ovarian cancer, based on recent results from ongoing phase 1/phase 2 FRAME trial www.healio.com/news/hematology-oncology/20210524/fda-gran… @VerastemOncolog
-
Verastem Oncology reposted
Endpoints News
@endpts
In today's News Briefing: Verastem has earned the FDA’s breakthrough therapy designation for its novel RAF/MEK inhibitor VS-6766.
endpts.com/verastem-wins-breakthrough-nod-for-combo-thera… -
Verastem Oncology reposted
OncLive.com
@OncLive
#icymi: The combination is under evaluation in the ongoing phase 1/2 FRAME trial, and data from the LGSOC cohort have shown that the doublet elicited an overall response rate of 52% in 11 of 21 evaluable patients. @US_FDA @FDAOncology www.onclive.com/view/fda-grants-breakthrough-therapy-desi…
-
Verastem Oncology
@VerastemOncolog
Following @US_FDA Breakthrough Therapy designation for VS-6766 + defactinib, $VSTM CEO, Brian Stuglik, reflects on the need for continued progress in diseases that have seen little to no progress, such as low-grade serous #ovariancancer #lgsoc
-
Verastem Oncology
@VerastemOncolog
$VSTM will present at the 2021 @Jefferies Virtual Healthcare conference on Tuesday, June 1, 2021 at 4:00 p.m. ET. Live webcast will be available on our website. #oncoalert #cancerresearch
-
Verastem Oncology
@VerastemOncolog
With the Breakthrough Therapy designation granted by the @US_FDA, our RAF/MEK inhibitor VS-6766 in combo with our FAK inhibitor defactinib is one step closer to potentially providing a targeted therapy option to all patients with recurrent #lgsoc who had prior platinum therapy.
-
Verastem Oncology
@VerastemOncolog
$VSTM announces it has received Breakthrough Therapy designation by the @US_FDA for their investigational RAF/MEK inhibitor VS-6766 in combo with their FAK inhibitor defactinib for all patients with recurrent low-grade serous ovarian cancer #lgsoc who had prior platinum therapy.
-
Verastem Oncology
@VerastemOncolog
For many, joining a #clinicaltrial is a chance – one at a better future for themselves and others. We are enrolling for our #ramp201 and #ramp202 studies for recurrent #lgsoc and KRAS+ #nsclc. Click here for more info on clinical trials: www.cancer.net/sites/cancer.net/files/asco_answers_clinic… #ctd2021
-
Verastem Oncology
@VerastemOncolog
Based on new clinical data, our #ramp201 #clinicalstudy has expanded enrollment to now include those with #kras wild-type low-grade serous ovarian cancer #lgsoc, providing opportunity to more women who are in need of options. Learn more: www.ramp201study.com
-
Verastem Oncology reposted
CDC Cancer
@CDC_Cancer
It's National Women's Health Week! You can take steps every day to lower your chance of getting #cancer, like making healthy choices and getting the right screening tests. Find out how! www.cdc.gov/cancer/dcpc/resources/features/womenandcancer/ #nwhw
-
Verastem Oncology
@VerastemOncolog
$VSTM announces first quarter 2021 financial results and highlights recent company progress. #earnings #oncology #investornews
-
Verastem Oncology
@VerastemOncolog
.@Tech_Networks: new treatments are needed for RAS mutant cancer as "not all RAS mutants are created equal and occur at different frequencies.” $VSTM's RAF-MEK inhibitor VS-6766 (CH5126766) showed antitumor activity in multiple cancer types & deemed tolerable in early studies.
-
Verastem Oncology
@VerastemOncolog
On #ovariancancerday, we stand with patients by furthering research to provide better treatment options for women with recurrent low-grade serous ovarian cancer #lgsoc. @OvarianCancerDY #powerfultogether #wocd2021
-
Verastem Oncology
@VerastemOncolog
#ramp201, our #clinicalstudy investigating potential new treatments that target #kras mutations, is currently enrolling women with recurrent low-grade serous ovarian cancer #lgsoc. Learn more: www.ramp201study.com
-
Verastem Oncology reposted
NCI Office of Cancer Survivorship
@NCICancerSurv
More people are living longer after a cancer diagnosis. The Office of Cancer Survivorship works to enhance the quality and length of survival of all persons diagnosed with cancer. Learn more: survivorship.cancer.gov #ocs25 #cancersurvivorship
-
Verastem Oncology
@VerastemOncolog
Prevention and early detection are key for #cancer. Unfortunately, not all cancers are preventable. Our #cancercontrolmonth pledge is to continue our research on improving cancer treatments to provide options to patients who are in need. Learn more: www.verastem.com/research/disease-areas/
-
Verastem Oncology
@VerastemOncolog
$VSTM is committed to delivering options for patients w/ #lgsoc, who often face low response rates & excess toxicity with current treatments. Thank you @rachelgrishamMD from @sloan_kettering @TeamOvary_MSK for leading the #ramp201 #trial. @OncLearnNetwork www.hmpgloballearningnetwork.com/site/onc/interviews/clin…
-
Verastem Oncology
@VerastemOncolog
Dr. Camidge's team at the @CUCancerCenter are leading the #ramp202 #clincalstudy to assess $VSTM's dual RAF/MEK inhibitor VS-6766 for patients with recurrent, KRAS mutant #nsclc. The trial is enrolling & is outlined in @OncLearnNetwork. #oncology #lcsm www.hmpgloballearningnetwork.com/site/onc/interviews/pers…
-
Verastem Oncology
@VerastemOncolog
Dr. Ross Camidge, M.D. @CUCancerCenter, lead investigator of the #ramp202 #study discusses the many challenges of treating non-small cell lung cancer #nsclc. Learn more about the ongoing #clinicalstudy here: www.ramp202study.com
-
Verastem Oncology reposted
ESMO - Eur. Oncology
@myESMO
We need your input to assess the current landscape of Precision #cancer Medicine 👉 Complete this ESMO survey exploring:
- use of genomic tests in clinical practice
- barriers for optimal adoption
- available educational material
📝 esmo.eu.qualtrics.com/jfe/form/SV_73qEf8n5px5RtpY
#precisionmedicine -
Verastem Oncology
@VerastemOncolog
#ramp202, our #clinicalstudy investigating potential new treatments that target #kras mutations, is currently enrolling people with #kras mutant non-small cell lung cancer #nsclc. Learn more: www.ramp202study.com
-
Verastem Oncology
@VerastemOncolog
A new article in @BrJCancer highlights clinical activity and safety of an intermittent dosing schedule with novel RAF/MEK inhibitor VS-6766, which could be a backbone of therapy for combinations to treat #kras mutant tumors. Learn more: go.nature.com/2PZT0r7
-
Verastem Oncology reposted
udaibanerji
@udai_banerji
Intermittent dosing can improve therapeutic windows, don’t be shy to try…..Defining the backbone for future combination studies of the RAF-MEK inhibitor VS-6766. @ICR_London @royalmarsdenNHS @ECMC_UK @cancerBRC @DrChristinaGuo @ICR_DDU_IIT
-
Verastem Oncology
@VerastemOncolog
Low-grade serous ovarian cancer #lgsoc is a difficult to treat disease with limited treatment options. For those that have seen their cancer return, a #clinicalstudy called #ramp201 is now enrolling. Learn more about criteria for participating: www.ramp201study.com
-
Verastem Oncology
@VerastemOncolog
Hear from Dr. Ross Camidge, M.D., University of Colorado Cancer Center, lead investigator of the #ramp202 #study about the importance of knowing if your non-small cell lung cancer tumor has a gene mutation. Learn more about the ongoing #clinicalstudy at www.ramp202study.com
-
Verastem Oncology reposted
Ovarian Cancer Research Alliance
@ocrahope
Though there are different types of ovarian cancer, they can all be diagnosed with similar tests and procedures. Learn more about how a medical professional may check for #ovariancancer: ocrahope.org/news/how-is-ovarian-cancer-diagnosed/
-
Verastem Oncology reposted
Lung Cancer Research Foundation
@lcrf_org
LCRF will be a part of the CISCRP’s virtual “AWARE For All” Northeast clinical research educational event April 15, 4:30-6 PM ET to increase awareness of the importance of clinical research and clinical trial participation! Learn more and register: lcrf.org/awareforall
-
Verastem Oncology
@VerastemOncolog
Non-small cell lung cancer is hard to detect and often diagnosed after it has progressed. #ramp202, our #clinicalstudy for people previously treated for KRAS+ #nsclc, is enrolling. Learn more and download a fact sheet to share with your doctor: www.ramp202study.com
-
Verastem Oncology
@VerastemOncolog
If you or a loved one has been diagnosed with recurrent low-grade serous ovarian cancer #lgsoc, our #clinicalstudy is currently enrolling called #ramp201. To find out more: www.ramp201study.com
-
Verastem Oncology
@VerastemOncolog
$VSTM Q4 and full year 2020 corporate highlights include expanded eligibility of the #ramp201 #clinicalstudy for people with recurrent low-grade serous ovarian cancer #lgsoc, based on new clinical results from the FRAME study. Read more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
$VSTM announces Q4 and full year 2020 financial results, clinical updates and guidance for key milestones in 2021 and early 2022 and highlights recent company progress. Read the press release: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Comprehensive new review on potential of #fak inhibitor anticancer combination therapies, including with RAF/MEK inhibitor for #kras mutant tumors, published in @NatureRevCancer. Read more: go.nature.com/3rY2UqV
-
Verastem Oncology
@VerastemOncolog
$VSTM will be presenting two #preclinical abstracts at the @AACR Annual Meeting #aacr21 on combination therapy with our RAF/MEK inhibitor VS-6766 in #ras-dependent solid tumors. View abstracts here:
www.abstractsonline.com/pp8/
www.abstractsonline.com/pp8/ -
Verastem Oncology
@VerastemOncolog
Join us for a fireside chat from the virtual @HCWCO Global Life Sciences Conference, here: investor.verastem.com/events
-
Verastem Oncology
@VerastemOncolog
$VSTM will take part in a virtual fireside chat on Tuesday, Mar 9 during @HCWCO Global Life Sciences Conference. For more info: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
There are over 6,000 identified #rarediseases around the world. Recurrent low-grade serous ovarian cancer #lgsoc is one of them. On #rarediseaseday we pledge our commitment to providing treatment options and hope for this patient group.
-
Verastem Oncology reposted
Cancer Support Community
@CancerSupportHQ
By answering a few brief questions, lung cancer patients and their loved ones can receive personalized information about their biomarker testing options and how targeted therapy could impact the course of their treatment.www.cancersupportcommunity.org/biomarker-testing-tool
-
Verastem Oncology
@VerastemOncolog
We're proud to present preclinical data on VS-6766 synergies with several target-specific agents for #ras-driven cancers today during the RAS-Targeted Drug Discovery summit. View the abstract here: www.verastem.com/news/posters/
-
Verastem Oncology
@VerastemOncolog
$VSTM Chief Scientific Officer Jonathan Pachter shares his thoughts on collaboration and combinations to further accelerate progress in #ras-targeted R&D in advance of moderating panels at this week’s RAS-Targeted Drug Discovery summit. www.linkedin.com/posts/activity-6770003104705376256-dMiE
-
Verastem Oncology
@VerastemOncolog
Data in @CCR_AACR details potential of FAK w/ MEK for #uvealmelanoma. $VSTM supports investigator-initiated Phase 2 trial by @TJUHospital evaluating combination of dual RAF/MEK inhibitor + FAK inhibitor in metastatic uveal melanoma:aacrjournals.org/clincancerres/article/27/11/3190/671413/… clinicaltrials.gov/study/NCT04720417
-
Verastem Oncology
@VerastemOncolog
On #worldcancerday, we pause to appreciate all who continuously advocate and care for patients and we remain committed to supporting them in their work. #iamandiwill
-
Verastem Oncology
@VerastemOncolog
Congratulations to #vstm co-founder Robert Weinberg, a recipient of the 2021 Japan Prize.
Whitehead Institute
@WhiteheadInst
Whitehead Institute Member Robert Weinberg has received the 2021 Japan Prize with Bert Vogelstein for contributions to the development of a multi-step carcinogenesis model, the model’s application & its impact on improving cancer treatment—congratulations! www.japanprize.jp/en/press_releases20210129.html
-
Verastem Oncology
@VerastemOncolog
Thank you @cancerhealthmag @LizHIVHep for including Verastem Oncology in an article about research under way to crack the #kras code & our focus on targeting mutations involved in the RAF/MEK & FAK signaling pathway. www.cancerhealth.com/article/new-kras-inhibitors-show-pro…
-
Verastem Oncology
@VerastemOncolog
Dr. Ross Camidge from @CUCancerCenter and Verastem Oncology’s Andrew Koustenis discussed Phase 2 #rampnsclc clinical trial evaluating RAF/MEK & FAK inhibition for KRAS+ tumors in #nsclc with @mydocwire www.docwirenews.com/docwire-pick/hem-onc-picks/dr-camidge…
-
Verastem Oncology
@VerastemOncolog
$VSTM proudly welcomes Frank Neumann, M.D., Ph.D., as Chief Medical Officer. He shares our passion for advancing novel medicines for patients battling #cancer – and joins as enrollment begins in our #ramp trial program in #lgsoc and KRAS-positive #nsclc. investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
$VSTM CEO Brian Stuglik spoke with @kRasKickers founder @TerriConneran about making progress for #patients in 2021. www.linkedin.com/pulse/rising-challenges-2021-improving-c…
-
Verastem Oncology
@VerastemOncolog
$VSTM CEO, Brian Stuglik will take part in a virtual fireside chat on Monday, Jan 11 during
@HCWCO BioConnect 2021 Conference. For more info: investor.verastem.com/news-releases/news-release-details/… Access fireside chat here, investor.verastem.com/events -
Verastem Oncology
@VerastemOncolog
#btig hosted Kathleen Moore, MD, MS of @StephensonCC and $VSTM for an in-depth discussion on critical unmet need in #lgsoc treatment and the emerging role of RAF/MEK & FAK inhibition. Click to access the Webcast: investor.verastem.com/events/event-details/kol-event-focu… #ramplgsoc
-
Verastem Oncology
@VerastemOncolog
#nsclc patients with a KRAS-G12V mutation need effective treatment options due to resistance to current #cancer therapies. Learn about RAMP 202, our #clinicaltrial in KRAS mutant non-small cell #lungcancer here: clinicaltrials.gov/study/NCT04620330
-
Verastem Oncology
@VerastemOncolog
About 25% of #nsclc patients have a KRAS mutation. Learn about RAMP 202, our #clinicaltrial evaluating RAF/MEK & FAK in KRAS-G12V mutant non-small cell #lungcancer, led in the U.S. by Dr. Camidge of @CUCancerCenter here: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
NEWS: $VSTM announces initiation of RAMP 202, a Phase 2 RAF/MEK & FAK #clinicaltrial in KRAS mutant #nsclc with a focus on #g12v, where there is a significant unmet need for patients with treatment-resistant #lungcancer #tumors. Read more here: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Response rates to current #lgsoc therapies have historically been low, reinforcing the need for new approaches to treating this recurrent #ovariancancer and discovering more effective options for patients. Learn about our #clinicaltrial here: clinicaltrials.gov/study/NCT04625270
-
Verastem Oncology
@VerastemOncolog
#lgsoc is often diagnosed in women 45-55 yrs. old w/ a median survival of 10 yrs. Learn about our ongoing RAF/MEK & FAK #clinicaltrial in recurrent low-grade serous #ovariancancer, led in the U.S. by Dr. Grisham of the @TeamOvary_MSK of @sloan_kettering: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
NEWS: $VSTM announces initiation of a Phase 2 registration-directed #clinicaltrial in recurrent #lgsoc evaluating a RAF/MEK inhibitor alone and in combo with a FAK inhibitor for this difficult to treat #ovariancancer. Read more in the press release: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
$VSTM Q3 strengthens financial position with finalized sale of PI3K inhibitor to focus on moving RAF/MEK & FAK #kras mutant #tumor development programs forward. Read more in our press release: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
$VSTM announces new data published in @TheLancetOncol from an investigator-initiated phase 1 study evaluating dual RAF/MEK inhibitor targeting #kras mutant tumors. Read more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
$VSTM announces closing of #pi3k inhibitor sale to Secura Bio, supporting commitment to advancing treatment for RAS mediated tumors through targeted development. Read more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
#clinical data in low-grade serous ovarian cancer from the ongoing investigator-initiated Phase 1/2 FRAME study will be presented today at 3:35 PM ET at the 2nd Annual RAS-Targeted Drug Development Summit.
-
Verastem Oncology
@VerastemOncolog
$VSTM announces #lgsoc data from ongoing investigator-initiated Phase 1/2 FRAME study to be presented at the 2nd Annual RAS-Targeted Drug Development Summit today. Details on the data and information to join our investor webcast can be found here: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Join our #investor conference call to discuss updated clinical data in low-grade serous ovarian cancer from the investigator-initiated Phase 1/2 FRAME study on Wed, Sept 16 at 8:00AM ET. The call will feature our management and @rachelgrishamMD. More info: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
NEWS: $VSTM will be presenting virtually at the 22nd @HCWCO Annual Conf. on Mon, Sept 14 and the @CantorFitzgerald Global Healthcare Conf. on Thurs, Sept 17. Read our announcement here, investor.verastem.com/news-releases/news-release-details/… and join the live webcasts here, investor.verastem.com/events
-
Verastem Oncology
@VerastemOncolog
NEWS: $VSTM announces Q2 2020 financial results and highlights recent company progress. Read the press release: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
NEWS: $VSTM signs definitive agreement to sell #pi3k inhibitor rights to Secura Bio to advance the development of our RAF/MEK/FAK program targeting #kras mutant solid tumors. Read more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Preclinical combination data on FAK + RAF/MEK in metastatic #uvealmelanoma presented today at #aacr20 Virtual Annual Meeting II. See announcement here: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Today at #aacr20, Dr. Banerji will be virtually presenting Phase 1 RAF/MEK + FAK combination data in #kras mutant advanced solid #tumors. Join us at Poster # CT143.
-
Verastem Oncology
@VerastemOncolog
Join us today for a virtual presentation at #aacr20 of data from a multicenter Phase 1 study in advanced pancreatic ductal adenocarcinoma (PDAC).
-
Verastem Oncology
@VerastemOncolog
#clinical data in #kras mutant advanced solid #tumors presented today at #aacr20. More details on data being presented here: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Reminder: call today on clinical data from RAF/MEK + FAK combination study in #kras mutant advanced solid #tumors being presented at #aacr20.
-
Verastem Oncology
@VerastemOncolog
NEWS: $VSTM announces the appointment of John H. Johnson to its Board of Directors. Read more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
$VSTM investor call on Monday, April 27, 2020, to discuss clinical data from RAF/MEK + FAK combination study in #kras mutant advanced solid #tumors being presented at #aacr20. investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Today we announced that Phase 1 RAF/MEK & FAK combination data in #kras mutant advanced solid #tumors is being presented at the #aacr20 Virtual Annual Meeting on Monday, April 27, 2020. More details on this & additional data accepted for presentation here: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology team would like to express our deepest appreciation to all physicians caring for patients during these challenging times. We thank you! #nationaldoctorsday #nationaldoctorsday2020
-
Verastem Oncology
@VerastemOncolog
NEWS: $VSTM announces Q4 and full-year 2019 financial results and provides an overview of recent corporate highlights. Read more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
NEWS: $VSTM announces new strategic direction to advance the development of therapies targeting #kras mutations and R/R #ptcl. Read more: investor.verastem.com/news-releases/news-release-details/… #cancerresearch
-
Verastem Oncology
@VerastemOncolog
PRESS RELEASE: $VSTM announces $100 million private placement offering of common stock. Net proceeds will be used to advance the development of therapies targeting #kras mutations and R/R #ptcl. Read more: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology reposted
TCLL Foundation
@TCLLF
Did you know that cutaneous T-cell lymphoma (CTCL) occurs 2x MORE in individuals of African-American descent? Get the facts here: rarediseases.org/rare-diseases/cutaneous-t-cell-lymphomas/
-
Verastem Oncology
@VerastemOncolog
Around 40% of cancer cases can be prevented. Help reduce your risk of cancer this #cancerpreventionmonth and every month by following @AICR recommendations like eating right, staying active and not smoking.
-
Verastem Oncology
@VerastemOncolog
February Is National Cancer Prevention month. Today, 44M people are alive within 5 years of a cancer diagnosis. As information, diagnostics and treatments improve, our chance of surviving cancer is getting better. Progress in #cancer treatment is possible.
#cancerpreventionmonth -
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
Warriors walk among us and before us. 💪#fightbloodcancer
-
Verastem Oncology reposted
David Steensma, MD
@DavidSteensma
I'm often asked by patients, family members, referring physicians, or clinical trial sponors: "So how do you guys pick which clinical trials to do, anyway?" There are hundreds of trials in hematologic malignancy ongoing... how to choose? Here are some thoughts. Image: @NIH
-
Verastem Oncology
@VerastemOncolog
Today is #worldcancerday
Every person battling #cancer inspires us to do more. Within each patient, we see individuals courageously fighting the disease with tenacity and strength. We stand with you.
#worldcancerday2020 #iamandiwill -
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
Today and every day, we're tackling blood cancer head-on. Our end game? A world without blood #cancer. Visit lls.org to learn more. 🏈 #facts
-
Verastem Oncology
@VerastemOncolog
Peripheral T-cell #lymphoma (PTCL) is a rare and aggressive disease. This week, at the 12th Annual T-Cell Lymphoma Forum, findings from ongoing PRIMO PTCL study will be presented. #tcell
-
Verastem Oncology
@VerastemOncolog
Today, Verastem Oncology $VSTM announced dosing of 1st patient in CSPC’s Chinese pivotal study evaluating duvelisib in patients with relapsed or refractory Follicular #lymphoma.
Press release: investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology reposted
Smilow Cancer Hospital
@SmilowCancer
.@DrRoyHerbstYale discussed with @cancertodaymag treatments to target the #kras protein. A mutated form of the gene frequently drives cancer development. @YaleCancer @YaleMed @YNHH www.cancertodaymag.org/Pages/cancer-talk/New-Drugs-for-an…
-
Verastem Oncology reposted
HemOnc Today
@HemOncToday
An interview with @DrGwenNichols of @LLSusa about creation of a Clinical Trial Support Center in partnership with @ASH_hematology that helps clinicians find appropriate clinical trials for their patients www.healio.com/news/hematology-oncology/20200123/collabor…
-
Verastem Oncology
@VerastemOncolog
Today, we honor the life and work of Dr. Martin Luther King, Jr. A quote from Dr. King is a reminder for Verastem Oncology employees of daily service to our patients.
#mlkday #mlk -
Verastem Oncology
@VerastemOncolog
$VSTM President and COO shares how our Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. will help us toward our goal of expanding options for patients in need. #kras #mutation investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology reposted
Pearl Freier
@PearlF
New KRAS-focused drug licensing deal: Verastem Oncology pays $3M upfront to Tokyo-based Chugai Pharma for worldwide development & sales rights to RAF/MEK inhibitor CH5126766 (CKI27) which is in tests for KRAS mutant solid tumors www.fiercebiotech.com/biotech/verastem-pens-kras-focused-… $VSTM #oncology
-
Verastem Oncology
@VerastemOncolog
$VSTM Investor call today on RAF/MEK program in KRAS mutant tumors, including lead investigator Dr. Udai Banerji from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Details: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
NEWS: #vstm announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to develop and commercialize therapy targeting #kras #mutations investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology reposted
Leukemia Research Foundation
@LeukemiaRF
Blood cancer patients, survivors and caregivers are invited to our Annual Town Hall Meeting on Sunday, January 26. Ask any blood cancer-related questions to a panel of medical experts including Dr. Paul Rubinstein from @CookCtyHealth. Info & register: www.allbloodcancers.org/town-hall-meeting
-
Verastem Oncology
@VerastemOncolog
Wishing everyone a #happynewyear!
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
It was a year of progress in the fight against blood #cancer! We're proud to have helped advance 12 out of the 14 therapies approved by the @US_FDA in 2019 to date, & grateful to supporters that make this progress possible. Your support helps save lives >> donate.lls.org/lls/donate
-
Verastem Oncology
@VerastemOncolog
Thank you, @LS_Cares for partnering with us to give back this holiday season with a @CITCBoston toy drive and @Thehopefactory Happy Hope activity, where we assembled Happy Bingo Care Packets for children undergoing long stays in local hospitals.
-
Verastem Oncology reposted
Nature Reviews Disease Primers
@DiseasePrimers
The tumour microenvironment in follicular #lymphoma
go.nature.com/2RJdIKb #curefl -
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Jon Pachter, Chief Scientific Officer at Verastem, shares his thoughts on the unmet needs of the #ptcl treatment landscape as #ash19 wraps up. Read more: www.linkedin.com/pulse/shedding-light-unmet-needs-periphe…
-
Verastem Oncology reposted
The ASCO Post
@ASCOPost
Jennifer Crombie, MD, on Relapsed or Refractory CLL/SLL: Results From a Phase I Trial of Duvelisib and Venetoclax www.ascopost.com/videos/2019-ash-annual-meeting-expositio… #leusm #lymsm #hematology #ash19 #ash2019 @DanaFarber
-
Verastem Oncology reposted
Nature Reviews Disease Primers
@DiseasePrimers
Our new Primer on Follicular #lymphoma is now live! Check it out! go.nature.com/38yl5Kf #curefl
-
Verastem Oncology
@VerastemOncolog
Jon Pachter, Chief Scientific Officer at Verastem, shares his thoughts on the unmet needs of the #ptcl treatment landscape as #ash19 wraps up. Read more: www.linkedin.com/pulse/shedding-light-unmet-needs-periphe…
-
Verastem Oncology
@VerastemOncolog
And it's a wrap of #ash19 for team Verastem!
-
Verastem Oncology reposted
Dana-Farber News
@DanaFarberNews
Duvelisib and Venetoclax are currently used as monotherapies in relapsed or refractory #cll and #sll. Dana-Farber's Jennifer Crombie, MD, is studying whether these drugs can be combined for an improved therapy #ash19 #leusm #lymsm
Abstract link: ash.confex.com/ash/2019/webprogram/Paper127343.html -
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Today we announced #clinical data in relapsed/refractory peripheral T-cell #lymphoma, #cll, #sll, and more, being presented at #ash19. Read here: investor.verastem.com/news-releases/news-release-details/… #inhl #ptcl
-
Verastem Oncology reposted
CLL Society Inc.
@CllSociety
Proud to be presenting our abstract 4716 An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL) at ASH 2019 between 6 and 8 PM tonight in Orlando.
-
Verastem Oncology reposted
Matthew Davids, MD, MMSc
@DrMDavids
Nice summary of our ph1 study from @DanaFarber of duvelisib + venetoclax in R/R CLL presented here at #ash2019 Online+Only journals.lww.com/oncology-times/blog/onlinefirst/pages/po… @VerastemOncolog
-
Verastem Oncology reposted
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
Together, LLS & @ASH_hematology are teaming up to expand clinical trial access for blood #cancer patients, giving physicians and their patients easy access to LLS’s clinical trial nurse navigators. Read more: www.lls.org/lls-us-hq/news/lls-and-the-american-society-o… #fightbloodcancer
-
Verastem Oncology
@VerastemOncolog
RT From #ash19, PRIMO Study in Relapsed or Refractory Peripheral T-Cell Lymphoma www.oncozine.com/ash-2019-primo-study-evaluates-duvelisib… via @OncoZine
-
Verastem Oncology reposted
TCLL Foundation
@TCLLF
Last night @VerastemOncology awarded Dr. Andrei Shustov, president and co-founder of TCLLF, with their 2nd annual ‘Innovation in Care Award.’ For him it’s all about the patients—but last night was about him. Please join us in congratulating Dr. Shustov on this well-deserved award
-
Verastem Oncology
@VerastemOncolog
Today we announced #clinical data in relapsed/refractory peripheral T-cell #lymphoma, #cll, #sll, and more, being presented at #ash19. Read here: investor.verastem.com/news-releases/news-release-details/… #inhl #ptcl
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Join us tomorrow at #ash19 poster session, with @DrMDavids sharing #data from an investigator-sponsored Phase 1 study on relapsed or refractory #cll and #sll. Poster #1763 from 5:30-7:30 pm ET
-
Verastem Oncology reposted
Matthew Davids, MD, MMSc
@DrMDavids
Early start here at #ash2019 —happy to be moderating the 1L CLL therapy oral abstract session this am at 7:30. Excited to hear all six abstracts, especially the very first presentation of our Investigator-initiated Ph2 AVO trial from @DanaFarber.
-
Verastem Oncology
@VerastemOncolog
Tonight at #ash19 we’re honoring Dr. Andrei Shustov with the 2019 Innovation in Care Award. As a leader in the field, Dr. Shustov has dedicated his career to supporting research efforts for those affected by T-cell #leukemia and #lymphoma. @TCLLF
Verastem Oncology
@VerastemOncolog
Thank you for your dedication to patients @TCLLF
-
Verastem Oncology
@VerastemOncolog
Join us tomorrow at #ash19 poster session, with @DrMDavids sharing #data from an investigator-sponsored Phase 1 study on relapsed or refractory #cll and #sll. Poster #1763 from 5:30-7:30 pm ET
-
Verastem Oncology reposted
ASH
@ASH_hematology
We're pleased to announce that @LLSusa and @ASH_hematology are collaborating to expand access to LLS’s unique free service providing clinical trials navigation and support to blood cancer patients and their families. www.hematology.org/Newsroom/Press-Releases/2019/10094.aspx
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
We will be at #ash19 presenting 4 posters featuring data on relapsed/refractory peripheral T-cell #lymphoma, #cll, #sll, and more. investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology reposted
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
Your support on #givingtuesday is critical to a cure for blood cancer. LLS has made breakthroughs in immunotherapy, genomics and personalized medicine that are improving and saving the lives of patients. Support us to #fightbloodcancer >> www.lls.org/givingtuesday
-
Verastem Oncology reposted
CLL Society Inc.
@CllSociety
CLL Society to Present Innovative Telemedicine Platform Study at American Society of Hematology Annual Conference benzinga.com/z/14908396 via @benzinga
-
Verastem Oncology reposted
Blood Journals Portfolio
@BloodPortfolio
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in #cll after chemoimmunotherapy ashpublications.org/blood/article/134/22/1951/374988/Mini…
-
Verastem Oncology
@VerastemOncolog
We look forward to connecting with you and hearing the latest #hematology research at the 61st @ASH_hematology Annual Meeting. Visit us at Booth 601. #cll #lymsm #ash19
-
Verastem Oncology
@VerastemOncolog
Today we announced the submission of Marketing Authorization Application to the European Medicines Agency (EMA) for duvelisib. $VSTM
Read more investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology reposted
PeerView
@PeerView
Register now for our #lymphoma Friday December 6th symposium: Realizing the Promise of Novel Therapeutics in NHL with @JohnPLeonardMD, @lymphomaphilia, @rule_simon, and @DrNathanFowler www.peerview.com/815/19NHL #ash19
-
Verastem Oncology reposted
Light The Night
@LightTheNight
Strength 💪
Courage 🏅
Love 💙
Hope 🕯️
Family 🤝
Which of these has been the most important in your life? Reply with the word that helps you get through your trying times. #lightthenight -
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
Patrick Quinlan has experienced blood #cancer from many different perspectives: as a caregiver, advocate, and as a survivor himself. Listen to Patrick's moving story here, as he describes his role as a caregiver to his son & his own non-Hodgkin lymphoma diagnosis. #llscaregiver
This media couldn't be displayed. See it on the original post. -
Verastem Oncology
@VerastemOncolog
Today, we announced Dr. Andrei Shustov as the 2019 Innovation in Care Award recipient. Recognizing lack of resources for patients with T-cell #lymphomas and #leukemias, he’s dedicated his career to advocating for those affected by these diseases. investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology reposted
Blood Journals Portfolio
@BloodPortfolio
Blood Spotlight: Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma ashpublications.org/blood/article/134/19/1573/375003/Duve…
-
Verastem Oncology reposted
Carey Jansen, MD PhD
@careyjans
awesome @sitcancer poster presentation yesterday by @RonnieFunk8 of @ekwaller lab... exciting results — looking forward to the full manuscript! @WinshipAtEmory @EmoryMedicine @VerastemOncolog #sitc2019
-
Verastem Oncology reposted
Francesco Bertoni
@frbertoni
Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma | Blood | American Society of Hematology ashpublications.org/blood/article/134/19/1573/375003/Duve…
-
Verastem Oncology
@VerastemOncolog
We will be at #ash19 presenting 4 posters featuring data on relapsed/refractory peripheral T-cell #lymphoma, #cll, #sll, and more. investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology announces Q3 2019 financial results. Read the press release $VSTM
investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
NEWS: Verastem Oncology will be presenting five posters at #lymphomamyeloma2019 highlighting clinical data in #cll, #sll, and refractory #marginalzonelymphoma. investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Our team members gathered to show Verastem's support for patients with #bloodcancer with @LLusa New England Chapter @LightTheNight.
-
Verastem Oncology
@VerastemOncolog
Join us in Boston tonight as we bring light to the darkness of #bloodcancer. We’re supporting #lightthenight @LLSusa New England Chapter as @LightTheNight Corporate Walk Chair.
-
Verastem Oncology
@VerastemOncolog
ANNOUNCEMENT: Join us on Oct. 29 at 4:30 pm ET for a live call and webcast as we share Q3 financial results and a corporate update. #earnings $vstm investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
Never underestimate the power of the human spirit. 💪#fightbloodcancer #mondaymotivation
-
Verastem Oncology
@VerastemOncolog
Congratulations!
Dana-Farber
@DanaFarber
🚨 BREAKING NEWS 🚨 We are thrilled to announce that Dana-Farber’s William G. Kaelin Jr., MD, has been named one of three researchers awarded the 2019 #nobelprize in Physiology or Medicine! Learn more: www.nobelprize.org/prizes/medicine/2019/press-release/
-
Verastem Oncology
@VerastemOncolog
We’re partnering with Yakult Honsha Co., Ltd., who recently enrolled the first patient in a study to form the basis for their regulatory submission in Japan. An important step toward expanding potential treatment options for #cll and SLL in Japan. investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Yesterday, we announced #orphandrugdesignation by @US_FDA in t-cell #lymphoma. Our CEO reflects on how this milestone will help us toward our goal of expanding options for patients in need. investor.verastem.com/news-releases/news-release-details/… #raredisease
-
Verastem Oncology
@VerastemOncolog
NEWS: #orphandrugdesignation granted to Verastem Oncology by @US_FDA for treatment of t-cell #lymphoma patients. #raredisease Read press release: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Today we announced preclinical data in mantle cell #lymphoma to be presented at the 5th International Conference on New Concepts in Lymphoid Malignancies #eshlymphoid2019 Annual Meeting. See details:
investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
Blood Cancer Awareness Month may end, but the fight will not. Thank you to all of our partners who strive daily to support people living with blood cancers. You inspire us. #bloodcancer #bcam #lightitred
-
Verastem Oncology
@VerastemOncolog
On 9/22, Verastem Oncology took part in the @AmericanCancer Pulling For Hope event to honor cancer survivors, and raise awareness of blood cancers, the third leading cause of cancer deaths in the U.S. #bloodcancer #bloodcancerawarenessmonth
-
Verastem Oncology
@VerastemOncolog
Honored to support @LLSusa New England Chapter as @LightTheNight Corporate Walk Chair. Join us in Boston on October 17. Learn more: lightthenight.org/new-england/article/verastem-oncology-n…
#lightthenight #bloodcancer -
Verastem Oncology
@VerastemOncolog
We’re at #iwcll2019, the world’s largest meeting dedicated to #cll to present three posters highlighting clinical data. Looking forward to connecting with attendees advancing care for patients with CLL. investor.verastem.com/news-releases/news-release-details/…
#lymsm #leusm -
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
A new study published in @eLife highlights research from the ROCKIF trial at @UCSanDiego with an investigational #fak inhibitor being studied for use in combination with chemotherapy for chemo-resistant #ovariancancer. health.ucsd.edu/news/press-releases/2019-09-03-FAK-protei…
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
Our mission: Cure blood cancer and improve the quality of life of patients, survivors and their families. #fightbloodcancer #bloodcancerawarenessmonth
-
Verastem Oncology
@VerastemOncolog
A new study published in @eLife highlights research from the ROCKIF trial at @UCSanDiego with an investigational #fak inhibitor being studied for use in combination with chemotherapy for chemo-resistant #ovariancancer. health.ucsd.edu/news/press-releases/2019-09-03-FAK-protei…
-
Verastem Oncology
@VerastemOncolog
Lymphoma is the most common blood cancer. In honor of #worldlymphomaawarenessday on September 15, support and empower people living with #lymphoma by sharing a fact with hashtag #wlad2019 and help the Confidence Tree grow. www.worldlymphomaawarenessday.com/en/confidence-tree @knowyournodes
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology is working to #lightitred this September in honor of #worldlymphomaawarenessday today. Learn how you can get involved: www.lymphoma.org/aboutlrf/impact/awareness/lightitred/
#lymphoma #bloodcancer @lymphoma -
Verastem Oncology
@VerastemOncolog
RT. Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL www.onclive.com/conference-coverage/soho-2019/duvelisib-d…
-
Verastem Oncology
@VerastemOncolog
Excited to present four posters highlighting our clinical data and analyses at #soho2019
-
Verastem Oncology
@VerastemOncolog
Each year, 100K+ Americans are diagnosed with #lymphoma – the most common type of blood cancer. That’s why Verastem Oncology is partnering with @lymphoma for #lightitred to shed a “light” on this cancer during #bloodcancerawarenessmonth
www.lymphoma.org/aboutlrf/impact/awareness/lightitred/ -
Verastem Oncology
@VerastemOncolog
September is #bloodcancerawarenessmonth. Verastem Oncology is committed to raising awareness and supporting those living with or affected by blood cancers and we encourage everyone to help spread the word. #bloodcancer #bcam
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology to Present at the 21st Annual H.C. Wainwright Global Investment Conference on Tuesday, September 10, 2019 at 10:25 a.m. EDT in New York, NY investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology reposted
Light The Night
@LightTheNight
Have you heard about the #kissbloodcancergoodbye challenge? Start thinking of your post ideas! Get the details here: www.lls.org/kissbloodcancergoodbye
Blood Cancer United
@BloodCancerUtd
September is #bloodcancerawarenessmonth! We CHALLENGE you to #kissbloodcancergoodbye! 😘 Raise awareness & funds for a world without blood #cancer. Post a photo/video kissing blood cancer goodbye & tag 3 friends to post or donate to LLS! Get more info: www.lls.org/kissbloodcancergoodbye
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology announces four poster presentations highlighting clinical data at the Society of Hematologic Oncology 2019 #soho19 Annual Meeting on September 11-14, 2019 in Houston. #cll #hemeonc
See details investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
RT www.onclive.com/peer-exchange/follicular-lymphoma-managem…
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
As we gear up for Blood Cancer Awareness Month, we are spreading education and lifting our voices for a cure. Together with the Office of Public Policy, your voice can make a difference. Become an #advocate: www.lls.org/advocate/public-policy. #fightbloodcancer @LLSAdvocacy
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
We are committed to helping improve patients' experience with VerastemCares, our comprehensive program designed to provide information and support to eligible patients. copiktrahcp.com/cll-sll/support/
-
Verastem Oncology reposted
Light The Night
@LightTheNight
Which city has the most passionate #lightthenight participants? 🌃🌇 Comment with the name of the city where your walk takes place and show your love. The city that receives the most mentions will receive a special SHOUT OUT!
-
Verastem Oncology reposted
OncLive SOSS
@OncLiveSOSS
Sameem Abedin, MD, of @MedicalCollege, highlights the administration schedules of PI3K inhibitors in CLL www.onclive.com/onclive-tv/dr-abedin-on-pi3k-inhibitors-i…
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
From coast to coast, we're bringing light to the darkness of #cancer by honoring patients, survivors and loved ones during our inspirational @LightTheNight events. Join us for this uplifting experience in a community near you: lightthenight.org
-
Verastem Oncology
@VerastemOncolog
Today Aug 1, @VerastemOncolog $VSTM reported Q2 2019 financial results and an overview of recent company progress: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology reposted
Sanofi
@sanofi
#sanofi announces exclusive licensing agreement with
@VerastemOncolog, a collaboration that will enable us to deliver enhanced patient care and expand our presence in emerging markets. Learn more about our work in #oncology: www.sanofi.com/en/your-health/oncology -
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Join our live webcast on Aug 1 to review Q2 2019 financial results and corporate updates. View details here: investor.verastem.com/news-releases/news-release-details/… $VSTM
-
Verastem Oncology
@VerastemOncolog
RT Verastem taps board director and Eli Lilly vet Brian Stuglik to right the commercial boat - endpts.com/verastem-taps-board-director-and-eli-lilly-vet…
-
Verastem Oncology
@VerastemOncolog
Risk Assessment in Follicular Lymphoma www.onclive.com/peer-exchange/follicular-lymphoma-managem… via @onclive
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology proudly announces the appointment of Brian Stuglik as Chief Executive Officer. Read press release investor.verastem.com/news-releases/news-release-details/… $VSTM
-
Verastem Oncology
@VerastemOncolog
Join our live webcast on Aug 1 to review Q2 2019 financial results and corporate updates. View details here: investor.verastem.com/news-releases/news-release-details/… $VSTM
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology is proud to partner with @Sanofi to bring our treatment to patients in Russia and CIS, Turkey, the Middle East and Africa. investor.verastem.com/news-releases/news-release-details/…
#lymsm #leusm #cll $VSTM -
Verastem Oncology reposted
Sarah Cannon Docs
@SarahCannonDocs
Watch as Dr. Ian Flinn discusses findings from the DUO trial and the effect of dose modifications on response to duvelisib #cll #sll
jnccn360.org/cll/videos/effect-of-dose-modifications-on-r… -
Verastem Oncology reposted
Lymphoma Hub
@lymphomahub
CONGRESS | #15icml | Steven M. Horowitz, @sloan_kettering, discusses rationale for phase II PRIMO trial of duvelisib in R/R peripheral T-cell lymphoma #lymsm promising early activity of PI3ki duvelisib in patients with PYtCL.
-
Verastem Oncology
@VerastemOncolog
Thanks to the @CLLSociety and @briankoffman for their CLL Society Alert and blog post. We’re honored to have this study highlighted by the CLL Society. #cll #leusm #lymsm #ash19 cllsociety.org/2019/06/ash-2018-dr-davids-on-the-efficacy…
-
Verastem Oncology
@VerastemOncolog
At #icml2019, Dr. Steven Horwitz from MSK presented Phase 1 data from two studies in patients with relapsed or refractory PTCL. Full details are available at: investor.verastem.com/news-releases/news-release-details/…
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology Announces Leadership Changes
investor.verastem.com/news-releases/news-release-details/… -
Verastem Oncology
@VerastemOncolog
Verastem Oncology Presents New Data at the European Hematology Association 2019 Annual Meeting $VSTM #eha24
investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… -
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
#happyfatherday to all dads who are with us today and with us always in spirit. ❤️
-
Verastem Oncology
@VerastemOncolog
Our team having a great time at #eha24 Congress! Last few days were full of cutting edge updates in so many areas of #hematology. Exiting times to be in this field.
-
Verastem Oncology
@VerastemOncolog
Missed our #eha24 poster presentation? You can still view it, abstract #ps1157 or here www.verastem.com/wp-content/uploads/2019/06/DUO_Lymphocyt…
Verastem Oncology
@VerastemOncolog
Verastem team is heading to #eha24 Congress tomorrow in Amsterdam. Stop by our Booth 1010 to learn more about our pipeline and clinical trials. #cll #lymsm #leusm
-
Verastem Oncology reposted
Zack Pemberton-Whiteley (he/him)
@ZPWHITELEY
Kicking off #eha24 with the patient advocacy capacity building session
First up @jangeissler shares his insight into how to get the best out of the conference
70 advocates of 12,000 delegates! #leukemia -
Verastem Oncology
@VerastemOncolog
View NEW data on effect of dose modifications in patients with relapsed/refractory CLL/SLL, presented at #eha24 this Saturday June 15.
#cll #pi3k #leusm -
Verastem Oncology
@VerastemOncolog
Verastem team is heading to #eha24 Congress tomorrow in Amsterdam. Stop by our Booth 1010 to learn more about our pipeline and clinical trials. #cll #lymsm #leusm
-
Verastem Oncology reposted
VJHemOnc
@VJHemOnc
VIDEO: DUO trial: duvelisib for #cll / #sll, with Ian Flinn from Tenessee Oncology, Nashville: www.vjhemonc.com/video/_pnmppi1a0-duo-trial-duvelisib-for… @ASCO #asco19 #chroniclymphoidleukemia #smalllymphocyticlymphoma #leukemia #immunoonc #hemeonc #leusm
-
Verastem Oncology
@VerastemOncolog
Great work recently published in @nresearchnews. Broad @broadinstitute and @DanaFarber scientists examining how genomic features of cancer relate to growth dynamics in naturally progressing chronic lymphocytic leukemia. #cll
www.nature.com/articles/s41586-019-1252-x -
Verastem Oncology reposted
Michele Nadeem-Baker
@MicheleNadeemB
#cll Folks: Patterns of chronic lymphocytic leukemia growth identified - Broad Institute www.broadinstitute.org/news/patterns-chronic-lymphocytic-… via @broadinstitute @dana-farber @CLLSociety @CLLFighters @PatientPower
-
Verastem Oncology reposted
National Cancer Institute
@theNCI
A vaccine to treat non-Hodgkin lymphoma is being tested in two clinical trials: www.cancer.gov/news-events/cancer-currents-blog/2019/in-s… #nonhodgkinlymphoma #lymsm #immunotherapy
-
Verastem Oncology
@VerastemOncolog
Last #asc019 day on Tuesday! Another fantastic @ASCO meeting wrapping up with some great remaining #hemeonc sessions tomorrow.
-
Verastem Oncology reposted
Amy C. Cavers
@cavemom11
Just a fraction of the confidence, courage and spirit of the women in the room. Thank you @VaniamGroup! Women Leaders in Oncology INSPIRED! #asco19 #wlo #conquercancer @ConquerCancerFd @ASCO #jodieemery #leadership
-
Verastem Oncology reposted
OncLive SOSS
@OncLiveSOSS
Don't miss your chance to register for the June 12th #stateofscience on Hematologic Malignancies in Pittsburgh, where the faculty of @UPMCnews will cover the current and emerging treatment landscapes of Hodgkin's and NHL, multiple myeloma, and more! www.onclive.com/meetings/soss
-
Verastem Oncology
@VerastemOncolog
Monday at #asco19: view NEW data on effect of dose modifications in patients with relapsed/refractory CLL/SLL. Poster #277 at “Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia”.
investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… @SarahCannonDocs
#cll #lymsm #leusm -
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
Today we celebrate #nationalcancersurvivorsday by honoring those who have fought and continue to fight #cancer each day. Your strength is inspirational!
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Excited to kick off #asco19 today in Chicago! Looking forward to present new CLL/SLL data on Monday, June 3rd. Stop by Verastem Oncology Booth 4063 to meet us and learn more. #cll #lymsm #leusm
-
Verastem Oncology reposted
The Lancet Oncology
@TheLancetOncol
#asco19: @BidenCancer session on increasing #clinicaltrial participation to break 5% barrier. Great ambition. See a new paper on improving conduct of trials with master protocols (free with reg til Jun 4) www.thelancet.com/journals/lanonc/article/PIIS1470-2045(1…
-
Verastem Oncology
@VerastemOncolog
What is #asco19 without cornets? What is a cornet? Come by Verastem’s booth and find out!
-
Verastem Oncology reposted
Jamie Holloway, PhD
@jamienholloway
Biggest barrier to clinical trial enrollment? Geography. Trial is not offered at local clinic. #asco19
-
Verastem Oncology reposted
Blood Cancer United Research
@bcutd_research
Another excellent study in @nature by #llsscholar Catherine Wu of @DanaFarber @DanaFarberNews and @gaddyg of @broadinstitute on #cll growth patterns.
Dana-Farber News
@DanaFarberNews
Dana-Farber study identifies patterns of chronic lymphocytic leukemia growth: www.dana-farber.org/newsroom/news-releases/2019/patterns-… via @nresearchnews #cll
-
Verastem Oncology
@VerastemOncolog
Excited to kick off #asco19 today in Chicago! Looking forward to present new CLL/SLL data on Monday, June 3rd. Stop by Verastem Oncology Booth 4063 to meet us and learn more. #cll #lymsm #leusm
-
Verastem Oncology reposted
Sarah Cannon Docs
@SarahCannonDocs
@dave6408 looks forward to sharing the latest in immunotherapies and targeted therapies. Retweet and share with us what you’re excited to see @ASCO this weekend #asco19
-
Verastem Oncology reposted
ASCO
@ASCO
The #asco19 theme is “Caring for Every Patient, Learning From Every Patient” – but to do that successfully, our workforce must represent the population it serves. @ASCOPres explains why we’re tackling #diversity in the oncology workforce.
-
Verastem Oncology reposted
Oncology Times
@OncologyTimes
ASCO Launches New Initiative to Improve Rural Cancer Care journals.lww.com/oncology-times/Fulltext/2019/05200/ASCO_… #tuesdaymotivation #healthcare #asco19 via @CliffordHudis
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
NEW data being presented by Verastem Oncology at #asco19. Effect of Dose Modification on Response in Patients with Relapsed or Refractory #cll/SLL in the Phase 3 DUO Study investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology
@VerastemOncolog
We are committed to helping improve patients' experience with VerastemCares, our comprehensive program designed to provide information and support to eligible patients. copiktrahcp.com/cll-sll/support/
-
Verastem Oncology reposted
Nature Reviews Molecular Cell Biology
@NatRevMCB
Fresh from press excellent #review by Vanhaesebroeck, Posor and Bilanges @uclcancer
on #pi3ks in #cellsignaling and #memrbanetrafficking go.nature.com/2JWw86j -
Verastem Oncology reposted
PeerView
@PeerView
Live expert MasterClass on novel targeted agents, #immunotherapy, and immunomodulators for #bcell #lymphoma during #asco19 at the Hyatt Regency Chicago www.peerview.com/810/Lymphoma19
-
Verastem Oncology reposted
OncLive SOSS
@OncLiveSOSS
Danielle M. Brander, MD, highlights targeted agents in CLL, including PI3K inhibitors and anti-apoptotic inhibitors www.onclive.com/onclive-tv/dr-brander-on-targeted-agents-…
-
Verastem Oncology
@VerastemOncolog
NEW data being presented by Verastem Oncology at #asco19. Effect of Dose Modification on Response in Patients with Relapsed or Refractory #cll/SLL in the Phase 3 DUO Study investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology reposted
Oncology Tube
@oncologytube
Duvelisib and FCR: a recipe for success in CLL www.oncologytube.com/video/duvelisib-and-fcr-a-recipe-for…
-
Verastem Oncology reposted
Cancer News
@Cancer_bio
Verastem Oncology to Present New COPIKTRA Duvelisib Dose Modification Data from Patients Treated in the Phase 3 DUO Study: Abstract Highlights the Effect of Dose Modification on Response to COPIKTRA in Adult Patients with CLLSLL After At Least Two Prior… bioportfol.io/R4mwq1
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
We are committed to helping improve patients' experience. Learn about VerastemCares, our comprehensive, personalized program designed to provide information and product support to eligible patients throughout treatment.
www.verastem.com/patients/verastemcares/ -
Verastem Oncology reposted
Targeted Onc
@TargetedOnc
In this interview with Targeted Oncology, Dr. Barrientos discussed the emerging treatment options for patients with CLL, as well as some of the other strategies being looked at in clinical trials: ht.ly/pF9830oHpWg
#leusm #bloodcancer -
Verastem Oncology reposted
Mike Thompson, MD, PhD, FASCO
@mtmdphd
#alliancespring19 #lymsm @JohnPLeonardMD Chair - Mehta-Shah - Ph2 T- cell lymphoma - CHOP or CHOEP +/- (duvelisib or 5-azacitidine)
-
Verastem Oncology
@VerastemOncolog
To all the amazing nurses - you rock! Thank you for your dedication, for supporting patients and families every day, for giving them strengths to go on, for being a heart of the healthcare. #nationalnursesweek
Dana-Farber
@DanaFarber
It’s National Nurses Week, and we’re celebrating our nurses at Dana-Farber who play a critical role in cancer care. Thank you for all you do! ❤️ #nursesweek
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Dr. Abedin Discusses Key Updates in CLL shar.es/a01JV1 via @onclive
-
Verastem Oncology reposted
OHSU Knight Cancer Institute
@OHSUKnight
A #nursesweek message from Dr. Brian Druker:
“In our mission to eliminate the burden of cancer, you are on the front line, providing care for our patients and their families every day... On behalf of the physicians and the @OHSUKnight Leadership Team, thank you for all you do!” -
Verastem Oncology reposted
Nature Reviews Disease Primers
@DiseasePrimers
Chronic lymphocytic #leukaemia is a malignancy of CD5+ B cells.
Signalling via the B cell receptor and several genetic alterations play a part in #cll pathogenesis
go.nature.com/2Sg6T3q -
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Verastem Oncology to Announce First Quarter 2019 Financial Results and Corporate Update on May 9, 2019 $VSTM investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
What inspires your strength? #fightbloodcancer
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology to Announce First Quarter 2019 Financial Results and Corporate Update on May 9, 2019 $VSTM investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology
@VerastemOncolog
Dr. Abedin Discusses Key Updates in CLL shar.es/a01JV1 via @onclive
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Proud to see DYNAMO, a Phase II Study in Patients With Refractory Indolent Non-Hodgkin Lymphoma, published in this week's issue of @JCO_ASCO @SarahCannonDocs investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology reposted
Oncology Times
@OncologyTimes
DYNAMO Study Supports Duvelisib for Indolent Non-Hodgkin #lymphoma journals.lww.com/oncology-times/Fulltext/2019/03201/DYNAM… #hemonctimes #bloodcancer
-
Verastem Oncology
@VerastemOncolog
We are committed to helping improve patients' experience. Learn about VerastemCares, our comprehensive, personalized program designed to provide information and product support to eligible patients throughout treatment.
www.verastem.com/patients/verastemcares/ -
Verastem Oncology reposted
OncLive.com
@OncLive
The introduction of novel agents such as ibrutinib, idelalisib, venetoclax and duvelisib, though not curative, are showing potential for deep remissions both as monotherapy and in combination in patients with CLL @DanaFarber #leusm www.onclive.com/web-exclusives/novel-agents-show-enhanced…
-
Verastem Oncology reposted
Rafael Gaiolla
@rafagaiolla
Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma www.bloodjournal.org/content/133/15/1664
-
Verastem Oncology
@VerastemOncolog
Proud to see DYNAMO, a Phase II Study in Patients With Refractory Indolent Non-Hodgkin Lymphoma, published in this week's issue of @JCO_ASCO @SarahCannonDocs investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology reposted
Sarah Cannon Docs
@SarahCannonDocs
Important data released in Journal of Clinical Oncology led by Dr. Ian Flinn on ‘DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma’. @VerastemOncolog Learn more about the advancements in research ascopubs.org/doi/full/10.1200/JCO.18.00915
-
Verastem Oncology
@VerastemOncolog
We’re excited to be at #onscongress this year. Come by booth 211 to say hi and learn more
-
Verastem Oncology reposted
Skip Burris, MD
@BurrisSkip
Proud of Dr Flinn & the Sarah Cannon team in leading this trial. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma | Journal of Clinical Oncology @SarahCannonDocs @Verastem Oncology ascopubs.org/doi/full/10.1200/JCO.18.00915
-
Verastem Oncology reposted
Dr T. Comeau , MD
@SCTNB
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/full/10.1200/JCO.18.00915
-
Verastem Oncology reposted
UT MD Anderson
@UTMDAnderson
B-cell #lymphoma survivor Michael Baker shares his advice for dealing with a #cancer diagnosis: “Look at this disease right between the eyes and laugh at it.” www.mdanderson.org/cancerwise/for-follicular-lymphoma-sur… #lymsm #cancermoonshot #endcancer
-
Verastem Oncology reposted
Light The Night
@LightTheNight
When we walk, cancer runs. See the power we have as a community - together we will find a cure for cancer.
-
Verastem Oncology reposted
MassBio
@MassBio
Great meetings today with @RepMcGovern @joekennedy @USRepKeating and the rest of the MA federal delegation as part of @IAmBiotech BIO Fly-In talking patient access, value, and biotech as economic driver. @VerastemOncolog @SQZBiotech @FlexionInc
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
The ASCO Post
@ASCOPost
DYNAMO: Duvelisib in Refractory Indolent Non-Hodgkin Lymphoma www.ascopost.com/News/59768 #lymsm #hematology
-
Verastem Oncology reposted
John F.X. Heffernan
@jfxheff
Great group assembled for @IAmBiotech @MassBio Capitol Hill visits @AprilFoolSue @FlexionInc @SQZBiotech @VerastemOncolog
-
Verastem Oncology reposted
Sarah Cannon Docs
@SarahCannonDocs
On this #doctorsday our CMO, @burrisskip shares why he loves being a doctor #fightingcancertogether
-
Verastem Oncology
@VerastemOncolog
We are committed to helping improve a patient’s experience. That’s why we created VerastemCares, a comprehensive, personalized program designed to provide information and product support to eligible patients throughout treatment.
-
Verastem Oncology reposted
The ASCO Post
@ASCOPost
DYNAMO: Duvelisib in Refractory Indolent Non-Hodgkin Lymphoma www.ascopost.com/News/59768 #lymsm #hematology
-
Verastem Oncology
@VerastemOncolog
RT Honoring #womeninscience from @sloan_kettering
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Wonder Woman didn't need to wear a cape to be a superhero and neither did these "Sheroes" of science. In honor of Women's History Month, meet three MSK women who shook up cancer care. www.mskcc.org/news/scientist-turned-activist-mathilde-kri…
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
At Verastem Oncology, we are driven by the strength, tenacity and courage of those battling #cancer. Hear our stories to learn about who we are as a company and why we care differently.
youtu.be/J2uQp2g_4I4 via @YouTube -
Verastem Oncology
@VerastemOncolog
Verastem Oncology will be presenting at these upcoming investor conferences:
investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… -
Verastem Oncology reposted
Journal of Clinical Oncology
@JCO_ASCO
Targeting PI3K-gamma in non-Hodgkin lymphoma ascopubs.org/doi/abs/10.1200/JCO.19.00215 #lymsm
-
Verastem Oncology reposted
Blood Journals Portfolio
@BloodPortfolio
Inside Blood Commentary: Targeting CD20 takes the backseat in #cll www.bloodjournal.org/content/133/10/1003?sso-checked=true @OhioState
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Verastem Oncology to announce fourth quarter and full-year 2018 financial results and corporate updates on March 12, 2019. $VSTM
investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… -
Verastem Oncology
@VerastemOncolog
Announcing Q4 results tomorrow 3/12 $VSTM
Verastem Oncology
@VerastemOncolog
Verastem Oncology to announce fourth quarter and full-year 2018 financial results and corporate updates on March 12, 2019. $VSTM
investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… -
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Verastem Oncology presents Phase 3 DUO™ data in patients with CLL/SLL who have progressed following two prior lines of therapy at the 23rd Annual International Congress on Hematologic Malignancies. #cll #leusm #leukemia #hemeonc
investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… -
Verastem Oncology
@VerastemOncolog
Verastem Oncology Presents Further Data at the 23rd Annual International Congress on Hematologic Malignancies investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology reposted
Mayo Clinic Comprehensive Cancer Center
@MayoCancerCare
#infographic: #leukemia, #lymphoma & #myeloma - Understanding and treating #bloodcancer #mmsm #lymsm #leusm mayocl.in/2GSOjIt
-
Verastem Oncology reposted
Paul Knoepfler
@pknoepfler
Seriously bad news: Commissioner @SGottliebFDA leaving the FDA www.washingtonpost.com/health/2019/03/05/fda-commissioner… Bad on many levels including re: #stemcell clinics
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology presents Phase 3 DUO™ data in patients with CLL/SLL who have progressed following two prior lines of therapy at the 23rd Annual International Congress on Hematologic Malignancies. #cll #leusm #leukemia #hemeonc
investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… -
Verastem Oncology reposted
Light The Night
@LightTheNight
"Be brave enough to travel the unknown path, and learn what you are capable of." - Rachel Wolchin
-
Verastem Oncology reposted
Biden Cancer
@BidenCancer
On #rarediseaseday, we celebrate the #cancerfierce that we know drives each patient, family, and community to navigate the twists and turns of their cancer journeys.
-
Verastem Oncology reposted
Nathan Fowler
@DrNathanFowler
Fowler Highlights Trials Accruing at MD Anderson for Relapsed/Refractory Follicular Lymphoma shar.es/am7OEK via @TargetedOnc
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Verastem Oncology to present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019 at 10:30 a.m. EST investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology
@VerastemOncolog
Welcome Amy, so glad to have you at Verastem Oncology!
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology to announce fourth quarter and full-year 2018 financial results and corporate updates on March 12, 2019. $VSTM
investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… -
Verastem Oncology reposted
CancerNetwork®
@CancerNetwrk
Could oral duvelisib be a potential new option for indolent non-Hodgkin #lymphoma? www.cancernetwork.com/view/oral-duvelisib-potential-new-o… #cancer
-
Verastem Oncology
@VerastemOncolog
The ASCO Post
@ASCOPost
DYNAMO: Duvelisib in Refractory Indolent Non-Hodgkin Lymphoma www.ascopost.com/News/59768 #lymsm #hematology
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology to present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019 at 10:30 a.m. EST investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology reposted
Lymphoma Research Foundation
@lymphoma
Read findings from the Foundation's @BidenCancer Community Summit panel addressing the early career scientist crisis. #lymphoma #lymphomaresearch www.lymphoma.org/newsarchive/foundation-releases-monograp…
-
Verastem Oncology reposted
CLL Society Inc.
@CllSociety
Do you or one of your loved ones have #cll? The CLL Society exists to help you become empowered to find the very best care for you or your loved one. We believe smart patients get smart care. Our DMs are open.
#cancersucks #bloodcancer #leukemia #letscurethis -
Verastem Oncology reposted
The Lancet Oncology
@TheLancetOncol
News: Duvelisib in indolent #nonhodgkinlymphoma www.thelancet.com/journals/lanonc/article/PIIS1470-2045(1…
-
Verastem Oncology
@VerastemOncolog
Being a #cancercaregiver is a jouney that tests the depths of our resilience and compassion. With enourmous gratitude, we honor the difference caregivers make every day in the lives of their loved ❤️ones. #nationalcaregiversday
-
Verastem Oncology reposted
Journal of Clinical Oncology
@JCO_ASCO
Phase II study of duvelisib in people with refractory indolent non-Hodgkin lymphoma ascopubs.org/doi/abs/10.1200/JCO.18.00915 #lymsm
-
Verastem Oncology
@VerastemOncolog
RT A Phase II Study in Patients With Refractory Indolent Non-Hodgkin Lymphoma published in @JCO_ASCO www.businesswire.com/news/home/20190214005211/en/Verastem…
-
Verastem Oncology reposted
Hayder Saeed, MD
@HayderSaeed_MD
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. #lymsm @JCO_ASCO ascopubs.org/doi/full/10.1200/JCO.18.00915
-
Verastem Oncology
@VerastemOncolog
At Verastem Oncology, we are driven by the strength, tenacity and courage of those battling #cancer. Hear our stories to learn about who we are as a company and why we care differently.
youtu.be/J2uQp2g_4I4 via @YouTube -
Verastem Oncology reposted
The Lancet
@TheLancet
>50% of medical students are men; only 10% of surgeons are women. Women's choice to leave #surgery deprives opportunity for those who leave AND their patients www.thelancet.com/journals/lancet/article/PIIS0140-6736(1… Tim Dornan @LiangRhea #lancetwomen
-
Verastem Oncology reposted
Targeted Onc
@TargetedOnc
Median progression-free survival was 15 months on duvelisib post-crossover compared to 9 months for the patients treated with ofatumumab pre-crossover.
www.targetedonc.com/news/duvelisib-effective-after-progre…
#cllsm #leukemia -
Verastem Oncology reposted
Weill Cornell Leukemia
@WCMLeukemia
.@LLSusa just launched a new Patient Aid Program to help offset treatment-related expenses for people with #bloodcancer. Details here: www.lls.org/support/financial-support/patient-aid-program
-
Verastem Oncology reposted
MDedge Hematology & Oncology
@MDedgeHemOnc
Combo emerges as bridge to #transplant in rel/ref #ptcl www.mdedge.com/hematology-oncology/article/193912/lymphom… #romidepsin #duvelisib #tclf2019 #tclf19
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
RT: Missed a #pi3k session at #ash2018? It is now available online at @MedscapeCME .
Medscape Education
@MedscapeCME
For #hematologists, #oncologists, & #nurses: Learn about who should receive PI3K inhibitors for relapsed/refractory #cll or #follicularlymphoma, and how to manage the adverse effects.
[WATCH NOW]: www.medscape.org/viewarticle/906413?src=soc_tw_190201_msc… #medscapeedu
Authors: @jonathonbcohen of @WinshipAtEmory -
Verastem Oncology reposted
Targeted Onc
@TargetedOnc
Dr. Davids discussed the clinical implications of the phase III DUO trial in patients with CLL: ht.ly/uWm930nAssD Duvelisib appears to be an effective treatment option for patients with relapsed/refractory disease.
#cllsm #bloodcancer #leusm -
Verastem Oncology
@VerastemOncolog
In 2018, over 1.7M cases of #cancer were diagnosed in the US alone. That’s why at Verastem Oncology, we’re resolved to find new therapies that can help keep cancer at bay. We’re inspired by strength, tenacity and courage of those battling cancer, on #worldcancerday and always
-
Verastem Oncology reposted
U.S. Surgeon General
@Surgeon_General
Today is #worldcancerday - especially meaningful as my wife only has 4 months of treatment left for her melanoma. Thanks to @NIH and all the scientists who are working on treatments, & @CDCgov and all who work on prevention- and prayers to those fighting #cancer
-
Verastem Oncology reposted
Light The Night
@LightTheNight
This year try to #empower and #inspire as many people as possible.
-
Verastem Oncology
@VerastemOncolog
RT www.onclive.com/peer-exchange/cll-systemic-therapy/duveli…
-
Verastem Oncology
@VerastemOncolog
RT: Missed a #pi3k session at #ash2018? It is now available online at @MedscapeCME .
Medscape Education
@MedscapeCME
For #hematologists, #oncologists, & #nurses: Learn about who should receive PI3K inhibitors for relapsed/refractory #cll or #follicularlymphoma, and how to manage the adverse effects.
[WATCH NOW]: www.medscape.org/viewarticle/906413?src=soc_tw_190201_msc… #medscapeedu
Authors: @jonathonbcohen of @WinshipAtEmory -
Verastem Oncology reposted
Targeted Onc
@TargetedOnc
Dr. Flinn @SarahCannonDocs discussed the potential impact of duvelisib on patients with CLL in this interview: ht.ly/CYXJ30nxEEq
#leusm #leukemia #cllsm -
Verastem Oncology reposted
ASH
@ASH_hematology
Medical students: Have you ever considered hematology? Check out @AmerMedicalAssn story featuring Dr. Alfred Lee of @YaleMed on "What it’s like to specialize in hematology" www.ama-assn.org/medical-students/preparing-residency/wha… #ashtrainee
-
Verastem Oncology reposted
ASCO
@ASCO
Just Released: ASCO’s Clinical Cancer Advances 2019 Report www.asco.org/research-progress/reports-studies/clinical-c…
-
Verastem Oncology reposted
Lymphoma Research Foundation
@lymphoma
LRF understands that receiving a #lymphoma diagnosis can be different for everyone. That is why LRF offers a wide range of support services to everyone's needs. Watch below to see how LRF's Support Services has helped real lymphoma patients!
www.youtube.com/watch?v=D4sk59ogIgE -
Verastem Oncology
@VerastemOncolog
RT #mondaymotivation A hope for improving cancer management is always a fantastic news!
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Hope for “Undruggable” Cancers. www.mskcc.org/blog/drugs-stall-don-t-kill-cancer-cells-ar…
-
Verastem Oncology reposted
ASH Clinical News
@ASHClinicalNews
Written in @BloodJournal: In the DUO trial, duvelisib improved survival compared with ofatumomab in rel/ref chronic lymphocytic #leukemia www.ashclinicalnews.org/news/duvelisib-bests-ofatumumab-r…
-
Verastem Oncology reposted
Fred Hutch Cancer Center
@fredhutch
Patients facing chronic diseases on top of cancer are often excluded from clinical trials. A study led by our Dr. Joe Unger (@junger47 ) w/ @SWOG suggests loosening eligibility criteria on comorbidities would open trials to thousands more patients. www.fredhutch.org/en/news/center-news/2019/01/cancer-clin…
-
Verastem Oncology reposted
OncLive.com
@OncLive
Duvelisib Provides CLL Patients With a Later Line of Therapy @SarahCannonDocs #leusm www.onclive.com/web-exclusives/duvelisib-provides-cll-pat…
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
Worry less and limit your stress, we're here to help! We know managing the costs of cancer care can be stressful—reach out to us! In addition to our various avenues of help, we're happy to offer financial support. www.lls.org/support/financial-support
-
Verastem Oncology reposted
Parker Institute
@parkerici
In 2020, legislation will require that pharma companies test potential cancer drugs in children as well as adults. “It is an incredibly exciting time,” says pediatric-cancer and PICI researcher at @StanfordMed Crystal Mackall (@cm35c). www.wsj.com/articles/for-children-with-cancer-hope-for-ne…
-
Verastem Oncology reposted
CLL Ireland
@CllIreland
Dr. Davids discusses the research undertaken with @CllSociety exploring how patients with #cll make therapy decisions. Recently presented at #ash18 results suggested patients want involvement in their therapy decisions.
| Journal of Clinical Pathways www.journalofclinicalpathways.com/news/understanding-fact… -
Verastem Oncology
@VerastemOncolog
Great article for #thursdaythoughts
Mikkael A. Sekeres MD, MS
@MikkaelSekeres
My latest essay in @nytimeswell, sweet and sad, about a patient who sang his goodbye to me in clinic. ‘Sentimental Journey’ in the Cancer Clinic - The New York Times www.nytimes.com/2019/01/17/well/live/a-sentimental-journe…
-
Verastem Oncology
@VerastemOncolog
Proud to have represented Verastem Oncology at an incredible gathering of T Cell experts from around the globe in La Jolla!
#tclf19 #tclf2019 -
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
“2018 was a pivotal year for Verastem Oncology, as the U.S. Food and Drug Administration’s approval of our first product and other key accomplishments strongly positioned us to execute on our 2019 corporate priorities” investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology reposted
Mayo Clinic Comprehensive Cancer Center
@MayoCancerCare
Many #bloodcancers and disorders are rare, intimidating, and can leave a person feeling isolated. #mayoclinicconnect members who share your diagnosis and the fear of the unknown offer their digital hands of support. Join an online welcoming community. mayocl.in/2Euooq4
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Great article about the importance of patient education from Dr. Koffman at @CllSociety. So true that “smart patients get smart care”.
CLL Society Inc.
@CllSociety
Dr Brian Koffman: It Is Critical That Patients Educate Themselves and Leverage Their Advantages www.ajmc.com/interviews/dr-brian-koffman-it-is-critical-t… via @AJMC_Journal
-
Verastem Oncology
@VerastemOncolog
Great article about the importance of patient education from Dr. Koffman at @CllSociety. So true that “smart patients get smart care”.
CLL Society Inc.
@CllSociety
Dr Brian Koffman: It Is Critical That Patients Educate Themselves and Leverage Their Advantages www.ajmc.com/interviews/dr-brian-koffman-it-is-critical-t… via @AJMC_Journal
-
Verastem Oncology reposted
Carlos Chiattone
@CarlosChiattone
T-cell Lymphoma Forum in La Jolla: Two drug combination beginning to hit ORR 80-90% and CR 50%
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
Every step in the right direction counts. A journey of a thousand miles begins with a single step as we rise with iconic buildings across the country to help #fightbloodcancer. Read more about The Big Climb here: www.lls.org/big-climb
-
Verastem Oncology reposted
Andy Biotech
@AndyBiotech
Blood cancers are probably the best examples to demonstrate how #biotech innovations have made huge impact on patient lives.
5-Yr survival rate from 1970s to 2010s
CML: 22% -> 68%
NHL: 47% -> 73%
Myeloma: 25% -> 53% -
Verastem Oncology reposted
CURE Today
@cure_today
VIDEO: Brian Koffman is a family physician who used his own CLL diagnosis to start a group that informs other patients and their loved ones. www.curetoday.com/cure-tv/physician-turns-personal-diagno…
-
Verastem Oncology
@VerastemOncolog
Only 10 more minutes until Verastem Oncology #jpm2019 presentation!
-
Verastem Oncology reposted
Andy Biotech
@AndyBiotech
BioPharma made most significant impact on these cancer types:
Breast - HER2, CDK4/6
Prostate - ADT/Zytiga/Xtandi
Myeloma - PI/IMiDs/CD38
Kidney - VEGF, mTOR, I/O
NHL - CD20
CML - Gleevec
Melanoma - BRAF/MEK, I/O
Still much work to be done in GI/lung/brain
Andy Biotech
@AndyBiotech
Intriguing question on whether we got its worth for the cumulative trillion dollar we paid for oncology drugs
x.com/SteveJoffe/status/1082843492341243904
As a whole, I believe the answer is a strong YES!
This chart probably best captures the value -- millions of lives saved by #biotech innovation! -
Verastem Oncology reposted
Nature Biotechnology
@NatureBiotech
In our January issue: How companies pick a virus to win at #genetherapy - @Cormac_Sheridan rdcu.be/bfJKn
-
Verastem Oncology reposted
Oncology Board
@mb_Oncology
Verastem Oncology Outlines Strategic Priorities for 2019 and Highlights Recent Progress - Business Wire: Verastem Oncology Outlines Strategic Priorities for 2019 and Highlights Recent Progress Business Wire Verastem, Inc. (Nasdaq: VSTM) (Verastem… www.businesswire.com/news/home/20190103005706/en/Verastem…
-
Verastem Oncology reposted
OncLive.com
@OncLive
Duvelisib monotherapy achieved robust and durable responses in patients with relapsed/refractory chronic lymphocytic leukemia @DanaFarber #leusm www.onclive.com/web-exclusives/crossover-to-duvelisib-fea…
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
⚡️ 37th J.P. Morgan Healthcare Conference officially kicked off in San Francisco. Don't miss Verastem presentation on Thursday. #jpmhc19
Verastem Oncology
@VerastemOncolog
Verastem Oncology to present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 11:00 a.m. PST in San Francisco $VSTM www.verastem.com
-
Verastem Oncology reposted
CURE Today
@cure_today
According to a recent study, single agent Copiktra induced robust, durable responses in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. www.curetoday.com/articles/crossover-study-offers-additio…
-
Verastem Oncology reposted
CU Anschutz Cancer Center
@CUCancerCenter
CU Cancer Center study finds that #leukemia #cancer cells steal glucose from normal cells to drive tumor growth...news.cuanschutz.edu/cancer-center #leusm #bloodcancer #microbiome
-
Verastem Oncology
@VerastemOncolog
⚡️ 37th J.P. Morgan Healthcare Conference officially kicked off in San Francisco. Don't miss Verastem presentation on Thursday. #jpmhc19
Verastem Oncology
@VerastemOncolog
Verastem Oncology to present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 11:00 a.m. PST in San Francisco $VSTM www.verastem.com
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology to present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 11:00 a.m. PST in San Francisco $VSTM www.verastem.com
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
#icymi 2018: we received #fda approval this year for a new treatment option for people living with relapsed or refractory #cll
Verastem Oncology
@VerastemOncolog
It is a very exciting time for Verastem Oncology! @VerastemOncolog first product is now available in the US. Read Press Release
investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… -
Verastem Oncology
@VerastemOncolog
“2018 was a pivotal year for Verastem Oncology, as the U.S. Food and Drug Administration’s approval of our first product and other key accomplishments strongly positioned us to execute on our 2019 corporate priorities” investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology reposted
OncLive.com
@OncLive
7) Dr. O'Brien Discusses Duvelisib in CLL #leusm @UCIrvine www.onclive.com/onclive-tv/dr-obrien-discusses-duvelisib-…
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
“Having lived the dual status of a physician and patient, I recognize that it takes a village to make a difference in the lives of those who are battling #cancer,” said Dr. Koffman, a first recipient of Care Differently Award for excellence. @CllSociety investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology reposted
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Our team at Verastem Oncology is deeply grateful for the meaningful work we had a chance to do in 2018. Now it's time to reflect, to relax and to celebrate! Wishing everyone #happyholidays and a fruitful #newyear2019
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Verastem Oncology is added to the NASDAQ Biotechnology Index® (#nasdaq: NBI) effective prior to market open on December 24, 2018. $VSTM
investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… -
Verastem Oncology reposted
Parker Institute
@parkerici
Our top read story in 2018: How brave, little Emily Whitehead, the first child to receive #carttherapy, overcame death. She was saved by her own immune system, engineered to fight her #cancer and keep her cancer-free six years later. @EWhiteheadFdn www.parkerici.org/2017/08/30/leukemia-cancer-free-how-car…
-
Verastem Oncology reposted
NEJM
@NEJM
PI3K plays an integral role in translating extracellular growth signals into the intracellular actions that facilitate growth. Cancer cells exploit the regulatory role of PI3K, and PI3K inhibitors in cancer treatment have produced mixed results. www.nejm.org/doi/full/10.1056/NEJMra1704560
-
Verastem Oncology
@VerastemOncolog
Our team at Verastem Oncology is deeply grateful for the meaningful work we had a chance to do in 2018. Now it's time to reflect, to relax and to celebrate! Wishing everyone #happyholidays and a fruitful #newyear2019
-
Verastem Oncology
@VerastemOncolog
Verastem Oncology is added to the NASDAQ Biotechnology Index® (#nasdaq: NBI) effective prior to market open on December 24, 2018. $VSTM
investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… -
Verastem Oncology reposted
The ASCO Post
@ASCOPost
In the Clinic: Duvelisib for Relapsed or Refractory CLL/SLL and for Relapsed or Refractory Follicular Lymphoma www.ascopost.com/issues/december-10-2018/duvelisib-for-re… #lymsm #hematology
-
Verastem Oncology
@VerastemOncolog
“Having lived the dual status of a physician and patient, I recognize that it takes a village to make a difference in the lives of those who are battling #cancer,” said Dr. Koffman, a first recipient of Care Differently Award for excellence. @CllSociety investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology reposted
Matthew Herper
@matthewherper
Some big news for FDA and @flatironhealth ! @US_FDA is naming Flatiron exec @dramyabernethy as deputy commissioner, reporting to @SGottliebFDA. www.forbes.com/sites/matthewherper/2018/12/17/fda-names-f…
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
So thrilled to partner with @LLSusa Therapy Acceleration Program® (TAP) on our development program for the treatment of peripheral t-cell lymphoma! investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… #lymphoma #leusm #bloodcancer
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Dr. Jennifer Brown's @DanaFarber commentary in @BloodJournal
Blood Journals Portfolio
@BloodPortfolio
Inside Blood Commentary: DUO delivers for duvelisib www.bloodjournal.org/content/132/23/2422?sso-checked=true @DanaFarber
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
RT if you celebrated a milestone this year.
-
Verastem Oncology
@VerastemOncolog
#icymi 2018: we received #fda approval this year for a new treatment option for people living with relapsed or refractory #cll
Verastem Oncology
@VerastemOncolog
It is a very exciting time for Verastem Oncology! @VerastemOncolog first product is now available in the US. Read Press Release
investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… -
Verastem Oncology reposted
Blood Journals Portfolio
@BloodPortfolio
Inside Blood Commentary: DUO delivers for duvelisib www.bloodjournal.org/content/132/23/2422?sso-checked=true @DanaFarber
-
Verastem Oncology
@VerastemOncolog
Dr. Jennifer Brown's @DanaFarber commentary in @BloodJournal
Blood Journals Portfolio
@BloodPortfolio
Inside Blood Commentary: DUO delivers for duvelisib www.bloodjournal.org/content/132/23/2422?sso-checked=true @DanaFarber
-
Verastem Oncology reposted
Blood Journals Portfolio
@BloodPortfolio
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory #cll/SLL www.bloodjournal.org/content/132/23/2446?sso-checked=true
-
Verastem Oncology reposted
Cancer Cell
@Cancer_Cell
Stegmaier @DanaFarber @broadinstitute & colleagues discover the PI3K pathway facilitates resistance to BET inhibitors in neuroblastoma and PI3K inhibitors synergize with BET inhibition www.cell.com/cancer-cell/fulltext/S1535-6108(18)30526-9
-
Verastem Oncology reposted
Blood Journals Portfolio
@BloodPortfolio
Check out this week’s issue of Blood: www.bloodjournal.org/content/132/23 #hematology
-
Verastem Oncology
@VerastemOncolog
Didn't have a chance to attend #ash18 or had too many sessions to choose from? Here's a recap of data Verastem Oncology presented. investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
Verastem Oncology
@VerastemOncolog
Join us today at #ash18 to hear Drs. Flinn and Davids present data on long-term efficacy and safety of a new oral monotherapy in patients with r/r #cll and #sll. Poster session # 642 from 6:00PM in the Hall GH. @SarahCannonDocs @DrMDavids @DanaFarber
-
Verastem Oncology reposted
Dr T. Comeau , MD
@SCTNB
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL | Blood Journal www.bloodjournal.org/content/132/23/2446
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
Listen as Karen Hartman, Clinical Social Worker and Social Work Manager at @sloan_kettering speaks with us about 10 ways to cope with the holidays after a cancer diagnosis here: thebloodline.org/coping-with-the-holidays/
-
Verastem Oncology reposted
ASH
@ASH_hematology
Thanks to all who presented, attended, and followed the 60th ASH Annual Meeting! We hope you enjoyed #ash18
-
Verastem Oncology
@VerastemOncolog
⚡️ “ASH18”
x.com/i/moments/1068956897955405825
Verastem Oncology
@VerastemOncolog
-
Verastem Oncology reposted
Bill Wierda, MD, PhD
@wwierda
#ash2018 @anthonymatomd @DrMDavids @OncLive Great ASH2018 CLL summary and discussion with my CLL colleagues on OncLive Peer Exchange. Stay tuned for the link to view!!!
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
“Verastem Oncology is delighted to have presented a wide range of data from our ongoing development programs, including updated long-term follow-up data from the Phase 3 DUO study as well as the DUO crossover extension study” #ash18 investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology reposted
JAMA
@JAMA_current
The @US_FDA recently approve duvelisib, marketed as Copiktra, for treatment of relapsed or refractory CLL or SLL after at least 2 prior therapies jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20…
-
Verastem Oncology reposted
1stOncology
@1stOncology
#verastemoncology Announces Presentation of Updated #duvelisib Combination Clinical Data in #peripheraltcelllymphoma at #ash18 $VSTM www.1stoncology.com/blog/verastem-oncology-announces-pres…
-
Verastem Oncology
@VerastemOncolog
Grateful to have the opportunity and partner with @MsgOfHopeFndtn Looking forward to many more!
Happy Hope Factory
@Thehopefactory
Thank you for being H🌟PE HEROES!!
Life Science Cares
@LS_Cares
Today we’re sharing hope with kids in the hospital this holiday season! #happyhopefactory @MsgOfHopeFndtn
-
Verastem Oncology reposted
Life Science Cares
@LS_Cares
Today we’re sharing hope with kids in the hospital this holiday season! #happyhopefactory @MsgOfHopeFndtn
-
Verastem Oncology reposted
Dana-Farber News
@DanaFarberNews
#ash18 Interview: @DrMDavids speaks to @onclive on #cll research #lymsm
-
Verastem Oncology
@VerastemOncolog
“Verastem Oncology is delighted to have presented a wide range of data from our ongoing development programs, including updated long-term follow-up data from the Phase 3 DUO study as well as the DUO crossover extension study” #ash18 investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology reposted
Graham Collins
@graham74GC
Horwitz et al - duvelisib and romidepsin in R/R R-cell #lymphoma. Does show activity but CRR modest at 24% with median PFS of 6mo - confounded by 6 CR patients censored at transplant. #ash18 #lymsm
-
Verastem Oncology reposted
John Reneau
@LymphomaMD
Horwitz abs 683: duvelisib with romidepsin or bortezomib. ph1 expansion cohort in r/r PTCL/CTCL. Excellent response rates, romi seems better and PTCL seems to respond better than CTCL.
#lymsm #lymphoma #ash18 -
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Today at 11:30, an oral presentation by Dr. Horwitz, abstract 683 on r/r peripheral T-cell lymphoma. #ash18 #leusm #lymphoma @sloan_kettering
Verastem Oncology
@VerastemOncolog
On 12/3 at #ash18, Dr. Horwitz will be sharing new data in relapsed/refractory peripheral T cell #lymphoma. Join us on 12/3 at 11:30AM in Room 6F investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… @sloan_kettering
-
Verastem Oncology reposted
UT MD Anderson
@UTMDAnderson
Congratulations and thanks for all you do to help us #endcancer!
-
Verastem Oncology
@VerastemOncolog
Today at 11:30, an oral presentation by Dr. Horwitz, abstract 683 on r/r peripheral T-cell lymphoma. #ash18 #leusm #lymphoma @sloan_kettering
Verastem Oncology
@VerastemOncolog
On 12/3 at #ash18, Dr. Horwitz will be sharing new data in relapsed/refractory peripheral T cell #lymphoma. Join us on 12/3 at 11:30AM in Room 6F investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… @sloan_kettering
-
Verastem Oncology reposted
Sarah Cannon Docs
@SarahCannonDocs
Tonight from 6-8 at #ash18, remember to check out Dr. Flinn's characterization of the long-term efficacy and safety of duvelisib monotherapy in patients w/ relapsed/
refractory CLL/SLL #fightingcancertogether -
Verastem Oncology
@VerastemOncolog
Join us today at #ash18 to hear Drs. Flinn and Davids present data on long-term efficacy and safety of a new oral monotherapy in patients with r/r #cll and #sll. Poster session # 642 from 6:00PM in the Hall GH. @SarahCannonDocs @DrMDavids @DanaFarber
-
Verastem Oncology
@VerastemOncolog
Happy Hanukkah to everyone who starts celebrating tonight! May the light cast rays of wisdom and peace around the world 💙 #happyhanukkah
-
Verastem Oncology
@VerastemOncolog
So encouraging to see social media platforms being used by physicians more and more to engage with patients and drive #clinicaltrials recruitment. #ash18 #ashsm
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Attending #ash18? Discover @VerastemOncolog commitment to #bloodcancer research. Drop by booth #1124 to meet us and get an insight into the data we present investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… #cll #leukemia
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
⚡️ “ASH18”
x.com/i/moments/1068956897955405825 -
Verastem Oncology
@VerastemOncolog
Dr. Susan O'Brien discusses novel therapy in #cll youtu.be/ojo_9Uw3Hbo via @YouTube
-
Verastem Oncology reposted
Medscape Education
@MedscapeCME
In case you missed yesterday's #medscapelive "PI3 Kinase Inhibitors: Community Perspectives for Optimizing Therapy" at #ash18, here are some highlights:
1) Approved #pi3k inhibitors in hematologic malignancy -
Verastem Oncology reposted
Matthew Davids, MD, MMSc
@DrMDavids
Dr. Jennifer Brown from @DanaFarber kicking off the CLL Ed Session #ash18
-
Verastem Oncology reposted
Medscape Education
@MedscapeCME
Thank you for tuning into the highlights of our #medscapelive "PI3 Kinase Inhibitors: Community Perspectives for Optimizing Therapy". Kudos to our speakers, Drs. Richard Furman, Ian W. Flinn, and @DrNathanFowler, for a great event! 👍
-
Verastem Oncology reposted
Medscape Education
@MedscapeCME
Highlights from yesterday's #medscapelive "PI3 Kinase Inhibitors: Community Perspectives for Optimizing Therapy" at #ash18:
5) DYNAMO: a phase 2 study demonstrating the clinical activity of duvelisib in patients with double-refractory indolent non-Hodgkin #lymphoma. -
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Today at #ash18! Dr. Jen Brown, Director of CLL Center @DanaFarber presents efficacy data in #cll from Phase 3 DUO study with exploratory analysis of clinical & biological indicators to identify patients more likely to respond to therapy. Join us at poster # 642 at 6:15PM 📈
-
Verastem Oncology reposted
John P. Leonard, MD
@JohnPLeonardMD
Here is #leonardlist key #ash18 #lymphoma abstract number 7 - 683 Horwitz - PI3Ki Duvelisib + HDACi Romidepsin in rel/ref peripheral T cell #lymphoma (also arm with Duvelisib + Bortezomib) - short f/u but interesting ash.confex.com/ash/2018/webprogram/Paper115241.html
-
Verastem Oncology reposted
Thais Fischer, MD
@ThaisFischer4
“ The future of CLL is bright, but there is still unanswered questions...” #ash18
-
Verastem Oncology
@VerastemOncolog
Today at #ash18! Dr. Jen Brown, Director of CLL Center @DanaFarber presents efficacy data in #cll from Phase 3 DUO study with exploratory analysis of clinical & biological indicators to identify patients more likely to respond to therapy. Join us at poster # 642 at 6:15PM 📈
-
Verastem Oncology
@VerastemOncolog
60th ASH Annual Meeting officially started! Verastem Oncology team is ready to welcome you at the booth no. 1124. Proud to be presenting new #bloodcancer data at #ash18
-
Verastem Oncology reposted
Blood Cancer United Research
@bcutd_research
Panel #2 discussing novel models and our #llstap program. "LLS is a very sophisticated and influential business partner" "working with LLS for us was a no-brainer." Our partners on this panel are from @miragenrx, #neximmune, #travera, @SutroBio and @VerastemOncolog
-
Verastem Oncology
@VerastemOncolog
LIVE at #ash18 now: @DrNathanFowler, Dr. Flynn and Dr Furman review the rationale for using #pi3k signaling as a therapeutic target at #medscapelive lunch symposium.
-
Verastem Oncology
@VerastemOncolog
As #clinicaltrials get more complex with genomic testing and combo therapies, work of patient-focused organizations such as @LLSusa become critically important. Thank you @LouisJDeGennaro for bringing a fantastic panel together! #ash18 #leukemia #endbloodcancer
Blood Cancer United
@BloodCancerUtd
The onus is on us to design the clinical trial for the patient rather than the patient being for the trial @LouisJDeGennaro #llsroundtable #ash18
-
Verastem Oncology reposted
Lymphoma News Today
@lymphomanews
New Post: Verastem Advances Copiktra for Peripheral T-cell Lymphoma Under LLS Therapy Acceleration Program buffer.com
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
@OSUCCC_James John Byrd - The @US_FDA is bringing about a revolution in getting therapies to patients as quickly as possible #llsroundtable #ash18
-
Verastem Oncology
@VerastemOncolog
The Forbes Healthcare Summit is underway in New York. Verastem Oncology is excited to hear from inspirational speakers, cancer survivors, patient advocates and industry leaders about the future of healthcare. #forbeshealth
Forbes
@Forbes
Matthew Herper kicks off the 2018 Forbes Healthcare Summit—follow along with #forbeshealth and @ForbesHealth for real-time updates.
-
Verastem Oncology
@VerastemOncolog
Booth #1124 is getting ready to welcome you at #ash18 ✨
Verastem Oncology
@VerastemOncolog
Attending #ash18? Discover @VerastemOncolog commitment to #bloodcancer research. Drop by booth #1124 to meet us and get an insight into the data we present investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… #cll #leukemia
-
Verastem Oncology
@VerastemOncolog
Amazing how much blood (no pun intended), sweat and tears goes into pulling off such event successfully. Big thanks to all behind-the-scene people working tirelessly to make #ash18 happen!
ASH
@ASH_hematology
Here’s a sneak peek behind the scenes at #ash18. Can you guess what this will be?
-
Verastem Oncology reposted
Oncology Tube
@oncologytube
Duvelisib: New Treatment For Relapse Refractory CLL oncologytube.com/video/duvelisib-new-treatment-for-relaps…
-
Verastem Oncology reposted
jewlz fahn
@jewlzf
My son Matt is a fighter. He is fighting Hodgkin's Lymphoma right now. He will win this fight. He is a sports lover and would love for you to retweet this to get the word out to pro athletes, and see if they can give him words of encouragement. Lets see how far this can go...
-
Verastem Oncology reposted
Patient Power
@PatientPower
What is the relationship between genes, prognosis and treatment decisions? During this #genetics101 replay, esteemed #cll experts Dr. @wwierda of @LeukemiaMDA & Dr. Jennifer Brown from @DanaFarber explain: www.patientpower.info/video/replay-genetics-everything-yo…
-
Verastem Oncology reposted
Oncology Tube
@oncologytube
Update on PI3K inhibitors for CLL: Idelalisib, copanlisib, duvelisib, and umbralisib oncologytube.com/video/update-on-pi3k-inhibitors-for-cll-…
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
Join us for our free tele/web education program on caregivers with @docapplebaum of @sloan_kettering happening today at 12pm EST. Register here: www.lls.org/events/who-gives-care-to-the-caregiver?src1=2…
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
We are excited to present 8 clinical abstracts at #ash18 featuring new data on relapsed/refractory peripheral T-cell #lymphoma, prognostic and immune-related factors for response to investigational therapy in #inhl, and much more. Read here investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… #cll #ptcl
-
Verastem Oncology reposted
calliecoombs
@calliecoombsmd
Here’s some thoughts on duvelisib! (It’s not just AML drugs getting approved in 2018... 🙄)
-
Verastem Oncology
@VerastemOncolog
On 12/3 at #ash18, Dr. Horwitz will be sharing new data in relapsed/refractory peripheral T cell #lymphoma. Join us on 12/3 at 11:30AM in Room 6F investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… @sloan_kettering
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
Beating cancer is in our blood and that's why we need your help to continue to #fightbloodcancer. Don’t forget to #donate tomorrow for #givingtuesday: www.lls.org/givingtuesday?mrkgcl=1227&mrkgadid=3320009118…
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
We are leading the way to cancer cures, and our president and CEO @LouisJDeGennaro, shares what the progress in 2018 means for patients. Learn more here: www.lls.org/blog/reflecting-on-a-groundbreaking-year-for-…
-
Verastem Oncology reposted
CU Anschutz Cancer Center
@CUCancerCenter
#leukemia #cancer cells steal energy in the form of glucose to fuel tumor growth...news.cuanschutz.edu/cancer-center #leusm
-
Verastem Oncology reposted
Oncology Times
@OncologyTimes
NEW in our resource center: Duvelisib Shows Response, Survival Benefit in Difficult-to-Treat Leukemia know.lww.com/lymphoma-leukemia/articles/survivalbenefit.h… via @SarahCannonDocs #leusm
-
Verastem Oncology reposted
Targeted Onc
@TargetedOnc
After the FDA approval of duvelisib in #follicularlymphoma and #cll, an expert said it "is a significant addition to physicians’ treatment armamentarium that I believe will address an unmet need for patients who have limited options..." Read on: ht.ly/y4Qu30mEdV3
#lymsm -
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
Great news: Miles Scott aka "Batkid," once a 5-year-old #leukemia patient, has reportedly been in remission for the last 5 years. Read more via @ABCNewsHealth: abcn.ws/2OLbVz2
-
Verastem Oncology reposted
ASH
@ASH_hematology
Hey Alexa, Ask ASH Meeting: When will the late-breaking abstracts be announced? #ash18
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
“We’re focusing our largest efforts on the approaches that will have near‐term measurable success on the crucial issues facing #cll patients.” Thank you @MDAndersonNews for your relentless commitment to #endcancer
UT MD Anderson
@UTMDAnderson
72: the average age at a #cll diagnosis.
As more people age and become susceptible to this disease, our #cancermoonshot is offering hope: www.mdanderson.org/cancer-types/leukemia/leukemia-researc… #endcancer -
Verastem Oncology reposted
National Cancer Institute
@theNCI
.@NCIDirector The ability to do #clinicaltrials rapidly and at low cost is critical to progress in cancer. All major advances in the disease come from clinical trials. www.cancer.gov/about-cancer/treatment/clinical-trials/wha… #chasingcancer
-
Verastem Oncology reposted
BSH - Haematology
@BritSocHaem
Recommended: @bloodwise_uk scientists at the University of Birmingham have revealed the roles that different types of gene mutations play in causing blood cancers: bloodcancer.org.uk/news/
-
Verastem Oncology
@VerastemOncolog
“We’re focusing our largest efforts on the approaches that will have near‐term measurable success on the crucial issues facing #cll patients.” Thank you @MDAndersonNews for your relentless commitment to #endcancer
UT MD Anderson
@UTMDAnderson
72: the average age at a #cll diagnosis.
As more people age and become susceptible to this disease, our #cancermoonshot is offering hope: www.mdanderson.org/cancer-types/leukemia/leukemia-researc… #endcancer -
Verastem Oncology reposted
Eric Topol
@EricTopol
It's projected that in 2020 #cancer will override heart disease as the #1 cause of death in the US @CDCgov www.ncbi.nlm.nih.gov/pmc/articles/PMC5127176/pdf/PCD-13-E…
But the shift is not homogeneous and v influenced by inequities
annals.org/aim/fullarticle/2715460/socioeconomic-differen…
annals.org/aim/article-abstract/2715461/shift-from-heart-… @AnnalsofIM -
Verastem Oncology reposted
Gary Reedy
@GaryReedyACS
Today and every day, we salute #veterans for all the sacrifices they have made for our country and our freedoms. We can’t thank you enough and remain committed to Veterans touched by cancer #veteransday2018
-
Verastem Oncology
@VerastemOncolog
Attending #ash18? Discover @VerastemOncolog commitment to #bloodcancer research. Drop by booth #1124 to meet us and get an insight into the data we present investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… #cll #leukemia
-
Verastem Oncology reposted
Blood Cancer United
@BloodCancerUtd
We are excited to host our 3rd annual roundtable, “Innovations in Research: Blood Cancers and Beyond,” on November 29 in San Diego prior to #ash18. We will address timely issues and innovations in #cancer research and treatment. Register here: www.eiseverywhere.com/llsash18
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Verastem Oncology is pleased to present preclinical data supporting dual #pi3k-delta and PI3K-gamma inhibition in combination with immunotherapy at Society for Immunotherapy of Cancer @sitcancer 33rd annual meeting on 11/9 investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology reposted
Odi Bruckman
@odibro
$VSTM Collab with The Leukemia & Lymphoma Society to Accelerate Development of Duvelisib for the Treatment of Peripheral T-Cell Lymphoma www.businesswire.com/news/home/20181107005418/en/Verastem…
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
"The selection of our research program for a TAP collaboration with @LLSResearch underscores the potential of this innovative oral monotherapy for patients with relapsed or refractory peripheral T-cell #lymphoma" www.lls.org/who-we-are/research-investment/tap
-
Verastem Oncology reposted
Bill Wierda, MD, PhD
@wwierda
Looking forward to discussing with clinical relevance of genetics testing for patients with CLL with Dr. Jennifer Brown.
www.patientpower.info/nov13 -
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Partnering with @LLSusa is a fantastic opportunity for Verastem Oncology. Proud to join forces on the mission to #fightbloodcancer. Thank you @LLSResearch
Blood Cancer United
@BloodCancerUtd
Good news! We just granted $42 million to 80 blood cancer research teams around the world. This latest infusion of funding brings the organization’s current commitment to more than $188 million in multi-year grants. Read more here: www.lls.org/lls-us-hq/news/lls-fuels-next-generation-of-c…
-
Verastem Oncology reposted
Naveen Pemmaraju, MD
@doctorpemm
As we finish up Friday clinic, I wanted to send a major shout out to all of the nurses, PAs, APNs, PharmDs & healthcare team in @LeukemiaMDA who are the absolute best in the world for their compassion, dedicated care, and brilliance. We could not do this without each of you!
-
Verastem Oncology
@VerastemOncolog
"The selection of our research program for a TAP collaboration with @LLSResearch underscores the potential of this innovative oral monotherapy for patients with relapsed or refractory peripheral T-cell #lymphoma" www.lls.org/who-we-are/research-investment/tap
-
Verastem Oncology
@VerastemOncolog
Partnering with @LLSusa is a fantastic opportunity for Verastem Oncology. Proud to join forces on the mission to #fightbloodcancer. Thank you @LLSResearch
Blood Cancer United
@BloodCancerUtd
Good news! We just granted $42 million to 80 blood cancer research teams around the world. This latest infusion of funding brings the organization’s current commitment to more than $188 million in multi-year grants. Read more here: www.lls.org/lls-us-hq/news/lls-fuels-next-generation-of-c…
-
Verastem Oncology
@VerastemOncolog
So thrilled to partner with @LLSusa Therapy Acceleration Program® (TAP) on our development program for the treatment of peripheral t-cell lymphoma! investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… #lymphoma #leusm #bloodcancer
-
Verastem Oncology reposted
Verastem Oncology
@VerastemOncolog
Thank you Dr. Flinn and Dr. Danilov for sharing your perspectives on treatment of relapsed and refractory #cll / SLL. Over 300 participants tuned in on November 1 for an engaging live panel discussion! @SarahCannonDocs @OHSUKnight
-
Verastem Oncology reposted
Cancer News
@Cancer_bio
$VSTM Collab with The Leukemia & Lymphoma Society to Accelerate Development of Duvelisib for the Treatment of Peripheral TCell Lymphoma httpswww.businesswire.comnewshome20181107005418enVerastemOncologyAnnouncesCollaborationLeukemiaLymphomaS:… bioportfol.io/QqgClj #cancer
-
Verastem Oncology reposted
The Nobel Prize
@NobelPrize
Happy birthday to Marie Curie, née Sklodowska, who was born #onthisday in 1867!
Marie Curie was the first person to be awarded the #nobelprize twice, and is still the only individual to receive the prize in two different science categories. -
Verastem Oncology
@VerastemOncolog
Verastem Oncology is pleased to present preclinical data supporting dual #pi3k-delta and PI3K-gamma inhibition in combination with immunotherapy at Society for Immunotherapy of Cancer @sitcancer 33rd annual meeting on 11/9 investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…
-
Verastem Oncology
@VerastemOncolog
Thank you Dr. Flinn and Dr. Danilov for sharing your perspectives on treatment of relapsed and refractory #cll / SLL. Over 300 participants tuned in on November 1 for an engaging live panel discussion! @SarahCannonDocs @OHSUKnight
-
Verastem Oncology
@VerastemOncolog
We are excited to present 8 clinical abstracts at #ash18 featuring new data on relapsed/refractory peripheral T-cell #lymphoma, prognostic and immune-related factors for response to investigational therapy in #inhl, and much more. Read here investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA… #cll #ptcl
-
Verastem Oncology
@VerastemOncolog
It is a very exciting time for Verastem Oncology! @VerastemOncolog first product is now available in the US. Read Press Release
investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsA…

































































































































































































































































































































































































































































































